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8Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the
leading cause of dementia. According to the prevailing amyloid cascade hypothesis
of AD, degeneration results from accumulation of toxic beta­amyloid peptide (Aβ) in
the brain. Therapeutic strategies based on removal of Aβ from the brain, however,
have failed to stop the progression of the disease. One promising approach to tackle
AD is the protection of neurons and restoration of synaptic connections with
neurotrophic factors. The neurotrophin NGF (nerve growth factor) promotes survival
of basal forebrain cholinergic neurons (BFCNs) through TrkA receptor and may
prevent cholinergic system dysfunction in AD. Another neurotrophin, BDNF (brain­
derived neurotrophic factor), and its receptor, TrkB, are critical molecular mediators
of activity­dependent synaptic plasticity. BDNF is involved learning and memory,
and may counteract synaptic dysfunction and cognitive impairment in AD.
Neurotrophin precursors, proneurotrophins, by contrast, bind to the p75 neurotrophin
receptor (p75) and promote apoptosis and synaptic depression, and possibly
contribute to synaptic failure and degeneration in AD. Furthermore, p75 also
mediates some of the toxic effects of Aβ. Thus, both activation of brain Trk signaling
and inhibition of p75 function are potential targets for novel drugs for AD.
The first aim of this study was to examine the effects of cholinesterase inhibitors
(ChEi), the first­line drugs for AD, on Trk neurotrophin receptor activity in the
mouse brain. We show that donepezil and galantamine, two clinically used ChEis,
rapidly phosphorylated both TrkA and TrkB receptors in the mouse hippocampus.
Subsequent pharmacological studies suggest that cholinergic activation of Trk
receptors required simultaneous stimulation of nicotinic and muscarinic acetylcholine
receptors. Moreover, we report that drug­induced Trk receptor phosphorylation
response was unaltered in Sortilin1­/­ mice and Bdnf+/­ mice, which show defects in
anterograde transport and synaptic targeting of Trk receptors and BDNF signaling,
respectively. Our results show that drugs commonly used to treat AD activate
neurotrophin receptors in the mouse brain. Unveiling the mechanism of drug­induced
Trk receptor activation may allow for development of better neurotrophic therapies
for AD.
In the second part of this work, we wanted to elucidate the molecular mechanisms
underlying impairment of BDNF­TrkB signaling in a mouse model of AD and to gain
ABSTRACT
9insight to the potential of this pathway as a target for novel plasticity­enhancing drug
therapies against AD. We discovered that Aβ accumulation in the APdE9 mouse
model of early­onset familial AD resulted in an age­dependent increase in the levels
of TrkB.T1, a dominant­negative form of TrkB in the brain. Furthermore, we
detected aberrant accumulation of BDNF protein in the cortex of APdE9 mice.
Moreover, we show that overexpression of TrkB.T1 and Bdnf gene deficiency
aggravated the memory impairment in APdE9 mice, whereas overexpression of TrkB
alleviated this memory deficit. These findings may in part explain the failure of
synaptic plasticity in APdE9 mice and suggest that activation of TrkB signaling could
alleviate memory impairment in patients with AD.
Finally, we developed an assay to detect signaling of p75 in vivo based on proteolytic
processing of the receptor. We show that the assay can detect proteolytic processing
of p75 in vitro and present our strategy to generate a p75 signaling reporter mouse
based on the same methodology. Our knock­in mouse will allow accurate temporal
and spatial localization of p75 activity in healthy, aging and injured nervous systems.
In addition, it will serve as screening platform to discover novel drugs to inhibit the
detrimental effects of the p75 receptor in AD and other diseases.
In conclusion, our results provide new evidence of the effects of ChEIs on brain
neurotrophin signaling and elucidate functional and neurobiological interactions
between Aβ accumulation and BDNF­TrkB signaling.
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Alzheimer’s disease (AD) is a progressive neurodegenerative illness and the leading
cause of dementia. In 2010, dementia affected 6.3 million people in Europe and 35.6
million people worldwide, and WHO has estimated that the number will reach 115
million by the year 2050. The economic burden of AD is tremendous: estimated
health care costs and direct non­medical costs total over 105 billion euros in Europe
alone, making AD the second most expensive disease of the brain (Olesen et al.
2012). Clearly, AD will become an enormous challenge for health care systems in
ageing societies in the near future. Moreover, AD has a profound impact on the
quality of living of the patients with illness, their families and their caregivers.
AD is characterized by progressive synapse loss, neurite dystrophy, neuronal
degeneration, formation of neurofibrillary tangles, and accumulation of β­amyloid
(Aβ) plaques in the brain (Terry et al. 1991, Querfurth and LaFerla 2010). The
groundbreaking amyloid cascade hypothesis of Hardy and Higgins (1992) stated that
accumulation of Aβ peptide initiates a cascade of events that leads to dysfunction and
degeneration of neurons and eventually to formation of the β­amyloid plaques Dr.
Alois Alzheimer described more than 100 years ago. Neuronal degeneration in AD
first affects limbic structures, such as the entorhinal cortex and hippocampus, which
are critically involved in consolidation of new memories (Scoville and Milner 1957,
Gomez­Isla et al. 1996, Kordower et al. 2001). Degeneration eventually spreads to
other brain areas and manifests as generalized cognitive impairment and behavioral
disturbances (Querfurth and LaFerla 2010).
Basal forebrain cholinergic neurons (BFCNs) are among the degenerating neuron
populations, which provided the rationale for development of the first successful
pharmacotherapy against AD, the cholinesterase inhibitors (ChEI). These drugs
inhibit the catalysis of the neurotransmitter acetylcholine (ACh) restoring cholinergic
neurotransmission and improving cognition in patients (Birks 2006, Nestler et al.
2009). ChEIs remain the first­line pharmacotherapy for AD to this day, but are
unable to stop progression of the disease. Efforts to develop disease­modifying drugs
have been driven by the amyloid cascade hypothesis. Unfortunately, therapies based
on removal of Aβ have so far failed and the need for novel disease­modifying drugs
remains as great as ever (Mullard 2012).
1. INTRODUCTION
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One possible approach to confront neuronal degeneration is protection of neurons
and restoration of synaptic plasticity with neurotrophic factors. In fact, the
neurotrophin family of neurotrophic factors was at the forefront of AD research
before the amyloid cascade hypothesis. The classic neurotrophin, nerve growth factor
(NGF), discovered by Levi­Montalcini and Cohen in the 1950’s, is a specific growth
factor for BFCNs capable of supporting their survival and sustaining their
neurotransmitter phenotype (Gnahn et al. 1983, Hefti et al. 1985, Alderson et al.
1990). Indeed, the early neurotrophin hypothesis of AD stated that the disease would
result from unavailability of target­derived NGF and suggested neurotrophins as
potential treatments for AD (Appel 1981, Hefti 1983). Since then NGF has been
tested in a several clinical trials and novel ways to deliver the neurotrophin to the
brain are being investigated (Mandel 2010, Wahlberg et al. 2012). Appreciation of
synaptic loss as a fundamental histopathological correlate to cognitive impairment in
AD, on the other hand, suggests the molecular mechanisms of synaptic plasticity as
potential targets for drug development. One of the candidates for such
neurorestorative therapies is brain­derived neurotrophic factor (BDNF), another
member of the neurotrophin family with a pivotal role in neuronal plasticity, learning
and memory (Park and Poo 2013).
Furthermore, new findings in the 21st century have sparked interest in neurotrophins
not only as treatments, but also as contributing factors in disease pathogenesis.
NGF’s precursor proNGF, for example, is an active signaling molecule functionally
very different from the mature neurotrophin and may contribute to cholinergic
dysfunction and neuronal degeneration in AD (Fahnestock et al. 2001, Lee et al.
2001). At the same time, a several recent findings suggest intimate bidirectional but
incompletely understood interplay between NGF and Aβ signaling in AD. Strikingly,
genetic manipulation of NGF signaling in the mouse brain produces a
neurodegenerative phenotype bearing more resemblance to sporadic AD than any
mouse model based on mutations in APP (Capsoni et al. 2000). Moreover, p75
neurotrophin receptor (p75) mediates some of the toxic effects of Aβ (Sotthibundhu
et al. 2008, Knowles et al. 2009). Thus, activation of trophic growth factor signaling
and inhibition of p75 activity are potential targets for novel drugs against AD.
This review of literature will introduce the reader to the basics of neurotrophin
biology and highlight the potential role of neurotrophins in the pathophysiology and
treatment of AD.
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Neurotrophins are small, secreted proteins that regulate fundamental processes of the
nervous system, such as neuronal differentiation, survival, death and plasticity (Park
and Poo 2013). The mammalian neurotrophin family consists of four members: NGF,
BDNF (Leibrock et al. 1989), and neurotrophins three and four (NT­3, NT­4; Hohn et
al. 1990, Maisonpierre et al. 1990, Hallbook et al. 1991). Neurotrophins are widely
expressed in the brain with the highest mRNA levels detected in the cerebral cortex
and the hippocampus (Korsching et al. 1985, Ernfors et al. 1990, Hofer et al. 1990,
Phillips et al. 1990). Cells synthesize neurotrophins as immature precursors,
proneurotrophins (Fig. 1). Proneurotrophins are enzymatically cleaved to mature
neurotrophins inside the cell by the proprotein convertase furin (Seidah et al. 1996a,
Seidah et al. 1996b), or outside the cell by plasmin or matrix metalloproteases
(MMPs; Lee et al. 2001, Pang et al. 2004, Bruno and Cuello 2006). Neuronal activity
governs neurotrophin synthesis, maturation and release: seizure activity robustly
increases NGF mRNA in the hippocampus (Gall and Isackson 1989), and
depolarization of cultured hippocampal neurons with potassium or kainic acid
promotes synthesis of BDNF and NGF (Zafra et al. 1990) and stimulates their release
(Blöchl and Thoenen 1995, Goodman et al. 1996, Brigadski et al. 2005). Some
studies suggest, however, that hippocampal neurons can also constitutively release
NGF (Blochl and Thoenen 1995, Mowla et al. 1999, Brigadski et al. 2005). Notably,
Mowla et al. (1997) reported that cultured hippocampal neurons exclusively cleave
NGF intracellularly and constitutively release the neurotrophin. In contrast, others
have not been able to detect constitutive NGF release in vitro at all (Griesbeck et al.
1999, Bruno and Cuello 2006). In vivo, Fahnestock et al. (2001) discovered that the
majority of NGF in the human and mouse brain exists as proNGF. In agreement with
this finding, overexpression of NGF in transgenic mice increased levels of the
proneurotrophin in the brain (Buttigieg et al. 2007). Mature NGF, in contrast, can be
detected only in very low quantities with optimized immunoblotting protocols
(Allard et al. 2012). Bruno and Cuello (2006) showed that activity­evoked release of
proNGF from rat cortical microslices is accompanied by the release of tissue
plasminogen activator (tPA) and plasminogen. This enables conversion of
2. REVIEW OF THE LITERATURE
2.1 Neurotrophins and their receptors
2.1.1 Neurotrophin synthesis, release and maturation
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plasminogen to plasmin and permits immediate maturation of NGF (Bruno and
Cuello 2006). In agreement, local inhibition of plasmin with α2­antiplasmin results in
accumulation of proNGF in the rat frontal cortex (Allard et al. 2012). According to
Bruno and Cuello (2006), concomitantly released MMP­9 rapidly degrades mature
NGF, which could explain the difficulties in detection of this neurotrophin.
Contrary to proNGF, the amount of proBDNF is highest during synaptogenesis,
whereas mature BDNF becomes the dominant form of the neurotrophin in adulthood
(Matsumoto et al. 2008, Yang et al. 2009, Dieni et al. 2012). Contrary to proNGF,
The mature brain contains very little proBDNF, and a carefully designed
immunoprecipitation protocol is required to detect the proneurotrophin (Yang et al.
2009, Dieni et al. 2012). The question of how neurons in the central nervous system
(CNS) process and secrete BDNF, however, is controversial. Based on experiments
in cultured hippocampal neurons some groups have concluded that the neurons
preferentially secrete proBDNF, which is cleaved by simultaneously activated
plasmin (Lu et al. 2005, Nagappan et al. 2009, Yang et al. 2009). In support of this
idea, Pang and coworkers (2004) detected elevated proBDNF levels in the
hippocampi of plasmin and tPA knockout mice. ProBDNF did not accumulate,
however, when Allard et al. (2012) inhibited plasmin locally in the rat cortex in vivo,
Figure 1. Neurotrophins and their receptors. NGF binding to TrkA induces receptor
dimerization and phosphorylation of tyrosines in the tyrosine kinase domain (Y670, Y674,
Y675) (B). Kinase activity phosphorylates other tyrosines (Y490, Y751, and Y785) that serve
as docking sites for intracellular signaling molecules leading to activation of PLCγ1, PI3K/AKT
and Ras/ERK pathways. p75 consists a of ligand­binding extracellular domain, transmembrane
domain and TNFR­like death domain. The receptor interacts with various downstream
intracellular molecules (C). PI3K = phosphatidylinositide 3­kinase, PLCγ1 = phospholipase C
gamma 1, NRIF =neurotrophin receptor interacting factor, TRAF6 = tumor necrosis factor
receptor associated factor 6, NRAGE = neurotrophin­receptor interacting MAGE homolog,
RhoGDI = Rho dissociation inhibitor, RIP2 = Receptor­interacting serine/threonine­protein
kinase 2.
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despite clear elevation of proNGF protein levels. Moreover, some groups have been
unable to detect secretion of the proneurotrophin in vitro (Matsumoto et al. 2008).
Apparently, experimental setup is critical, since detection of proBDNF may require
use of plasmin inhibitors and elimination of glial cells, which potentially secrete
proteases (Nagappan et al. 2009, Yang et al. 2009). Questioning the relevance of in
vitro studies altogether, Dieni et al. (2012) reported that mature BDNF and the pro­
domain of the neurotrophin are packaged as dissociated peptides in the same
presynaptic vesicles, and suggested that intracellular proteases quickly cleave the
newly synthetized proBDNF to mature BDNF in the adult brain. Disagreeing with
this idea, other groups have not detected free BDNF pro­domain in the adult brain at
all (Nagappan et al. 2009, Yang et al. 2009), possibly because detection requires
particular Western blotting conditions (Dieni et al. 2012). Thus, mechanisms of
activity­dependent BDNF release in the adult CNS remain unresolved. If activity­
dependent maturation of proBDNF is indeed the main mechanism of conversion, the
presence of abundant amounts of mature BDNF in the brain requires explanation.
Instead, one would expect abundant presence of the proneurotrophin, and rapid and
transient pulses of neurotrophin cleavage, as described for NGF (Bruno and Cuello
2006). Clarifying the mechanisms of proneurotrophin cleavage is essential since
biological actions of mature and proneurotrophins are different.
2.1.2 Neurotrophin receptors
Each neurotrophin binds with high affinity to its cognate tropomyosin related kinase
(Trk) receptor: NGF to TrkA, BDNF and NT4 to TrkB, and NT3 to TrkC (Fig . 1 A;
Hempstead et al. 1991, Kaplan et al. 1991, Klein et al. 1991, Klein et al. 1991,
Soppet et al. 1991, Squinto et al. 1991, Klein et al. 1992). Trk receptors are widely
expressed in the brain: TrkA­immunoreactive somas are present in the basal
forebrain, olfactory tubercle, striatum and nucleus accumbens, thalamus,
hypothalamus and brainstem (Sobreviela et al. 1994). In the hippocampus, the
majority of TrkA is located in the cholinergic axons and terminals and glial cells,
although some immunoreactivity is present in postsynaptic structures (Barker­Gibb
et al. 2001). TrkB immunostaining, in contrast, is abundant in practically all brain
areas, including the neocortex, all hippocampal subregions and the basal forebrain
(Yan et al. 1997). In the hippocampus, TrkB is present in initial segments of axons,
axon terminals and dendrites of pyramidal and granule neurons, but also in axon
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terminals of inhibitory interneurons, cholinergic neurons and monoaminergic neurons
(Drake et al. 1999).
In addition to Trk receptors, all neurotrophins bind to p75 neurotrophin receptor
(Chao et al. 1986, Johnson et al. 1986, Radeke et al. 1987, Rodriguez­Tebar et al.
1990). P75 is widely expressed in the developing CNS (Schatteman et al. 1988, Yan
and Johnson 1988, Roux and Barker 2002). During maturation, expression decreases
and becomes limited to specific neuronal populations in the retina, hypothalamus,
hypophysis, pineal gland, brain stem and spinal cord as well as in the brain
vasculature (Schatteman et al. 1988, Roux and Barker 2002). Most prominent p75
immunoreactivity, however, is detected in BFCNs (Hefti et al. 1986, Kordower et al.
1988, Schatteman et al. 1988). In the human basal forebrain, 95% of neurons positive
for choline acetyltransferase (ChAT) are also positive for p75 (Mufson et al. 1989).
In contrast, p75 mRNA is absent in the adult rat hippocampus (French et al. 1999),
where receptor immunoreactivity is mostly confined to cholinergic presynaptic
structures (Yan and Johnson 1988, Dougherty and Milner 1999, Sanchez­Ortiz et al.
2012). Notably, some studies have also reported p75 immunoreactivity in glial cells,
and in postsynaptic structures, particularly in the developing CNS (Dougherty and
Milner 1999, Woo et al. 2005).
2.1.3 Neurotrophin signaling through Trk receptors
Neurotrophin binding dimerizes Trk receptors and phosphorylates tyrosine residues
in the catalytic domain of the receptor (Y670, Y674, Y675 in TrkA) initiating
receptor tyrosine kinase activity (Middlemas et al. 1994, Stephens et al. 1994, Segal
et al. 1996). This activation leads to the phosphorylation of other tyrosine residues,
which serve as docking sites for intracellular signaling molecules (Fig 1 B). The
small adaptor protein Shc, for example, binds to phosphorylated tyrosine 490 of
mouse TrkA (Y515 in TrkB) and activates the Ras­MAP kinase and PI3K/AKT
pathways (Stephens et al. 1994, Huang and Reichardt 2003). These pathways mediate
the survival and differentiation responses neurons to neurotrophins. Phosphorylated
tyrosine residue 794 in TrkA (Y816 in TrkB), on the other hand, serves as a docking
site for phospholipase C­γ1, which is implicated in the effects of neurotrophins on
neurite outgrowth and neuronal plasticity through activation of calmodulin­dependent
kinase II (CaMKII) and the transcription factor CREB (Middlemas et al. 1994,
Stephens et al. 1994, Huang and Reichardt 2003). TrkB mRNA may be spliced to
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produce two variants (TrkB.T1, TrkB.T2), which lack the tyrosine kinase domain
(Klein et al. 1990, Middlemas et al. 1991). These variants are capable of
heterodimerizing with full­length TrkB in response to BDNF, and act as dominant
negative inhibitors of TrkB signaling activity (Eide et al. 1996, Haapasalo et al.
2001). Thus, the ratio between full­length and truncated TrkB isoforms may control
how efficiently BDNF binding to TrkB activates downstream signaling.
2.1.4 Transactivation of Trk receptors independently of neurotrophins
In addition to neurotrophins, the G­protein coupled receptor (GPCR) ligands
adenosine and pituitary adenylate cyclase­activating polypeptide (PACAP)
phosphorylated TrkA and TrkB in PC12 cells and cultured hippocampal neurons,
respectively (Lee and Chao 2001, Lee et al. 2002). Moreover, dopamine D1 receptor
agonists activate TrkB in striatal neuron cultures (Iwakura et al. 2008). GPCR­
mediated transactivation takes place in intracellular membranes and is mediated
through Src family kinases (Lee and Chao 2001, Lee et al. 2002, Rajagopal et al.
2004). In addition to GPCR ligands, the small metal cation zinc activated TrkB in
cultured cortical neurons (Hwang et al. 2005). The effect of zinc requires Src family
kinases, but the cation also increases the release and cleavage of proBDNF (Hwang
et al. 2005, Huang and McNamara 2010). Activation of TrkB by BDNF
neurotrophin, on the other hand, activates Src family kinases suggesting that
neurotrophin­dependent and ­independent modes of Trk receptor activation are
complementary (Huang and McNamara 2010). Taken together, these findings
indicate that small­molecule GPCR ligands could be potentially used to activate
trophic Trk receptor signaling in the brain.
2.1.5 Neurotrophin signaling through p75 receptor
P75 is a member of the tumor necrosis factor receptor (TNFR) family and thus
structurally unrelated to Trk receptors (Blöchl and Blöchl 2007). The receptor is,
however, the only TNFR family member known to bind neurotrophins. P75 binds
multiple ligands, co­receptors and it activates various intracellular signaling
pathways. Thus, the outcome of p75 activation depends on the context (Fig. 2). First,
the receptor acts as a decision­making point between axonal growth or retraction
through modulation of RhoA signaling (Yamashita et al. 1999, Yamashita and
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Tohyama 2003). Axonal growth inhibitors derived from myelin, such as NOGO and
myelin­associated glycoprotein (MAG), bind to a complex of p75 and NOGO
receptor (NOGO­R; Wang et al. 2002). This ligand binding promotes interaction
between p75 and protein GDP dissociation inhibitor (RhoGDI), which releases and
permits activation of RhoA to prevent neurite outgrowth (Yamashita et al. 1999,
Yamashita and Tohyama 2003). Neurotrophins, on the other hand, release RhoGDI
from p75 allowing it to inhibit RhoA signaling and induce neurite outgrowth
(Yamashita et al. 1999). Binding of NGF to p75 also promotes survival of Schwann
cells in low serum conditions through interaction of p75’s death domain and
receptor­interacting serine/threonine­protein kinase 2 (RIP2), and activation of the
transcription factor NFκB (Carter et al. 1996, Khursigara et al. 2001,
Charalampopoulos et al. 2012). Intriguingly, RhoGDI and RIP2 bind to the same
Figure 2. Ligands, co­receptors and outcomes of p75 signaling in neurons. Binding of
myelin­associated growth inhibitors to complex of p75 and NOGO receptor activates RhoA
signaling,which leads to inhibition of neurite outgrowth (A). Neurotrophin binding to p75
enhances survival of neurons through activation of transcription factor NFκB (B). Neurotrophin
binding to p75 in the absence of Trk receptor, or proneurotrophin binding to a complex of p75
and sortilin activates apoptotic signaling (C). In the presence of a cognate Trk receptor, p75
supports trophic signaling (D). MAG = myelin­associated glycoprotein, NOGO­R = NOGO
receptor, RhoGDI = Rho dissociation inhibitor, RIP2 = Receptor­interacting serine/threonine­
protein kinase 2, NT = neurotrophin, NFκB = nuclear factor kappa­light­chain­enhancer of
activated B cells, proNT = proneurotrophin, NRAGE = neurotrophin­receptor interacting MAGE
homolog, NRIF =neurotrophin receptor interacting factor, TRAF6 = tumor necrosis factor
receptor associated factor 6, Trk = tropomyosin related kinase, PI3K = phosphatidylinositide 3­
kinase, AKT = protein kinase B, ERK = extracellular­signal­regulated kinase, PLCγ1 =
phospholipase C gamma 1. The figure is based on citations in chapters 2.1.5 and 2.1.6.
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residues of p75 making activation of the NFκB and RhoA pathways mutually
exclusive (Charalampopoulos et al. 2012). Therefore, depending on the availability
of neurotrophin and growth­inhibiting factors, p75 changes the balance of Ras and
Rho to guide growth towards trophic support (Blöchl and Blöchl 2007).
In addition to independent trophic signaling, p75 sensitizes Trk receptors to low
amounts of neurotrophins and enhances Trk signaling (Davies et al. 1993, Barker and
Shooter 1994, Ceni et al. 2010, Matusica et al. 2013). The exact nature of this co­
operation is incompletely understood, but recent studies suggest that the free
intracellular domain of p75 (p75ICD) mediates this facilitation (Fig 3). The p75ICD
is released by two­step proteolytic processing of the receptor (Skeldal et al. 2011).
First, the matrix metalloprotease ADAM17, also known as tumor necrosis α
converting enzyme (TACE), cleaves off the extracellular domain of p75 (p75ECD)
(Weskamp et al. 2004). Second, the remaining membrane­bound C­terminal fragment
is subject to regulated intramembrane proteolysis (RIP) by γ­secretase (Jung et al.
2003, Kanning et al. 2003). In PC12 cells neurotrophin binding to TrkA
phosphorylates ADAM17 through the MAPK/ERK pathway, promoting ectodomain
shedding and release of the p75ICD (Ceni et al. 2010, Kommaddi et al. 2011). The
Figure 3. p75 receptor supports trophic Trk signaling when the two receptors are
expressed in the same cell. Neurotrophin binding to Trk receptor activates MEK, which
phosphorylates and activates metalloprotease TACE (ADAM17). TACE cleaves off p75
extracellular domain (p75ECD), which is followed by γ­secretase processing of membrane
bound C­terminal domain (p75CTF) to release soluble intracellular domain (p75ICD). The
p75ICD interacts with TrkA increasing its affinity to NGF and enhancing downstream trophic
signaling. Adapted from Kommaddi et al. (2011).
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p75ICD increases the affinity of NGF to TrkA, enhancing downstream signaling and
promoting neurite outgrowth in PC12 cells (Ceni et al. 2010, Matusica et al. 2013).
2.1.6 p75 as a mediator of apoptosis
The role of p75 changes in the absence of trophic Trk signaling. Overexpression of
p75 increases rat striatal progenitor cell death in the absence of serum (Rabizadeh et
al. 1993). Moreover, neurotrophin binding to p75 in the absence of cognate Trk
receptors promotes apoptosis in retinal ganglion neurons (Frade et al. 1996), cortical
oligodendrocytes (Casaccia­Bonnefil et al. 1996), cultured hippocampal neurons
(Friedman 2000), and sympathetic neurons (Bamji et al. 1998, Kenchappa et al.
2006). Sympathetic neurons, commonly used to study mechanisms of p75­mediated
neuronal death, express p75 and TrkA, but not TrkB. Normal developmental death of
sympathetic neurons is compromised both in Bdnf­/­ and p75exonIII­/­ mice (Bamji et al.
1998). Deppman and colleagues (2008) showed that those sympathetic neurons that
are able to establish connections with their target tissues and receive NGF start
secreting BDNF, which acts as a paracrine factor that binds to p75 and eliminates
competing neurons that have failed to reach their targets (Fig. 4). The mechanisms of
p75 mediated apoptosis of sympathetic neurons are reasonably well characterized but
also disputed. Carter and colleagues showed that BDNF promotes interaction
between p75ICD and neurotrophin receptor­interacting MAGE homolog (NRAGE),
which is required for rapid activation of c­Jun N­terminal kinase (JNK3) and
subsequent apoptosis (Bertrand et al. 2008). Moreover, activation of JNK3 promotes
upregulation of TACE leading to ectodomain shedding of p75 (Kenchappa et al.
2006, Kenchappa et al. 2010). Subsequent γ­secretase processing of the receptor is
required for interaction between the soluble p75ICD, neurotrophin receptor
interacting factor (NRIF), and E3 ligase TRAF6 (Khursigara et al. 2001, Geetha et al.
2005, Kenchappa et al. 2006), and this complex induces a second phase of JNK3
activation (Kenchappa et al. 2010). In addition, the ubiquitination of NRIF by
TRAF6 and subsequent translocation to the nucleus is involved in p75­mediated
apoptosis (Geetha et al. 2005, Linggi et al. 2005, Kenchappa et al. 2006).
While most studies agree that proteolytic processing of p75 is involved in the
receptor death signaling (Kenchappa et al. 2006, Coulson et al. 2008, Volosin et al.
2008), the question whether p75ICD or p75CTF is more important for apoptotic
signaling is a matter of dispute. Coulson and co­workers reported that the 29 amino
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acid juxtamembrane Chopper domain in the membrane­bound p75CTF activates
potassium efflux through G­protein­coupled inwardly­rectifying potassium (GIRK)
channels, activating caspases and promoting cell death (Coulson et al. 2000, Coulson
et al. 2008). The Chopper domain only kills cells when it is membrane­bound
indicating that ectodomain shedding, but not intramembrane proteolysis is required
for p75­mediated death of sensory neurons. Coulson et al. (2008) argued that high­
potassium culture conditions used in previous studies (Kenchappa et al. 2006) could
mask GIRK­mediated cell death. Finally, studies on cultured hippocampal neurons
have identified caspases 3, 6 and 9 as mediators of p75­induced apoptosis (Troy et al.
2002). Figure 4 summarizes the pathways implicated in neurotrophin­induced death
of sympathetic neurons.
In addition to mature neurotrophins, p75 is a receptor for proneurotrophins.
Proneurotrophins were considered as inactive precursors until Lee et al. (2001)
Figure 4. Apoptotic p75 signaling in developing sympathetic neurons. Target­derived
NGF protects sympathetic neurons from BDNF produced by competing neurons. BDNF
binding to p75 activates JNK3 through NRAGE leading to ectodomain shedding of p75. The
juxtamembrane chopper domain in the membrane­bound p75CTF activates inward rectifying
GIRK potassium channels leadings to activation of caspases. Moreover, the tertiary complex of
p75ICD, NRIF and TRAF6 begins the second phase of JNK3 activation. Nuclear translocation
of NRIF initiates a transcriptional program leading to apoptosis. The figure is based on articles
cited in chapter 2.1.6
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discovered that proNGF promotes death of sympathetic neurons and smooth muscle
cells expressing p75. Later, Teng and co­workers (2005) showed that proBDNF also
promotes apoptosis of sympathetic neurons derived from wildtype, but not from p75
knockout mice. In the adult CNS proneurotrophin­induced apoptosis is of particular
importance after nervous system injury. P75 expression is restored, for example, in
the rat entorhinal, perirhinal and piriform cortices and hippocampal formation after
pilocarpine­induced seizures (Roux et al. 1999, Troy et al. 2002, Volosin et al. 2008);
in the spinal cord after contusion injury (Beattie et al. 2002); in the motor cortex after
axotomy of corticospinal neurons (Harrington et al. 2004); and in organotypic
hippocampal slices after CA3­CA1 axotomy (Shulga et al. 2012). Upregulation of
p75 is accompanied by increased production of proNGF, which, in a cytokine­like
manner, signals apoptosis of injured neurons through p75. (Beattie et al. 2002,
Harrington et al. 2004, Volosin et al. 2008, Shulga et al. 2012), Induction of p75
expression and proneurotrophin­induced apoptosis is not limited to these models
(Ibanez and Simi 2012). Instead, upregulation of p75 may be ubiquitous response to
CNS injury, permitting evaluation of viability of the damaged neuron. Drugs aimed
at inhibiting upregulation of p75 or signaling may have therapeutic value in limiting
the extent of post­traumatic apoptosis in the future (Ibanez and Simi 2012, Shulga et
al. 2012).
Taken together, depending on the ligand and the presence of co­receptors the
outcome of p75 signaling may be very different. Proteolytic processing of p75, on
the other hand, takes commonly place regardless of the signaling context and
therefore may serve as an indicator of receptor activity.
2.1.7 Regulation of neurotrophin signalin by sortilin
Proneurotrophin binding to p75 and consequent apoptosis requires presence of the
co­receptor sortilin (Nykjaer et al. 2004, Teng et al. 2005). Sortilin (neurotensin
receptor 3) belongs to a family of vacuolar protein sorting 10 (VPS10)­domain
receptors (Nykjaer and Willnow 2012). In addition to its role in proneurotrophin
signaling, the receptor interacts directly with Trk receptors and participates in their
anterograde axonal transport to synapses (Vaegter et al. 2011). Moreover, sortilin was
reported to interact with the pro­domain of proBDNF intracellularly and participate
in the trafficking of the proneurotrophin to secretory granules for activity­regulated
release (Chen et al. 2005).
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2.1.8 Neurotrophins as regulators of synaptic plasticity
Since the body of evidence showing that BDNF­TrkB is required for synaptic
plasticity is overwhelming this chapter summarizes only some of the key findings.
Kang and Schuman (1995) applied neurotrophins to hippocampal slices from young
rats and discovered that BDNF and NT­3 induced long­term enhancement of synaptic
transmission in CA3­CA1 synapses. In agreement with this finding, LTP is impaired
in Bdnf­/­ mice, and can be restored by expressing BDNF locally in the pyramidal cell
layer of the CA1 region (Korte et al. 1995, Korte et al. 1996). Moreover, conditional
knockdown of TrkB from forebrain glutamatergic neurons impairs synaptic plasticity
and hippocampus­dependent learning (Minichiello et al. 1999). Effects of BDNF on
neuronal plasticity require activation of the TrkB­PLCγ1 pathway (Minichiello et al.
2002).
While mature BDNF mediates synaptic strengthening, proBDNF is thought to
mediate synaptic depression (Park and Poo 2013). Cleavage­resistant proBDNF
enhances LTD in hippocampal slices prepared from P14 mice (Pang et al. 2004, Woo
et al. 2005). Nagappan et al. (2009) showed that low­frequency stimulation (LFS),
which promotes LTD, induces secretion of proBDNF from rat hippocampal slices;
whereas high­frequency stimulation (HFS), which induces LTP, results in release of
proBDNF, tPA and plasminogen, and thus enables neurotrophin maturation and
induction of LTP. In slices from young animals, p75 was present in dendrites of
pyramidal neurons of the CA1 area, and it was required for LTD induction (Woo et
al. 2005). It remains unclear, however, if this model applies to the mature nervous
system as well. Matsumoto et al. (2008) reported that while theta burst stimulation
could not induce LTP in hippocampal slices from Bdnf knockouts, LTD induced by
LFS was unaffected. The absence of proBDNF in these mice implies that the
neurotrophin is dispensable for adult hippocampal LTD. Intriguingly, Martinowich
and colleagues (2012) discovered that social conflict stress facilitates LTD in
wildtype, but not in p75exonIII­/­ mice indicating that the receptor indeed plays a role in
the adult LTD. This study suggested, however, that the loss of LTD in p75 knockouts
may reflect abnormalities in cholinergic neurotransmission rather than absence of the
receptor from pyramidal neurons.
Cholinergic system also mediates the effects of NGF on hippocampal plasticity:
unlike BDNF, NGF does not elicit synaptic potentiation when applied directly to rat
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hippocampal slices (Kang and Schuman 1995). Instead, the neurotrophin enhances
rat hippocampal LTP in vivo when injected to the septum, but not if septal cholinergic
neurons are lesioned (Conner et al. 2009). These findings suggest that efficacy of any
potential plasticity­enhancing therapies based on activation of NGF­TrkA signaling is
likely to depend on the state of cholinergic innervation.
2.2. Neurotrophin signaling in the basal forebrain cholinergic system
2.2.1 Cholinergic neurons of the brain
Cholinergic neurons affected by AD reside in the basal forebrain basal structure
called the Meynert complex. (Fig. 5; Woolf and Butcher 2011). The Meynert
complex consists of several cholinergic nuclei including the medial septum (ms); the
diagonal band complex, which is divided in vertical and lateral horizontal limbs (vdb,
lhdb); and the nucleus basalis of Meynert (bas, nbM). In addition, the laterodorsal
tegmental (ldt) and the pedunculopontine (ppt) nuclei in the mesopontine region
contain cholinergic projection neurons. Furthermore, some of the interneurons in the
striatum, the olfactory bulb and the islands of Cajella complex are cholinergic.
Cholinergic neurons of the ms and the vdb project to the hippocampus through white
matter tract called the fimbria fornix. Cholinergic projections originating from the
lhdb, on the other hand, reach out to the amygdala, olfactory bulb, and frontal cortex.
Other cortical areas receive innervation mainly from the nbM. Widespread
cholinergic innervation of the cortex suggests that any perturbation in the BFCN
function is likely to affect information processing in almost all brain areas.
2.2.2 Cholinergic neurotransmission
Cholinergic neurons use ACh as their primary neurotransmitter. ChAT transfers an
acetyl group from acetyl coenzyme A to choline to produce ACh (Nestler et al. 2009).
Vesicular ACh transporter then packs the neurotransmitter into vesicles, which fuse
to the cell membrane to release the neurotransmitter to the synaptic cleft upon
stimulation. ACh binds to two types of receptors: ionotropic nicotinic receptors
(nAChR) and G­protein­coupled muscarinic receptors (M). Nicotinic receptors are
fast acting, depolarizing Na+/Ca2+ channels. The channels consist of seven subunits
in various compositions, out of which the α7 homomers and α4β2 heteromers are the
most common in the brain. The G­protein coupled muscarinic receptors are divided
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Figure 5. Cholinergic neurons and their projections in the rat brain. ms = medial septum,
vdb = ventral diagonal band, hdb = horizontal diagonal band, si = substantia innominata, bas =
nucleus basalis of Meynert, ppt = pedunculopontine nuclei, ldt = laterodorsal tegmental nuclei.
Icj = Islands of Cajella, BLA = basolateral amygdala, EC = entorhinal cortex, LH = lateral
hypothalamus, SN = substantia nigra, IPN = interpeduncular nucleus, DR = dorsal raphe, LC =
locus ceruleus. From Woolf and Butcher (2011) with permission from Elsevier.
in five subtypes (M1­M5). ACh binding to M2 and M4 receptors activates potassium
channels through Gi proteins, whereas M1, M3 and M5 couple to Gq proteins and
activate phospholipase C. The M1, M3, and M4 subtypes are most abundant in target
areas of BFCNs, whereas M2 muscarinic receptors are autoreceptors located on
cholinergic neurons. Acetylcholinesterase (AChE) and butyrylcholinesterase
(BuChE) catalyze the hydrolysis of ACh to acetic acid and choline, which is taken up
by cholinergic terminals to be re­used in ACh synthesis.
2.2.3 The basal forebrain cholinergic system in learning and memory
The basal forebrain cholinergic system participates in cognitive processes, such as
attention, perception, consciousness, and various forms of learning and memory
(Woolf and Butcher 2011). The role of ACh in learning and memory, however, is
complex. Although the neurotransmitter is released in the hippocampus during
learning tasks, a specific lesion of cholinergic neurons with 192­IgG saporin
immunotoxin produces only subtle deficits in learning and memory (Parent and
Baxter 2004). Michaeu and Marighetto (2011) suggested that rather than being
permissive for memory, ACh regulates memory flexibility, and coordination between
different memory systems. The cholinergic system may regulate cognitive processes
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by generating various brain rhythms (Woolf and Butcher 2011). For example, an
immunolesion study by Apartis and co­workers (1998) showed that the rhythmically
bursting cholinergic neurons of the septum generate a hippocampal theta rhythm. The
loss of cholinergic innervation is therefore likely to contribute to cognitive decline,
but does not alone explain memory impairment in AD.
2.2.4 Neurotrophin receptors in the basal forebrain cholinergic neurons
Unlike hippocampal and cortical neurons, the vast majority of cholinergic neurons
continue to express p75 in adulthood (Mufson et al. 1989). In addition, the majority
of BFCNs also express TrkA (Mufson et al. 1989, Holtzman et al. 1992). Sobreviela
et al. (1994) reported that 95% of TrkA­positive neurons in the septum/diagonal
band, and 80% of neurons in the nbM, were also immunopositive for p75 and ChAT.
In addition, TrkB and TrkC are present in BFCNs, although at lower levels than TrkA
(Salehi et al. 1996, Ginsberg et al. 2006). Colocalization between different Trk
receptors is common (Salehi et al. 1996). The presence of all Trk receptor subtypes
and the continuous expression of p75 distinguish BFCNs from most other neuron
populations. Striatal cholinergic interneurons, for instance, express TrkA but not p75
(Sobreviela et al. 1994). TrkA­positive cholinergic fibers are present widely in the
brain, including the hippocampus and neocortex (Sobreviela et al. 1994, Cooper et al.
2001). These areas synthesize NGF, and only very low levels of neurotrophin mRNA
are present in the basal forebrain (Goedert et al. 1986). The cholinergic terminals
take up NGF and transport it to their somas in the basal forebrain (Seiler and Schwab
1984, Kramer et al. 1999). As may be expected from the expression of TrkB and
TrkC in BFCNs, cholinergic terminals also take up and transport BDNF and NT­3
(DiStefano et al. 1992), although to a lesser extent than NGF (Kramer et al. 1999,
Cooper et al. 2001). Unlike NGF, however, these neurotrophins are also taken up by
cells in the hippocampus where they have distinct local functions and thus cannot be
considered as specific growth factors for BFCNs (DiStefano et al. 1992). From
therapeutic perspective, potential benefits from activation of TrkA signaling may be
confined to cholinergic system whereas activation of TrkB could produce effects that
are more widespread.
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2.2.5 TrkA signaling in development of the basal forebrain cholinergic neurons
NGF and TrkA knockout mice are born alive but usually die by four weeks of age
due to massive loss of sympathetic neurons (Crowley et al. 1994, Smeyne et al.
1994). Their BFCNs, however, develop normally and start to express cholinergic
markers in the absence of the neurotrophin or its receptor (Crowley et al. 1994,
Smeyne et al. 1994, Fagan et al. 1997, Sanchez­Ortiz et al. 2012). Moreover, the
septohippocampal pathway in TrkA­/­ mice develops normally, and the number of
ChAT­positive neurons in the medial septum is unaltered at seven to eight days of
age (Fagan et al. 1997, Sanchez­Ortiz et al. 2012). During the period of
developmental apoptosis around P7­P13, however, more BFCNs die in TrkA­/­ mice
than in wildtype controls and by the age of 20­25 days the number of ChAT­positive
neurons in the septum is 36% lower in the knockouts (Fagan et al. 1997). Brain­
specific conditional TrkA knockouts survive to adulthood (Sanchez­Ortiz et al.
2012). By two weeks of age, however, the characteristic laminar pattern of
cholinergic innervation in their hippocampi is lost and cholinergic fiber density is
significantly decreased. By three months of age, p75 immunoreactivity in the
hippocampus is completely absent in conditional TrkA knockouts indicating that
TrkA is required for maintentance of correct target innervation and cholinergic
phenotype.
2.2.6 TrkA in maintenance of cholinergic neuron phenotype and survival
NGF and BDNF augment the expression of ChAT and AChE in vitro in neuronal
culture prepared from the rat embryonic septum (Hefti et al. 1985, Alderson et al.
1990). Intracerebroventricular infusion of NGF clearly increases the activity of ChAT
in the neonatal hippocampus, cortex and basal forebrain, and slightly in the adult
forebrain (Gnahn et al. 1983, Hefti et al. 1984, Conner et al. 2009). In contrast,
infusion of an antibody against NGF into the ventricles decreases ChAT
immunostaining density and enzyme activity in the vdb and the septum (Sofroniew et
al. 1990). Moreover, perturbation of the balance between mature and proNGF
profoundly affects BFCN phenotype: Allard et al. (2012) delivered α2­antiplasmin to
the rat prefrontal cortex with an osmotic minipump and detected local accumulation
of proNGF and a decrease in the number of VAChT­positive terminals and TrkA­
immunoreactive structures (Allard et al. 2012). In contrast, inhibition of MMP­9,
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which is responsible for degradation of mature NGF, results in accumulation of
mature neurotrophin and an increase in the density of cholinergic boutons (Bruno and
Cuello 2006, Allard et al. 2012).
NGF also protects cholinergic neurons in the medial septum and vdb after transection
of the septohippocampal pathway (Hefti 1986). This lesion decimates 50% of AChE­
positive cells on the ipsilateral side, but NGF treatment maintains the survival rate at
around 92% (Hefti 1986, Morse et al. 1993). BDNF also protects ChAT­ and p75­
positive neurons in the basal forebrain after fimbria transection, but only when the
neurotrophin is injected directly to the septum (Morse et al. 1993). Poor diffusion of
BDNF to the parenchyma from the ventricles may explain this difference. Curiously,
adult cholinergic neurons do not appear to depend on NGF derived from their target
neurons for survival. The number of cholinergic neurons in the rat basal forebrain
remained constant when Sofroniew and co­workers (1990) destroyed 90% of the
hippocampal formation with N­methyl­D­aspartate (NMDA) injections. The
cholinergic cell bodies shrunk, however, and expression of ChAT in the neurons was
reduced. In conclusion, NGF­TrkA signaling maintains the neurotransmitter
phenotype of cholinergic neurons and promotes survival of severed neurons, but may
not be required for their survival in physiological conditions.
2.2.7 The role of p75 in basal forebrain cholinergic neurons
Although BFCNs express p75 at high level, relatively few studies have specifically
addressed the role of the receptor in cholinergic neurons. Basic neurotrophin biology
postulates at least two possible roles: on the one hand, p75 could act in synergy with
Trk receptors, all of which are abundant in cholinergic neurons (2.1.2). On the other
hand, p75 could act as an antagonist and mediate atrophic effects. Moreover, it is
conceivable that this role depends on availability of mature and proneurotrophins and
is thus subject to change during development and under pathophysiological
conditions.
The majority of studies in p75 knockout mice favor an antagonistic role for p75 in
BFCNs. p75exonIII­/­ mice are viable and fertile but have deficits in sensory innervation
(Lee et al. 1992). One consistent finding in these mice has been enlargement of
cholinergic soma diameter in the basal forebrain (Yeo et al. 1997, Kramer et al. 1999,
Greferath et al. 2000, Greferath et al. 2012). This change is accompanied by clearly
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increased density of ChAT positive axons in the CA1 area (Greferath et al. 2000) and
increased ChAT enzyme activity both in the basal forebrain and hippocampus (Yeo et
al. 1997, Greferath et al. 2000, Krol et al. 2000). Some studies have reported reduced
number of cholinergic neurons in p75 knockouts (Peterson et al. 1999, Greferath et
al. 2000), but most show an increase in the number of ChAT­positive neurons (Yeo et
al. 1997, Naumann et al. 2002, Greferath et al. 2012). Recently, Greferath et al.
(2012) backcrossed the p75exonIII­/­ mice to 129/Sv mice for 12 generations and found
significantly more ChAT positive cells in the ms/vdb, hdb and in nbM of p75
knockout animals. Moreover, the group took advantage of the fact that while
p75exonIII­/­ mice do lack the extracellular ligand­binding domain they still express the
intracellular part of the receptor (Von Schack et al. 2001). Using antibodies against
p75ICD Greferath and co­workers (2012) were essentially able to stain p75­positive
neurons in p75exonIII­/­ mice. This approach revealed a subpopulation of p75­positive
and ChAT­negative neurons in the basal forebrain. In homozygous p75 knockouts,
however, all of these neurons were positive for ChAT. In other words, in the
absence of p75 these neurons adopted a cholinergic phenotype. Greferath and co­
workers suggested that these neurons may constitute a dormant cholinergic reservoir,
which can be drafted when increased cholinergic activity is required. This finding
directly indicates that p75 participates in the downregulation of cholinergic
phenotype. Signaling pathways mediating these processes are, however, unknown.
On the other hand, the absence of p75 also diminishes transport of mature
neurotrophins from the dorsal dentate gyrus to the basal forebrain (Kramer et al.
1999, Krol et al. 2000). Axonal transport, in general, is unaffected in p75 knockout
mice. Thus, likely explanations for transport deficiency in p75 knockouts include
altered neurotrophin binding to Trk receptors, reduced receptor internalization or
endosome formation (Kramer et al. 1999). Indeed, antibodies against TrkA and p75
equally disrupt the internalization of mature NGF (Gatzinsky et al. 2001).
Furthermore, p75 appears to be important for fine­tuning of cholinergic target
innervation of the hippocampus, where cholinergic innervation in p75 knockouts is
abnormally dense in the stratum radiatum and stratum oriens layers (Yeo et al. 1997).
Moreover, cholinergic innervation of the supragranular layer, and the border between
the former and the molecular layer of dentate gyrus appears denser (Peterson et al.
1999). Theoretically, these anomalies could limit access of the cholinergic terminals
to target­derived neurotrophin.
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2.3. Neurotrophin signaling in Alzheimer's disease
2.3.1 Molecular mechanisms of Alzheimer's disease
According to the prevailing amyloid cascade hypothesis, causative agent for AD is
Aβ peptide (Hardy and Higgins 1992). Neurons produce Aβ from APP through two­
step proteolytic processing: first, beta­site APP cleaving enzyme 1 (β­secretase,
BACE) sheds APP extracellular domain and, second, γ­secretase complex releases
soluble Aβ peptide in different lengths (Fig. 6, Quefurth and LaFerla 2010).
Accumulation of Aβ leads to oligomerization of the peptide and Aβ oligomers disturb
synaptic function, damage neurites and are toxic to neurons perturbing mitochondrial
function and releasing reactive oxygen and nitrogen radicals (Shankar et al. 2008,
Querfurth and LaFerla 2010). Moreover, β­amyloid pathology alters kinase and
phosphatase activities resulting in hyperphosphorylation of microtubule­asociated
protein tau and promoting protein self­assembly to insoluble neurofibrillary tangles.
Excessive Aβ further aggregates to form β­amyloid plaques that attract reactive
astrocytes and activated microglia, which release cytokines and maintain harmful
inflammation in the brain. Together these changes lead to widespread neuronal
dysfunction and degeneration, which manifest as dementia. The strongest support for
the amyloid cascade hypothesis originates from genetic studies: mutations in APP or
presenilin 1 and 2 genes, which result in increased production of Aβ1­42, cause early­
onset familial AD, whereas APP gene mutation (A673T), which prevents β­cleavage
of APP, protects its carriers from AD and age­related cognitive impairment
(Querfurth and LaFerla 2010, Jonsson et al. 2012). Animal models based on human
mutations causing early­onset familial AD, such as APP695Swe mice, show impaired
LTP, learning and memory (Chapman et al. 1999). Furthermore, the detrimental
effects of Aβ oligomers on synaptic function are well known. Shankar et al. (2008)
extracted Aβ from diseased brains and found that soluble Aβ oligomers inhibit LTP
and facilitate LTD in mouse hippocampal organotypic slices. In rat hippocampal
slices, the extract reduces spine density, and when injected to a ventricle, it impairs
learning in the passive avoidance task. Aβ oligomers are particularly toxic for
BFCNs (Sotthibundhu et al. 2008).
33
Figure 6. The amyloid cascade hypothesis of AD. Excessive proteolytic processing of APP
by β­ and γ­secretases produces soluble Aβ peptide. Particularly Aβ1­42 accumulates and forms
toxic oligomers that disturb synaptic transmission and damage neurites and neurons. Aβ
inhibits mitochondrial function, which causes oxidative stress and apoptosis, and alters kinase
and phosphatase function, which promotes hyperphosphorylation and aggregation of tau
protein to neurofibrillary tangles. Aβ further aggregates to form amyloid plaques. α = alpha
secretase, β = beta­site APP cleaving enzyme (BACE), APP = amyloid precursor protein.
2.3.2 Cholinergic degeneration in Alzheimer's disease
Loss of cholinergic cell bodies in the basal forebrain and cholinergic innervation of
the hippocampus and the cortex characterize advanced AD (Davies and Maloney
1976, Whitehouse et al. 1982) and the decline in AChE and ChAT protein levels
correlates with increasing numbers of β­amyloid plaques (Perry et al. 1978). These
findings suggested an intimate connection between cholinergic atrophy and amyloid
plaques and fuelled the formation of the cholinergic hypothesis of AD (Bartus et al.
1982). Cholinergic neuron death, however, is a rather late event in the course of the
disease and is not as widespread as was previously thought. Whitehouse (1982), for
example, used cell size and Nissl staining intensity to identify cholinergic neurons.
When Vogels et al. (1990) neglected these markers and carefully counted the total
number of neurons in all areas of the Meynert complex, they found only a 15 ­ 37%
loss in the number of cells in the basal forebrain cholinergic nuclei. Cell loss was
most prominent in the posterior nbM, but was notably almost nonexistent in the
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septum (Vogels et al. 1990). Moreover, while the number of magnocellular neurons
in the basal forebrain decreased, the number of small neurons was higher. Thus, most
BFCNs had not died but had lost their neurotransmitter phenotype and become
atrophic instead. Importantly, Vogel’s study shows that silenced cholinergic neurons
remain viable even in late stages of AD. In principle, successful neurotrophic therapy
could revive their function.
Furthermore, recent longitudinal clinical­histopathological studies, such as the
Religious Orders Study on elderly catholic clergy, have also reported changes in
BFCNs in early AD and mild cognitive impairment (MCI). Diagnostic criteria of
MCI are not well established, but the term means that the patient suffers from
cognitive impairment but does not meet the diagnostic criteria of dementia (Russ and
Morling 2012). Amnestic MCI, in particular, may precede dementia. Surprisingly,
Gilmor and colleagues (1999) discovered that the number of cholinergic neurons in
the nbM of patients with MCI was unaltered, and only slightly decreased in early
AD. In agreement with this, cortical ChAT and AChE enzymatic activities were
reduced only in severe AD (Davis et al. 1999). ChAT activity in the hippocampus, in
contrast, was actually elevated in patients with MCI (DeKosky et al. 2002). The
authors suggested that the increased ChAT activity in MCI may be a compensatory
response to the loss of entorhinal cortex input to the hippocampus, and could prevent
the mildly impaired from succumbing to dementia.
2.3.3 Anticholinesterases
A logical consequence of the cholinergic hypothesis was the development of the first
successful pharmacotherapy against AD, the ChEIs. These drugs increase cholinergic
neurotransmission through nicotinic and muscarinic receptors by inhibiting the action
of cholinesterase enzymes (Nestler et al. 2009). Currently three ChEIs are in clinical
use: donepezil, rivastigmine and galantamine. Donepezil is a piperidine­structured,
reversible and noncompetitive inhibitor of AChE with very low affinity to BuChE
(Nestler et al. 2009). Galantamine, on the other hand, is a phenanthrene alkaloid from
Galanthus caucasicus and a reversible and selective AChE inhibitor. In addition to
inhibiting AChE, galantamine acts as an allosteric potentiating ligand (APL) of
nicotinic receptors (Samochocki et al. 2003). In fact, patient plasma drug levels
rarely reach concentrations required to inhibit AChE, which makes potentiation of
35
nicotinic receptors the possible primary mechanism of galantamine action (Nestler et
al. 2009). The third ChEI, rivastigmine has a carbamate structure, and is a
pseudoirreversible inhibitor of both AChE and BuChE (Nestler et al. 2009). While
AChE levels decline in AD, the synthesis of BuChE increases (Perry et al. 1978).
Theoretically, inhibition of BuChE could have additional benefits in the treatment of
the disease. Nonetheless, all three ChEIs have similar beneficial effects on subjective
and objective measures of cognition, daily activities, and behavioral disturbances in
patients (Birks 2006). The drugs may stabilize the state of the patient and delay the
need for hospitalization and are cost­effective treatment (Birks 2006, Bond et al.
2012).
2.3.4 NGF protein levels in Alzheimer's disease
Findings of the role of NGF as a trophic factor for cholinergic neurons formed basis
for the neurotrophin hypothesis of AD, which stated that the disease develops when
availability of target­derived NGF is compromised (Appel 1981, Hefti 1983).
Surprisingly, post­mortem in situ hybridization studies gave no reason to believe that
NGF synthesis would be compromised in patients with AD (Goedert et al. 1986,
Phillips et al. 1991). In fact, NGF protein levels are elevated in cortical areas and the
hippocampus in AD (Crutcher et al. 1993, Scott et al. 1995, Narisawa­Saito et al.
1996, Hock et al. 2000). Notably, Scott et al. (1995) reported that while NGF protein
levels are elevated widely in the neocortex, the hippocampus, the amygdala and the
putamen, the amount of NGF in the nbM is reduced by 50%. Moreover, while
BFCNs in the healthy elderly are NGF­immunopositive, immunoreactivity is
significantly lower or absent in patients with AD (Mufson et al. 1995). Based on
these findings Mufson and colleagues (1995) hypothesized that failure of retrograde
NGF transport could underlie the cortical accumulation of the protein.
2.3.5 Failure of retrograde NGF transport induced by Aβ pathology in mice
The majority of patients with Down syndrome develop early onset dementia with β­
amyloid pathology similar to AD (Lott 2012). This dementia derives from an extra
copy of the APP gene located in the trisomic chromosome 21. The mouse homologue
of the Down syndrome critical region of this chromosome is triplicated in the Ts65Dn
model (Cooper et al. 2001, Salehi et al. 2006). Cooper et al. (2001) discovered that
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2.3.6 Post­translational modifications of proNGF in Alzheimer's disease
Levels of proNGF in the parietal and frontal cortex and in the hippocampus are
elevated in patients with AD patients (Fahnestock et al. 2001, Bruno et al. 2009,
Mufson et al. 2012). Moreover, in some brain areas this increase can be observed
already in patients with MCI (Peng et al. 2004, Mufson et al. 2012). Given the
contemporary findings of Lee et al. (2001) about the apoptotic actions of proNGF,
Fahnestock and co­workers (2001) suggested that the accumulating proneurotrophin
could contribute to the pathogenesis of Alzheimer’s disease. Moreover, Podlesniy et
al. (2006) discovered that the biological activity of proNGF extracted from the
frontal cortex of AD patients (AD­proNGF) differed from that of proNGF extracted
from age­matched non­demented controls. Whereas control proNGF maintained the
survival of serum­deprived PC12 cells, AD­proNGF promoted apoptosis instead
(Podlesniy et al. 2006). This difference is explained by post­translational
modifications of the proneurotrophin: AD­proNGF is nitroperoxidated,
hyperglycosylated and lipoxylated, and these changes are not without effect on the
biological activity of the proneurotrophin (Podlesniy et al. 2006, Bruno et al. 2009,
Kichev et al. 2009). Plasmin can no longer cleave glycosylated or lipoxylated
recombinant human proNGF (Kichev et al. 2009). Moreover, although plasmin does
convert peroxynitrated proNGF in vitro, the resulting peroxynitrated mature NGF is
less potent in phosphorylating TrkA (Bruno et al. 2009). Peroxynitrated proNGF is
Ts65Dn mice almost completely fail to transport NGF from the hippocampus to the
septum. Consequently, cross­sectional area and number of p75­positive neurons in
the medial septal nucleus are smaller in 12­18 month old Ts65Dn mice than in diploid
controls. Salehi et al. (2006) were able to partially rescue NGF transport by crossing
the Ts65Dn mouse with mice hemizygous for APP in order to normalize the APP
copy number. Thus, despite the 21 trisomy, these mutant mice have a normal copy
number of APP gene, which indicates that overproduction of APP protein plays a role
in the NGF transport defect (Salehi et al. 2006). In addition, NGF transport is
deficient in many mouse models based on human familial AD mutations in APP
(Salehi et al. 2006). Thus, these findings in the Ts65Dn mouse model of Down
syndrome support the idea of disturbed retrograde NGF transport in AD. One
possible explanation for the transport defect is post­translational modification of
proNGF by β­amyloid pathology.
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absent in young rats or aged rats with normal cognitive function, but is present in
aged rats with cognitive impairment (Bruno and Cuello 2012). Consistent with the
idea that the modified proneurotrophin is unable to support BFCNs, the cortical
ChAT levels were lower in rats with deficiencies in learning and memory than in rats
with normal memory function. These post­translational modifications are associated
with inflammation: infusion of soluble Aβ oligomers to the rat hippocampus activates
microglia, increases expression of inducible nitric oxide synthase (iNOS), and
peroxynitration proNGF (Bruno et al. 2009). These findings provide possible
explanation for proNGF accumulation in target areas of cholinergic innervation in
AD and in the Ts65Dn mouse model.
2.3.7 Changes in NGF receptors in Alzheimer's disease
In addition to these alterations in NGF protein levels and activity, neurotrophin
receptor expression also changes in AD. The number of TrkA immunoreactive
neurons in the nbM drops by almost 50% in patients with MCI or AD when
compared to people with normal cognitive capabilities (Boissiere et al. 1997, Mufson
et al. 1997, Mufson et al. 2000, Mufson et al. 2000). Patients with probable AD have
significantly less TrkA­, TrkB­, and TrkC­positive neurons in nbM than age­matched
controls (Salehi et al. 1996). Since BFCNs survive in this early stage of disease
(Gilmor et al. 1999), the loss of Trk immunoreactivity may reflect decreased
synthesis of the receptors in cholinergic neurons. Indeed, in situ hybridization and
expression profiling of individual cholinergic neurons revealed that TrkA, TrkB and
TrkC mRNAs are already downregulated in MCI (Mufson et al. 1996, Ginsberg et al.
2006). Accordingly, cortical TrkA protein levels in patients with mild to severe AD
are 50 percent lower than in healthy controls (Mufson et al. 1997, Counts et al.
2004). The expression of p75 in cholinergic neurons, in contrast, remains unaltered in
early AD (Mufson et al. 1996, Ginsberg et al. 2006). Since the ratio between p75 and
TrkA may determine whether proNGF has trophic or atrophic effects on the cell,
decreased TrkA protein levels could amplify the atrophic effects of proNGF on
BFCNs (Masoudi et al. 2009). Table 1 summarizes the changes in neurotrophin and
neurotrophin receptor synthesis and protein levels in MCI and AD based on post­
mortem studies cited in this review of literature.
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2.3.8 The role of proNGF­p75 signaling in neuronal degeneration
Changes in proNGF biology, protein levels and receptors described in previous
chapters suggest that imbalance between TrkA and p75 signaling contributes to
cholinergic dysfunction in AD. It is necessary, however, to distinguish between the
roles of p75 in the cholinergic system and other neurons. ProNGF becomes
upregulated in the injured CNS where it promotes neuronal apoptosis through sortilin
and p75 (Beattie et al. 2002, Harrington et al. 2004, Volosin et al. 2008, Shulga et al.
2012). Thus, the critical questions are: 1) is there injury­like upregulation of p75
outside the cholinergic system in AD, and 2) to what extent does proNGF­p75
signaling contribute to neuronal degeneration outside the cholinergic system. The
answers to these questions clearly have major implications for the potential of p75 as
a future therapeutic target in the treatment AD.
While Chakravarthy et al. (2012) detected increased p75 protein levels in
hippocampal membranes in patients with AD; Counts et al. (2004) reported that p75
levels remain stable in cortical areas in all stages of the disease. Podlesniy et al.
(2006), on the other hand, reported that while p75 protein levels remain stable in the
entorhinal cortex and frontal cortex in advanced AD, the levels of p75CTF and
p75ICD are elevated in the entorhinal cortex indicating that p75 signaling may
Table 1. Changes in neurotrophin synthesis and protein levels in the basal forebrain and
target areas of cholinergic innervation in mild cognitive disorder (MCI) or Alzheimer’s
disease (AD). ↔ = unaltered, ↓= decreased, ↑= elevated, (compared to healthy controls).
BF = basal forebrain, HC = hippocampus, CX = cortex. The table is based on articles cited in
chapter 2.3.
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increase in brain areas affected by the disease. The apparent stability of cortical p75
protein levels with simultaneous loss of p75­positive cholinergic neurons suggests
either increased synthesis of the receptor in the remaining cholinergic neurons, or
upregulation of the receptor outside the cholinergic system. Since Ginsberg et al.
(2006) showed that receptor synthesis is unaltered in BFCNs, extracholinergic
upregulation could account for this discrepancy. Direct evidence supporting
extracholinergic upregulation of the receptor in AD, however, is scarce. In most
studies p75 protein levels were analyzed with Western blotting, which cannot
discriminate the cholinergic terminals from other potential sources of the protein
(Counts et al. 2004, Podlesniy et al. 2006, Chakravarthy et al. 2012). Hu et al. (2002)
reported that 50% of hippocampal CA neurons in healthy aged individuals are
positive for p75 and that the number increases in patients with AD. It is unclear,
however, how such a widespread immunostaining would have escaped attention in
previous decades of study. Finally, Mufson and Kordower (1992) described a
population of small p75­positive neurons in layers II­IV of the temporal and
periamygdaloid cortex and the subicular and amygdaloid complexes. These neurons
were present in subjects with AD, but also in one healthy control. Notably, the
authors described the neurons as healthy­looking and noted the absence of
colocalization between p75 and neurofibrillary tangles. Taken together, current
evidence for widespread injury­like p75 upregulation and signaling in AD is
unconvincing, and the putative role of proNGF in degeneration of cortical and
hippocampal neurons awaits experimental confirmation.
2.3.9 p75 as a mediator of β­amyloid toxicity
Surprisingly, p75 may directly mediate toxic effects of Aβ. Rabizadeh et al. (1994)
discovered that expression of p75 in PC12 cells sensitizes the cells to Aβ toxicity.
Soluble monomeric Aβ1­40 binds to p75 in transfected fibroblasts and in cultured rat
embryonic cortical neurons (Yaar et al. 1997, Knowles et al. 2009). Moreover,
amyloid oligomers induce apoptosis in p75­expressing NIH313 cells and p75­
expressing melanocytes derived from the neural crest (Yaar et al. 1997). In contrast,
cultured hippocampal neurons prepared from p75exonIII­/­ mice are resistant to Aβ
toxicity, and amyloid­induced neurite dystrophy (Sotthibundhu et al. 2008, Knowles
et al. 2009). In addition, injection of Aβ1–42 to the hippocampus reduces the number
of ChAT immunoreactive somas in the basal forebrain by 50% in wildtype mice,
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whereas cholinergic neurons in p75exonIII­/­ mice are unaffected by the treatment
(Sotthibundhu et al. 2008). Knowles et al. (2009) went on to cross mutant mice
expressing two APP mutations linked to familial AD (Thy1­hAPPLond/Swe) with
p75 knockouts. ChAT­positive neurites in the basal forebrain are short, and the
density of cholinergic innervation of the anterior cingulate cortex is low in these APP
mutants at five to seven months of age. In contrast, cholinergic innervation in double
mutants lacking p75 is unaffected, indicating that the receptor mediates the
dystrophic effect of Aβ on cholinergic neurons.
Recent studies have revealed some details about Aβ­induced p75 signaling. Hu et al.
(2013) reported that in order to activate caspases in cultured cortical neurons Aβ
requires death receptor 6 (DR6) as a novel co­receptor for p75. Intriguingly,
Nikolaev and co­workers (2009) have previously connected DR6 to detrimental
effects of Aβ. Moreover, elevated DR6 protein levels are present in patients with AD
(Hu et al. 2013). Aβ also promotes proteolytic processing of p75 and increases
accumulation of the potentially detrimental membrane­bound p75CTF (Coulson et al.
2008, Sotthibundhu et al. 2008). The increased presence of p75CTF and p75ICD in
the entorhinal cortex of AD patients suggests that similar signaling may take place in
the AD (Podlesniy et al. 2006). Taken together, an accumulating body of evidence
clearly implicates p75 in the toxic effects of Aβ. Thus, the high levels of p75
expression in BFCNs may explain the particular vulnerability of cholinergic neurons
in AD.
2.3.10 Alzheimer­like neuronal degeneration in anti­NGF mice
The connection between amyloid and NGF receptors is bidirectional, and
perturbation of the balance of neurotrophin signaling may result in pathological
processing of APP. Ruberti et al. (2000) crossed two transgenic mice expressing
either the light or heavy chain component of a recombinant antibody against NGF to
produce a double transgenic mouse expressing the entire NGF antibody. Importantly,
expression of the antibody was undetectable in neonates, which enabled normal pre­
and postnatal development and function of the nervous system until one month of
age (Capsoni et al. 2000, Origlia et al. 2006). By the age of two months, the antibody
had neutralized 50% of the free NGF, and the number of ChAT positive neurons in
the basal forebrain had fallen to 55% of age­matched controls. First signs of synaptic
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failure appeared at two months of age (Origlia et al. 2006), and memory deficit
followed at four months. By eight to nine months of age, learning and memory were
significantly impaired in anti­NGF mice (De Rosa et al. 2005). This memory
impairment was much more severe than what could be expected from lesions of
cholinergic neurons (chapter 2.2.3). Surprisingly, Capsoni et al. (2000) described
widespread apoptosis, reduced cortical thickness and ventricular dilatation in old
anti­NGF mice. Moreover, immunohistochemical analysis revealed widespread
presence of phospho­tau positive neurofibrillary tangles and dystrophic neurites, and
significant accumulation of intra­ and extracellular Aβ­positive plaques. Aβ staining
appeared first in the walls of cerebral blood vessels around two months of age. By six
months of age accumulation of Aβ­immunopositive clusters of cells and extracellular
Aβ immunoreactivity became evident. Amyloid plaques were detected in 13 month
old animals. Furthermore, the progression of Tau pathology followed the Braak
staging of human AD: immunoreactivity developed first in the somas in entorhinal
cortex, followed by the parietal cortex and the hippocampus (Braak and Braak 1991,
Capsoni et al. 2000). Dendrites in the entorhinal cortex were affected by six months
of age (Capsoni et al. 2000). Thus, progressive neuronal degeneration in the anti­
NGF mouse bears marked resemblance to human sporadic AD.
Capsoni and Cattaneo (2006) suggested that the anti­NGF antibody prefers mature
NGF over proNGF, and suggested that the change in the balance between pro and
mature NGF could result in degeneration. Therefore, they went on to characterize the
roles of NGF receptors in AD­like neurodegeneration (Capsoni et al. 2010). They
used the same neuroantibody approach against TrkA and found that disturbed
receptor function leads to the loss of ChAT­positive BF neurons, deficit in the object
recognition task and accumulation of Aβ­immunoreactive material in both extra­ and
intracellular space at six months of age. In contrast, Aβ immunoreactivity fails to
develop when anti­NGF mice are crossed with p75exonIII­/­ mice. These findings
indicate that the loss of mature NGF or TrkA promotes accumulation of amyloid
through a mechanism that requires p75. In agreement with this, Constantini et al.
(2005) showed that p75 mediates age­dependent increase in β­APP­CTF protein
levels and production of Aβ, while activation of TrkA with mature NGF reduces
proteolytic processing of APP. In conclusion, anti­NGF mice place neurotrophin
signaling upstream of Aβ pathology and suggests the intriguing possibility that Aβ
accumulation could be tackled by activating NGF­TrkA signaling. Figure 7
summarizes potential interactions between NGF and Aβ signaling in AD.
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2.3.11 Changes in BDNF­TrkB signaling in Alzheimer's disease
Figure 7. Potential interactions between NGF and Aβ signaling in Alzheimer’s disease.
Synthesis of TrkA in basal forebrain cholinergic neurons decreases in AD (1), while synthesis
of p75 remains unaltered (2). ProNGF accumulates in target areas of cholinergic innervation
(3). Amyloid peptide induces an inflammatory response in the CNS (4), and the oxidative
stress promotes nitroperoxidation (NOX), lipoxylation and hyperglycolysation of proNGF
making it resistant to maturation (5) and weakening the affinity of mature NGF to TrkA (6).
These changes enhance proNGF­p75 signaling at the expense of NGF­TrkA signaling in
cholinergic neurons resulting in downregulation of cholinergic markers and atrophy of
cholinergic neurons. Elimination of mature NGF or TrkA (7) with antibodies expressed in
transgenic mice initiates p75­dependent accumulation of Aβ, which in turn binds to p75 and
activates signaling pathways leading to apoptosis (8), whereas activity of TrkA inhibits
production of Aβ (9).
Cognitive impairment in AD may ultimately reflect failure of plasticity and loss of
synapses in the brain (Terry et al. 1991, Selkoe 2002). Davies et al. (1987) discovered
a significant loss of synapses in the temporal and frontal cortex in AD. Later Scheff et
al. (2006, 2007) reported that MCI is associated with incipient loss of synapses in the
outer molecular layer of the dentate gyrus and in the stratum radiatum of
hippocampal CA1 area. Synapse loss correlates with symptoms of AD better than any
other histopathological hallmark of the disease (Terry et al. 1991). Given the
fundamental role of TrkB­BDNF signaling in neuronal plasticity, it is unsurprising
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In conclusion, abundant and constant expression of p75 in BFCNs could expose the
neurons to detrimental effects of Aβ (Sotthibundhu et al. 2008, Knowles et al. 2009).
At the same time, this noxious environment impedes trophic effects of NGF on the
declining numbers of TrkA receptors (Mufson et al. 1996, Ginsberg et al. 2006,
Podlesniy et al. 2006, Bruno et al. 2009, Kichev et al. 2009). Progressive synaptic
failure and loss of synapses is reflected in declining BDNF and TrkB receptor
synthesis and impaired activity­dependent neurotrophin signaling (Phillips et al.
1991, Narisawa­Saito et al. 1996, Connor et al. 1997, Ferrer et al. 1999, Peng et al.
2005).
2.4 Summary of the literature
that the loss of synapses in AD is accompanied by diminished BDNF synthesis in the
brain (Phillips et al. 1991, Holsinger et al. 2000). The number of BDNF­
immunopositive neurons and intensity of BDNF staining are decreased in the
hippocampus and temporal cortex of patients with AD (Connor et al. 1997). AD
patients also have less BDNF protein in the entorhinal cortex (Narisawa­Saito et al.
1996), frontal cortex (Ferrer et al. 1999), and hippocampus and parietal cortex (Hock
et al. 2000). In the parietal cortex both pro and mature BDNF protein levels are lower
in patients with MCI than in cognitively unimpaired controls, and protein levels
decline further when MCI progresses to AD (Peng et al. 2005). As a notable
exception, Durany et al. (2000) detected increased hippocampal BDNF levels in
patients with AD. Nevertheless, cortical BDNF protein levels were still diminished.
At the same time, the amount of full­length TrkB in the frontal cortex decreased,
whereas TrkB.T1 expression increased (Ferrer et al. 1999). Based on in vitro
findings, this change in full­length to truncated TrkB ratio is likely to perturb BDNF
signaling and synaptic plasticity. Whether the observed changes in BDNF­TrkB
protein levels only reflect declining numbers of synapse and neurons in the brain or
play a causal role in memory impairment remains unclear.
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3. AIMS OF THE STUDY
To study the effects of ChEis on Trk neurotrophin receptor signaling in the
mouse brain.
To examine the molecular mechanisms of drug­induced Trk receptor
phosphorylation in the mouse brain.
To examine BDNF­TrkB signaling in the APdE9 mouse model of AD, and to
clarify if changes in neurotrophin signaling contribute to memory impairment
in this mouse model.
To develop a method to detect p75 receptor signaling in vivo.
1.
2.
3.
4.
The aims of this study were:
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Table 2 summarizes mouse lines used in this work. Drug effects were tested on male
mice at two to four months of age, except in the experiment on sortilin knockouts,
where females were also used. C57BL6/N mice were obtained from Harlan
(Netherlands) and kept in animal facilities at the University of Helsinki for at least
one week before experiments. TrkB.TK mice, TrkB.T1 mice, Bdnf+/­ mice, and
Sortilin knockouts (kindly provided by Dr. Anders Nykjaer, Århus, Denmark) were
maintained at the University of Helsinki. The experiment on TrkB.Y816F mice was
executed in the laboratory of Dr. Liliana Minichiello, EMBL Monterotondo, Italy,
and frozen tissue was brought to Helsinki for analysis. APdE9 mice were from Dr. D.
Borchelt and J. Jankowsky, Johns Hopkins University, Baltimore, MD, USA. These
mice were crossed with TrkB.T1 mice, TrkB.TK mice, and Bdnf knockouts at
University of Eastern Finland, Kuopio. Behavioral experiments were carried out in
Kuopio, and frozen tissue was sent to Helsinki for biochemical analysis. Tissue from
cleavage resistant proBDNF knock­in mutant mice was received from Dr.Masami
Kojima in Ikeda, Japan. All animals in our hands were group­housed, and standard
pellet food and water were available at all times. Light­dark cycle was 12 hours. The
experiments were conducted according to the guidelines of the European
Communities Council Directive (86/609/EEC) and were approved by the National
Animal Experiment Board of Finland. Local authorities approved experiments done
outside University of Helsinki.
4. MATERIALS AND METHODS
4.1 In vivo drug experiments and biochemical analyses
4.1.1 Animals
4.1.2 Drug treatments
Table 3 summarizes drug experiments included in this work. Drugs were dissolved in
saline or sterile­filtered tap water and the same vehicle was used as a control. In
acute treatment experiments animals received a single intraperitoneal injection of
donepezil­HCl (3.0 mg/kg, Toronto Research Chemicals), galantamine­HBr (3.0­9.0
mg/kg, Toronto Research Chemicals), imipramine­HCl (30.0 mg/kg Sigma­Aldrich),
(­)­nicotinehydrogentartrate (1.0 mg/kg, Sigma­Aldrich) or oxotremorine­M (0.1
mg/kg, Sigma­Aldrich), or vehicle, in a volume of 5­10 ml/kg. All doses are given as
46
Table 2. Mouse lines used in this study.
free base. We chose these doses based on pharmacokinetic and pharmacodynamic
data in order to produce a robust increase in ACh levels in the mouse brain at the
time points studied (Yano et al. 2009). The galantamine dose was higher since,
according to previous studies, approximately threefold concentrations of galantamine
compared to donepezil are needed to produce a similar level of AChE inhibition
(Geerts et al. 2005). The lower galantamine dose (3 mg/kg), on the other hand,
results in brain concentrations optimal for allosteric potentiation of nicotinic
receptors (Geerts et al. 2005). Mice were killed 30 or 60 minutes after injection with
carbon dioxide and cervical dislocation. In the repeated galantamine treatment
paradigm, mice received daily intraperitoneal injection of galantamine­HBr (3.0
mg/kg) or saline. In addition to pharmacokinetic data mentioned above, we based this
dosing regimen on the work of Capsoni et al. (2002), who showed that a similar dose
of galantamine rescues the cholinergic deficit in the anti­NGF mouse model. Mice
repeatedly treated with galantamine were sacrificed 60 minutes after final injection.
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4.1.3 Tissue sampling, processing and the protein concentration assay
Table 3. Design of drug treatment experiments. H2O = sterile­filtered tap water, SAL =
saline, DON = donepezil, GAL = galantamine, IMI = imipramine, NIC = nicotine, OXT =
oxotremorine.
Mice were stunned with carbon dioxide and the brains were quickly dissected on an
ice­cold surface. The tissue was either frozen quickly or processed immediately. The
freshly dissected or frozen tissue was homogenized with a pestle in NP++ lysis
buffer containing inhibitors of proteases and phosphatases (Table 4). The lysate was
kept on ice for at least 30 minutes to allow lysis of cell membranes before
centrifugation (16 000 g, 15 min, +4°C). The supernatant containing soluble and
membrane­bound proteins was collected and stored at ­80 °C. Sample protein
concentrations were measured using the Lowry method (DC protein assay, Bio­Rad),
which is based on the reaction between protein and alkaline copper tartrate and
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4.1.4 Sample preparation for SDS­PAGE
subsequent reduction of folin reagent. The reduced folin absorbs light at 750 nm. The
absorbance was measured with a plate reader (Victor, Perkin Elmer), and the protein
concentration was calculated based on the absorbance of protein standard samples
(BSA, Bio­Rad) on the same plate.
Table 4. Solutions and culture mediums.
The samples (20­50 µg protein) were boiled (3­5 min, 100 °C) in 2x Laemmli buffer
(Table 4). The buffer contains 2­mercaptoethanol, which reduces the disulfide bonds;
and sodium dodecyl sulfate (SDS), which denaturates the proteins and covers them
with negative charge allowing separation of proteins based on molecular weight only.
Alternatively, Trk receptors were concentrated with lectin precipitation. Lysate
totaling 400 µg of protein was incubated (2h, +4°C, rotation) with 15 µl Wheat Germ
Agglutinin conjugated to agarose beads (EY Laboratories, San Matteo, CA, USA).
This lectin has high affinity to N­acetyl­β­D­glucosaminyl residues present in the
extracellular domains of Trk receptors. After precipitation the beads were centrifuged
(16 000 g, 1 min, +4°C), washed once with NP++ and boiled with 20 µl 2x Laemmli
buffer to release and denaturate the proteins. In the experiment on TrkB.TK mice (I),
the N­terminally FLAG­tagged TrkB receptors were pulled down by
immunoprecipitation. Samples containing 400 µg of protein were incubated (2h,
+4°C, rotation), in precipitation buffer consisting of a 1:1 mixture of NP and Triton­X
buffers (Table 4), in the presence of 5 µg anti­FLAG antibody (M2, F3165, Sigma
Aldrich), followed by incubation with 15 µl protein­G­sepharose (Invitrogen) to pull
down the immunocomplexes. Like in lectin precipitation, the samples were then
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4.1.5 SDS­PAGE and Western blotting
Samples were then loaded on polyacrylamide gels, which were either prepared from
acrylamide solution (Bio­Rad), or obtained from a supplier (NuPAGE 4­12 % Mini
Gels, Life Technologies). The proteins were separated under reducing conditions and
were transferred (300mA for 1h at 4 °C) to a PDVF membrane (Hybond­P,
Amersham). The membranes were blocked (1 h, RT) with either 3% BSA or 5%
NFDM prepared in TBS with 0.01% Tween (TBS­T), depending on the choice of
primary antibody (Table 5). Blocked membranes were incubated in primary antibody
solution (overnight, 4°C, on rocker). On the following day the membranes were
washed with TBS­T at least three times for 15 minutes, and incubated (1 h, RT) with
horseradish peroxidase conjugated secondary antibodies (Table 5). After subsequent
TBS­T washes, secondary antibodies were visualized using
electrochemiluminescence kits (Amersham Biosciences) and a Fuji LAS­3000
Camera (Tamro Medlabs, Vantaa, Finland). Optical density of bands was quantified
with ImageJ (NIH). The density of phosphoprotein bands was normalized to the
density of total protein bands of the corresponding protein. Charts show averaged
values of samples in treatment groups. Error bars are given as standard error of the
mean (SEM). Treatment groups were statistically compared using t­test or analysis of
variance, where appropriate.
4.1.6 Neurotrophin ELISAs
Neurotrophin protein concentrations were analyzed using two­site enzyme­linked
immunosorbent assays (ELISA). For BDNF analyses, the tissue samples lysed in
NP++ were diluted in Hanks buffer (Table 4). To improve immunodetection of
neurotrophins the samples were acidified (pH 3.0) with 1 M HCl. After 15 minutes,
the samples were neutralized with 1M NaOH. Samples (170 µl) were then transferred
to a Nunc Maxisorb ELISA plate (eBioscience), previously coated (overnight, +4°C,
shaker)with anti­BDNF antibody (Roche) and blocked with 2% BSA in Hanks buffer
containing 0.1% Triton­X (2h, RT, shaker). Similarly, BDNF standards (Alomone)
were prepared in the Hanks buffer. Peroxidase dismutase conjugated (POD)
centrifuged, washed carefully twice with precipitation buffer, and boiled in 20 µl 2x
Laemmli sample buffer.
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Table 5. Antibodies used in Western blotting. BSA = bovine serum albumin, NFDM = non­
fat dry milk.
secondary BDNF antibody (Roche) was added to the wells and the plate was
incubated overnight (+4°C, shaker). Next day, the plate was washed four times with
300 µl PBS­T, before adding 200 µl of chromogenic POD substrate (BM Blue,
Roche). The peroxidase­mediated development of yellow color was stopped with 1M
H2SO4 and the absorbance was measured at 490 nM. All samples were analyzed in
duplicates and the BDNF concentration was calculated from the standard curve and
normalized to the protein concentration in the samples.
NGF protein concentration was measured with a Chemikine NGF Sandwich ELISA
kit (Millipore) according to the manufacturer’s protocol. The samples were diluted in
assay diluent buffer and acid treated as described above. Strips coated with sheep
anti­NGF antibody were placed in the strip well plate holder and 100 µl of the
samples and NGF standards were added to the wells and incubated overnight (+4°C,
shaker). On the following day the wells were washed with the assay wash buffer (4x
250 µl), and the anti­mouse NGF antibody was added to the wells. After two hours of
incubation the plate was washed again, and peroxidase­conjugated donkey­anti­
mouse antibody was added. After another two hours washes were repeated and
chromogenic TMB/E substrate was added to the wells for 10 minutes. The reaction
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was stopped with the assay stop solution and absorbance at 450 nm was measured
with a plate reader. All samples were analyzed in triplicates and the NGF
concentration was calculated from the standard curve and normalized to the protein
concentration in the samples.
4.1.7 Real­time quantitative PCR
BDNF and NGF mRNA levels were analyzed from the left hippocampus after two
weeks of galantamine treatment using quantitative real­time PCR. RNA was
extracted from the left hippocampus with Trizol (Invitrogen) according to the
manufacturer’s instructions. The isolated RNA was treated with DNAse (Roche).
Complementary DNA synthesis and PCR were performed with a Phusion RT­PCR kit
(Finnzymes) from 1 μg of RNA. The primers used in the cDNA synthesis were
designed against the coding exons to amplify all neurotrophin isoforms. The primers
were 5′­ AGCTTTCTATACTGGCCGCA­3′ and 5′­TCTGTGTACGGTTCTGCCTG­
3′, and 5′­GAAGGCTGCAGGGGCATAGACAAA and 5′­
TACACAGGAAGTGTCTATCCTTATG­3′ for NGF and BDNF, respectively.
Relative levels of neurotrophin mRNA in the samples were measured based on
SYBR green incorporation during the linear phase of the PCR reaction, and were
calculated using the 2−ΔΔCT method (Livak and Schmittgen 2001). Neurotrophin
mRNA levels were normalized to the housekeeping gene GAPDH.
4.1.8 Amyloid β toxicity in cultured cortical neurons
Primary neuronal cultures were prepared from E17 rat cortex in the Neuronal cell
culture unit of Neuroscience center, University of Helsinki. Neurons were plated on
96­well culture plates (Cellstar, Greiner bio­one) coated with poly­L­lysine (Sigma).
Only the inner 60 wells were used in the experiments. The cells were grown in
standard Neurobasal medium (Table 4) containing B27­supplement. One third of the
medium was changed twice a week. After 7­8 days in vitro, the cells were treated
with galantamine (0,1 – 100,0 µM) or BDNF (50 ng/ml) for 24 h or 2 h before
exposure to amyloid. Aβ1­42 peptide (American Peptide Company) was diluted in
acetonitrile and stored as aliquots at ­80 C. One day before the experiment the
peptide was diluted to 50 µM in 1/3 PBS and incubated overnight at +37 C° to allow
for oligomerization of the peptide. Cultured neurons were incubated overnight in the
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presence of Aβ1­42 oligomers (0.01 – 1.0 µM), and the viability of cells was measured
on the following day based on their ability to reduce 3­(4,5­Dimethylthiazol­2­yl)­
2,5­diphenyltetrazolium bromide (MTT, Sigma) to formazan. MTT was dissolved in
water, and 5 µl of solution was added to the cells for a final concentration of 0.36
mg/ml. After incubation (2 h, +37°C) the medium was carefully removed and the
blue formazan crystals were dissolved in 100 µM DMSO. Absorbance was measured
at 540 nm. Viability is given as percentage of untreated cells. There were six parallel
wells per treatment condition.
4.2.1 Plasmids and molecular cloning
4.2 p75 cleavage reporter gene assay
To detect proteolytic processing of p75 we developed a reporter gene assay (Fig. 8).
Rat p75 cDNA was cloned into pcDNA3 plasmid containing a Gal4/VP16 (GVP)
cassette. The GVP domain is a strong transcription­activating domain that consists of
the DNA­binding fragment of yeast transcription activator Gal4 fused with herpes
simplex virus transcription activating protein 16 (VP16) (Sadowski et al. 1988). Gal4
binds to the yeast upstream activator sequence (UAS), a transcriptional enhancer,
which drives expression of neighboring genes (Webster et al. 1988). When α­ and γ­
secretases cleave p75­GVP, the released p75ICD­GVP can enter the nucleus and
activate transcription of a reporter gene, in our case firefly luciferase (Fig 8).
Plasmids used in this work were received from Dr. Elizabeth Coulson, University of
Queensland, Brisbane, Australia and reporter plasmid containing nine repeats of
Gal4­responsive upstream activation sequence (UAS) was obtained from Promega
(UAS_Luc2P, pGL4.35). Since some studies have connected p75ICD to apoptosis
(Kenchappa et al. 2006), we also developed a C­terminally truncated reporter
construct where p75 cDNA was cut at C287 and fused to the Gal4/VP16­containing
vector. The resulting EC/TMp75­GVP contains the extracellular and transmembrane
domains, and 14 amino acids of the intracellular juxtamembrane domain before the
Gal4/VP16 sequence (Fig 8). To produce a single plasmids containing both elements
of the assay p75­GVP and EC/TMp75­GVP plasmids were linearized with MunI. The
pGL4.35 reporter vector was digested with ClaI and the fragment containing
9xUAS_Luc2P was purified from a gel and inserted into p75GVP vectors by blunt­
end cloning after filling in the recessed 3' ends with Klenow fragment.
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Figure 8. p75 cleavage reporter gene assay. Detection of proteolytic processing of p75 is
based on a fusion protein construct where Gal4/VP16 (GVP) DNA binding and transcription
activating domain is fused to the C­terminus of rat p75 (FLp75­GVP). When FLp75­GVP is
proteolytically cleaved, the receptor intracellular domain enters the nucleus where GVP
domain can bind to Gal4­responsive upstream activation sequence (UAS) and promote
production of a co­transfected reporter protein. C­terminally truncated reporter construct
(p75EC/TM) contains only p75 extracellular and transmembrane domains, and 14 amino acids
of the intracellular juxtamembrane domain before GVP domain.
4.2.2 Transfections
HEK293T cells were plated on 24­well culture plates for immunoblotting, or on 96­
well culture plate with white walls and transparent bottoms (Viewplate, PerkinElmer)
for the reporter gene assay. Cells were transfected with 9xUAS_Luc2P and p75­GVP
constructs using lipofection (Lipofectamine2000, Invitrogen) when they had reached
50% confluency. For 96­well plates 0.1 µg of p75­GVP or EC/TMp75­GVP DNA,
and 0.1 µg of UAS_Luc2P DNA was incubated with 0.5 µl Lipofectamine reagent
per well. For cells grown on 24­well plates, the DNA to Lipofectamine ratio was 0.8
µg DNA to 2 µl of reagent per well. The transfection complexes were allowed to
form in DMEM (no additives) for at least 20 minutes before being added to cells.
Culture medium was changed to antibiotic­free medium before transfection.
Transgene expression was allowed to develop for at least 24 hours before
experiments. Efficacy of the transfection protocol was confirmed with fluorescent
reporters.
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4.2.3 Treatments and detection of luciferase activity
4.3 p75 cleavage reporter mouse
Transfected HEK293T cells were pretreated with the γ­secretase inhibitor DAPT (2
µM), or the proteasome inhibitor β­clasto­lactacystin (Lac, 5 µM) for 60­90 min.
Then the cells were treated with phorbol 12­myristate 13­acetate (PMA, 100 ng/ml).
For Western blotting the incubation was stopped after 40 minutes by discarding the
medium and by putting the plate on ice. The wells were washed and the cells lysed in
NP++. Western blotting was done as described in chapter 4.1.5 using an antibody
against p75ICD (Table 5). For the luciferase assay the incubation continued overnight
to allow for accumulation of the reporter protein. On the following day the culture
medium was discarded and luciferase substrate (One­Glo, Promega) mixed 1:1 with
25 µl DMEM was added to the cells. Luminescence was measured using a sensitive
plate reader (Varioskan, Thermo Scientific).
To detect proteolytic processing of p75 in vivo, we designed a knock­in strategy to
introduce GVP domain to the C­terminus of mouse p75 receptor. Thus, the
expression of p75­GVP reporter protein will be driven by the p75 promoter, which
enables natural pattern and levels of reporter receptor expression. The p75­GVP
knock­in mouse will be crossed to different Gal4­responsive reporter mouse lines:
with LacZ or a fluorescent protein as reporter protein, the mouse will enable accurate
temporal and spatial localization of p75 signaling. In the injured CNS, for example,
our reporter mouse will allow us to identify the cells where apoptotic signaling takes
place. Furthermore, fluorescent reporter protein could enable imaging of p75
signaling in the brain with 2­photon in vivo microscopy in almost real­time. On the
other hand, crossing the p75­GVP mouse with a UAS_Luciferase mouse creates
sensitive screening platform capable of detecting endogenous p75 signaling in
various conditions. Moreover, the mouse may reveal p75 signaling in non­nervous
tissue and prove to be a valuable tool for scientists outside the field of neuroscience.
In prostate cancer, for example, p75 acts as a tumor suppressor and inhibits
metastasis (Krygier and Djakiew 2001). As another example, proteolytic processing
of p75 promoted invasiveness of malignant glioma tumors (Wang et al. 2008).
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We designed a targeting vector to knock in a Myc epitope tag and GVP domain in
frame with p75 exon VI, followed by a sequence encoding last four C­terminal
amino acids and a STOP sequence (Fig. 9). Irie et al. (1999) reported that the C­
terminal TSPV­motif of p75 interacts with the PDZ domain of FAP­1 (Fas­associated
phosphatase­1), which limits apoptotic activity of the receptor. Therefore, we wanted
to keep the TSPV motif in the C­terminus of the receptor construct. The targeting
vector pFlexible (van der Weyden et al. 2005) was provided by Dr. Jaan­Olle
Figure 9: Schematic presentation of the targeting vector used to generate a p75­GVP
reporter mouse, and PCR and Southern blot strategies used to screen the embryonic
stem cells. Only restriction sites relevant for the generation of the vector are shown. The
restriction sites in parenthesis were removed in the final phase to correct the vector. B)
Example of PCR screening of ES cells. Clone 3D4 shows two PCR products corresponding to
the expected molecular weights from R’ (wt) 3.0 kB and R’(tg) 2.5 kB reactions. C) Southern
blot of PCR­positive clones (3D4, 5B5 and 6C1) and negative clone (4B3) shows successful
targeting in clones 3D4 and 5B5. D) Finally, p75­GVP mouse will be crossed with reporter
mouse expressing reporter gene driven by Gal4­sensitive promoter. FRT = Flippase (Flp)
recombination site; 3’UTR = 3’ untranslated region; Myc = Myc epitope tag; V, VI = p75 exons
V and VI; UAS = upstream activation sequence, GVP = Gal4/VP16.
4.3.1 Construction of targeting vector
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Andressoo, Institute of Biotechnology, University of Helsinki. The vector contains a
PGK­driven selection marker puromycin/ΔTK flanked by flippase (Flp)
recombination sites (FRT). Homologous arms and the p75 exon VI were amplified
from bacterial artificial chromosome (BAC) BMQ412N8 (Source Biosciences)
containing the p75 locus and generated from 129S7/SvEv Brd­Hprt b­m2 mouse ES
cells. The BAC was transformed into E.Coli and purified by Outi Nikkilä. Vector
integration was assessed using restriction analysis with NotI and AgeI, which
produced the expected 15 kB fragment (data not shown).
PCR primers were designed to amplify homologous arms and introduce the necessary
restriction sites for arm insertion. Homologous arms were designed to be as long as
possible while avoiding the long repetitive sequences in the 5’ intron and 3’
untranslated region (UTR). With these conditions, maximal homology was 2.0 kB for
the 5’ arm and 3.8 kB for the 3’arm. Sufficient overhangs were included to enable
restriction digestion of the PCR products. All PCR reactions were done with high­
Figure 10. Sequence of targeting vector used in generation of a p75­GVP knock­in
mouse showing p75 exon VI and modifications.
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The targeting vector was linearized with ClaI and delivered to Biocenter Oulu
Transgenic Core Facility for electroporation. W4/129S6 embryonic stem cells were
grown under selection pressure (puromycin 0.6 mg/ml). DNA from surviving clones
4.3.2 Homologous recombination and screening of embryonic stem cells
fidelity proofreading polymerases. Correct orientation of the inserted fragment was
confirmed with restriction digestions and the targeting vector was sequenced from
relevant parts after each ligation. First, p75 exon VI was amplified by PCR. The
primers introduced HindIII sites, which were used to insert the fragment to pFlexible.
In addition, the R’ primer was designed to delete nucleotides coding the C­terminal
TSPV motif and the STOP codon, and to introduce Myc epitope tag, and NheI
restriction site required for the next cloning step. Next, the GVP domain was
amplified from the p75­GVP vector described in chapter 4.2.1. The primers
introduced NheI sites to insert the PCR product after exon VI in the targeting vector.
In addition, the R’ primer reintroduced a sequence coding the TSPV motif and the
STOP codon. The resulting Gal4/VP16­Myc­PDZ­STOP fragment was then inserted
in frame with p75 exon VI in pFlexible with NheI. Thirdly, the 5’ homologous arm
was amplified with primers introducing AscI sites in order to insert the arm into
pFlexible. PCR was used to flank 3’ homologous arms with NotI sites. This time the
PCR product was first inserted into the TOPO vector (Zeroblunt, Invitrogen), and
then into pFlexible using NotI restriction sites.
At this point, however, we noticed that our cloning strategy had deleted the splicing
acceptor site preceding exon VI. Therefore, we digested the vector with EcoRI and
inserted the fragment into the Bluescript plasmid. This plasmid was then used as a
template for corrective PCR, which was designed to amplify the entire 6 kB vector
excluding the sequence preceding exon VI we desired to delete (AscI and HindIII
sites in parenthesis in figure 9). We then phosphorylated the resulting Bluescript and
circularized the vector. Then the fixed EcoRI fragment was inserted into the targeting
vector. Although time­consuming, this operation increased the homologous sequence
by 320 base pairs as the 5’ arm now included the exon VI, uninterrupted. The entire
vector was sequenced and we detected a single nucleotide mismatch in the 3’
homologous arm. The change was, however, outside the 3’UTR and we decided
proceed. Figure 10 presents partial sequence of targeting vector showing p75 exon VI
and modifications in the receptor C­terminus.
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was isolated and sent to us in 70 % EtOH for screening. Figure 9 presents the
screening strategy of ES cells. The first round of screening for successful
recombination was done with PCR. The forward primer (PCR F’ in Fig. 9) was
designed to map upstream of 5’ homology. The reverse primers were designed to
map either in the 3’UTR (PCR R’ wt) or in the Gal4/VP16 domain (PCR R’ tg) to
produce a 3.0 kB and 2.5 kB PCR products in wildtype and knock­in clones,
respectively. Prior to screening, PCR protocol was optimized to produce a wildtype
band from mouse DNA. DNA from ES cells was centrifuged (5 min, 14 000 rpm,
+4°C) and the pellets were dried at 37 °C for 10 min, and resuspended in 400 µl TE
buffer. Four µl of DNAwith unknown concentration was used as a template for PCR
reactions. Both R' primers were included in all PCR reactions to amplify both alleles.
PCR products were separated on agarose gel and visualized under UV­light. Out of
200 clones, three were PCR­positive and were analyzed by Southern blotting.
Southern blotting strategy is described in Figure 9. DNA (10 µg) from PCR­positive
ES cell clones 3D4, 5B5, 6C1; and from PCR­negative clone 4B3 was digested with
SpeI (+37°C, overnight). On the following day the digested DNA was precipitated
and resuspended in 30 µl loading buffer. DNA was separated by electrophoresis on a
0.7 % agarose­TAE gel (100 V, 3 h), and the gel was quickly imaged under UV light
with a ruler and DNA ladder to later identify the size of migrated bands. To allow
efficient transfer of DNA and subsequent hybridization, the DNA was denaturated by
incubating the gel in 0.4 M NaOH (30 min, rocker) and neutralized (1.5 M NaOH,
0.5 M Tris pH 7.0, 30 min, rocker). Southern blotting was carried out in neutral
conditions, using the capillary transfer method. Southern stack was assembled in a
plastic tray containing 20x saline­sodium citrate (SSC) buffer in the following order:
1) sponge, 2) Whatman paper, 3) the gel, 4) Amersham Hybond­N+ nylon membrane
(GE Healthcare), 5) Whatman paper, 6) a stack of paper towels (30 cm), and 7) a
glass tray as a weight. On the following day the stack was disassembled and the DNA
was immobilized with UV crosslinking. The membrane was rinsed with water,
allowed to dry and stored at 4°C.
Detection of hybridization was done using the digoxigenin system (DIG High Prime
DNA Labeling and Detection Kit II, Roche). First, the probe used in Southern
blotting was designed to hybridize upstream of the 5’ homologous arm and was
produced by PCR using BAC BMQ412N8 as a template. The probe (3 µg) was
denaturated (10 min, 98°C) and quickly chilled on ice. Then the probe (in 16 µl
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4.3.3 Generation of chimeras and removal of puromycin selection cassette
ES cells from clones 3D4 and 5B5 were cultured at GM mouse unit of University of
Helsinki. The modified ES cells were aggregated with morula­stage embryos to
generate chimeric mice. Chimeras were mated with C57BL6/RCC females and the
pups were screened with PCR. Out of nine chimeras chosen for mating one
transmitted the mutation to the germline. The heterozygous p75­GVP mice were
mated with Caq­FLP mice in order to remove the puromycin selection cassette to
produce the final knock­in.
H2O) was mixed with DIG­High Prime reagent mixture (4 µl) containing random
primers, all dNTPs, digoxigenin­11­dUTP and Klenow polymerase, and incubated
overnight (+37 °C) to produce digoxigenin­labeled probe. The dried nylon membrane
was wet in H2O and 2x SSC, and prehybridized in prewarmed DIG Easy­Hyb buffer
in a hybridization oven (30 min, 42°C, rotation). The labeled probe was denaturated
(98°C, 10 min), cooled on ice, and diluted in 20 ml Easy­Hyb buffer (50 ng/ml).
Hybridization was allowed to take place overnight (42°C, rotation). On the following
day, the membrane was rinsed twice and washed (2 x 5 min) with washing buffer (2x
SSC with 0.1% SDS, RT), followed by stringency washes (2 x 15 min) with warm
wash buffer (0.5x SSC with 0.1% SDS, 67.5°C, rotation).
For immunological detection, the membrane was first rinsed with maleic acid wash
buffer (0.1 M Maleic acid, 0.15 M NaCl, pH7.5, 0.3% Tween 20) and blocked with
the kit blocking solution (30 min). Sheep­anti­digoxigenin antibody conjugated to
alkaline phosphatase was diluted in blocking buffer (1:10000), and incubated with the
membrane for 30 min. This was followed by washes (2 x 15 min) and equilibration in
alkaline conditions (0.1 M Tris­HCl, 0.1 M NaCal, pH 9.5, 5 min). Finally, the
chemiluminescent substrate (CSPD) for the alkaline phosphatase was introduced, and
the membrane was visualized with a Fuji LAS­3000 Camera (Tamro Medlabs,
Vantaa, Finland). The migration of bands was compared to the image taken
previously from the gel with the ladder and a ruler. The clones 3D4 and 5B5 revealed
the expected 5.5 kB band. Thus, targeting efficacy was only one percent.
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To examine if ChEIs could activate brain neurotrophin signaling we tested two
chemically different AChE­selective anticholinesterases, donepezil and galantamine
in mice. We gave mice a single intraperitoneal injection of donepezil (3.0 mg/kg) or
galantamine (3.0­9.0 mg/kg) and analyzed Trk receptor activity 60 minutes later. We
assessed the neurotrophin receptor phosphorylation using antibodies raised against
the PLCγ1 binding site in the TrkB receptor (Y816) or TrkA receptor (Y794)
(Rajagopal et al. 2004, Bath et al. 2008). Both donepezil and galantamine
significantly increased (p < 0.001, ANOVA) phosphorylation of a 140 kDa band
corresponding to the molecular weight of full­length Trk receptors (Fig 11 A, B). In
addition, both antibodies recognized additional bands of unknown identity, which
appeared to be regulated by the treatments. These bands have been detected
previously in response to antidepressant drugs and G­protein coupled receptor
ligands and may be immaturely glycosylated intracellular Trk receptors (Saarelainen
et al. 2003, Rajagopal et al. 2004, Rantamaki et al. 2007).
The PLCγ1 binding sites of TrkA and TrkB share significant homology, which makes
antibody cross­reactivity possible. Therefore, we tested ChEIs in TrkB.TK mice,
which overexpress full­length TrkB cDNA driven by the Thy 1.2 cassette (Koponen
et al. 2005). This minigene drives TrkB expression in postnatal neurons of the cortex
and hippocampus, which results in increased TrkB signaling and improved improves
spatial and associative learning. Moreover, N­terminal FLAG epitope tag in the
receptor allows specific pulldown of overexpressed TrkB from the mouse brain.
Thus, we treated TrkB.TK mice with donepezil and galantamine, pulled down TrkB
receptors with an antibody against the FLAG tag and probed the membranes with
phospho­TrkB antibody. Donepezil increased phosphorylation of TrkB (118.1%, p <
0.05, unpaired T­test, Fig 11 C). Galantamine increased TrkB phosphorylation
(140.9% of control) but the change was insignificant due to variability (p = 0.367,
unpaired T­Test).
5. RESULTS
5.1 The effects of anticholinesterases on brain neurotrophin signaling
5.1.1 Phosphorylation of hippocampal Trk neurotrophin receptors by
cholinesterase inhibitors
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To study the contribution of other Trk receptors we turned to the TrkB.Y816F mutant
mice, which harbor a tyrosine­to­phenylalanine knock­in mutation in the TrkB
PLCγ1 binding site (Minichiello et al. 2002). Consequently, activation of TrkB in
these mice is unable to initiate PLCγ signaling, which results in impairment of
hippocampal LTP. In the absence of Y816 in these mice, any change in phospho­
TrkY816 immunoreactivity must result from phosphorylation of a homologous site in
other Trk receptors. We injected galantamine and the antidepressant imipramine to
the Y816F mice and analyzed Trk receptor phosphorylation with two different
antibodies. The number of animals in the experiment was too low for statistics (n =
2). However, both imipramine and galantamine appeared to increase phospho­
TrkY816 despite the absence of the tyrosine in TrkB (Fig. 11 D). Taken together,
these data indicate that ChEIs phosphorylate several different Trk receptors in the
mouse hippocampus. To discriminate between contributions of different Trk
receptors the drugs should be tested in conditional TrkA and TrkB knockouts.
Figure 11. The effect of donepezil and galantamine on Trk receptor tyrosine
phosphorylation in the mouse hippocampus. Donepezil (DON, 3.0 mg/kg, 60 min, i.p.) and
galantamine (GAL, 9.0 mg/kg, 60 min, i.p.) increased the phosphorylation of TrkB tyrosine 816
(A) and TrkA tyrosine 794 (B) in the mouse hippocampus. Donepezil increased Y816
phosphorylation of overexpressed TrkB, pulled down from TrkB.TK mice with an antibody
against the FLAG epitope tag (C). The Trk receptor phosphorylation induced by imipramine
(30 mg/kg, 60 min, i.p.) and galantamine (3.0 mg/kg, 60 min, i.p.) in wildtype (wt) and
TrkB.Y816F knock­in mice with normal (Y816) or mutated (Y816F) TrkB PLCγ1 binding site
(D). The number of animals in figures A and B were SAL = 8, DON = 8, GAL = 7, and in figure
C: SAL = 5, DON = 4, GAL = 5. *: p < 0.05, ***: p < 0.001 (ANOVA).
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In addition, we studied the activity of signaling pathways connected to Trk receptors
after ChEI treatment. Donepezil and galantamine significantly increased
phosphorylation of the transcription factor CREB (Fig. 12 A). The activity of AKT
was increased two­fold whereas the activity of MAPK42/44 was unaltered (Fig. 12
B, C).
Figure 12. The effect of donepezil and galantamine on Trk downstream signaling.
Donepezil (DON, 3.0 mg/kg, 60 min, i.p.) and galantamine (GAL, 9.0 mg/kg, 60 min, i.p.)
tended to increase phosphorylation of AKT (p = 0.067) and significantly increased
phosphorylation of cAMP response element­binding protein (CREB) in the mouse
hippocampus (A, B). Neither drug affected the phosphorylation of MAPK44/42 (C). The
number of animals was SAL = 8, DON = 8, GAL = 7. *: p < 0.05 (ANOVA).
5.1.2 Mechanisms of Trk receptor activation induced by anticholinesterases
We hypothesized that the activation of Trk signaling results from target­derived
neurotrophin release due to increased cholinergic neurotransmission through nicotinic
or muscarinic receptors or both. To study which receptor type mediates the effects of
ACh on hippocampal Trk signaling we treated mice with nicotine (1.0 mg/kg, 30
min, i.p.) or oxotremorine (0.1 mg/kg, 30 min, i.p), a non­selective agonist of
muscarinic receptors. Unlike ChEIs, neither agonist significantly increased Trk
receptor tyrosine phosphorylation 30 minutes after injection (Fig. 13 A, B). AChEIs,
however, increase the effect of ACh on both receptor types and we therefore decided
to treat mice with a mixture of the two agonists. Combination of nicotine and
oxotremorine induced a two­fold increase in Trk receptor phosphorylation in the
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Figure 13. The effect of nicotine and oxotremorine on Trk receptor activity in the mouse
hippocampus. Nicotine (NIC, 1.0 mg/kg, 30 min, i.p) and oxotremorine (OXT, 0.1 mg/kg, 30
min, i.p.) had no effect on Trk receptor tyrosine 674/5 phosphorylation when the drugs were
given separately (A, B), but increased it significantly when given at the same time (C, D). The
number of animals in the first experiment was SAL = 10, NIC = 8, OXT = 8, and in the second
experiment SAL = 9 and NIC/OXT = 7. * = p < 0.05 (unpaired t­test).
hippocampus (199.6%, p < 0.023, t­test, Fig. 13 C, D). Thus, the cholinergic
activation of hippocampal Trk signaling is unlikely to result from activation of
individual ACh receptor subtypes, but requires comprehensive activation of the
cholinergic system.
We then went on to study the role of BDNF in ChEI­induced activation of TrkB
using heterozygous Bdnf knockout mice. Whereas Bdnf­/­ mice die soon after birth
due to loss of sympathetic neurons, Bdnf+/­ mice avoid these problems and survive to
adulthood (Ernfors et al. 1994, Korte et al. 1995). Importantly, BDNF protein levels
in Bdnf+/­ mice are 50 % lower and the mice show marked deficits in hippocampal
LTP indicating that BDNF signaling in their brain is significantly perturbed (Korte et
al. 1995, Kolbeck et al. 1999). We treated Bdnf+/­ mice with galantamine (5.0 mg/kg)
and studied Trk receptor phosphorylation 60 minutes later. Western blot analysis
showed a significant increase in phosphorylation of 145 kDa [treatment: F (1, 8) =
6.221, p = 0.037; Fig 14 A, B] and 105 kDa [treatment: F (1, 8) = 24.00, p = 0.001;
Fig. 14 A, C] pTrkB immunoreactive bands in response to galantamine treatment.
Notably, galantamine treatment failed to increase phosphorylation of TrkB in
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wildtype mice in this experiment. Regardless, even conservative interpretation of this
data suggests that the phosphorylation response to galantamine was present in Bdnf+/­
mice despite significant deficiency in brain BDNF­TrkB signaling.
Next, we tested donepezil in Sortilin1­/­ mice (Jansen et al. 2007). Sortilin interacts
directly with Trk receptors and participates in their anterograde axonal transport to
synapses (Vaegter et al. 2011). The amount of TrkB receptors in synaptic fractions
prepared from the hippocampus of Sortilin1­/­ mice was significantly lower than in
wildtype controls (Vaegter et al. 2011). Moreover, sortilin is reported to interact with
the pro­domain of proBDNF intracellularly, and participate in the trafficking of the
proneurotrophin to secretory granules, which is a prerequisite for activity­regulated
release (Chen et al. 2005). Sortilin knockouts therefore serve as an indirect way to
manipulate synaptic neurotrophin signaling.
We injected vehicle or donepezil (3 mg/kg, i.p) to 24 Sort1 wildtype mice and 8
homozygous knockouts and analyzed the activity of hippocampal Trk receptors 30
minutes after injection. Due to the less­than­mendelian reproduction of sortilin
knockouts, we needed to use both females and males for the experiment. Therefore,
we first asked if gender might affect the response to donepezil treatment. To test the
treatment effect in males and females we used a two­way ANOVA. Gender had no
effect on Trk receptor activity [Gender (F 1, 20) = 0.03, p = 0.865] or on response to
the donepezil treatment [Interaction (F 1, 20) = 0.35, p = 0.560; Fig. 15 A, B]. Thus,
Figure 14. The effect of galantamine on TrkB receptor phosphorylation in Bdnf+/­ mice.
Galantamine (GAL, 5.0 mg/kg, 30 min, i.p.) promoted full­length TrkB receptor Y816
phosphorylation in Bdnf+/­ mice [F (1, 8) = 6.221, p = 0.037; Fig A, B], and increased the
phosphorylation of a 105 kDa phospho­Trk immunoreactive protein in both genotypes [F (1, 8)
= 24.00, p = 0.001; Fig. A, C]. The number of animals was three per group.
65
we pooled males and females for further analysis. We then proceeded to compare the
effect of donepezil on Trk receptors in sortilin knockout and wildtype mice.
Donepezil treatment significantly increased Trk signaling [Treatment (F 1, 28) =
9.661, p = 0.004; Fig. 15 C, D] and this was unaffected by knockdown of sortilin
[Interaction (F 1, 28) = 0.015, p = 0.903]. Basal Trk receptor phosphorylation in
sortilin knockouts was 84.3% of that in wildtype controls, but the difference was
statistically insignificant.
Taken together, these experiments suggest that the activation of Trk receptors in
response to ChEIs may be independent of synaptic neurotrophin release. Previously,
G­protein coupled receptor ligands, such as adenosine and PACAP, were reported to
transactivate Trk receptors through Src family kinases (Lee and Chao 2001, Lee et al.
2002). Indeed, transactivation is a plausible mechanism for ChEI­induced Trk
receptor phosphorylation. Transactivation takes place in intracellular membranes
Figure 15. The effect of donepezil on Trk receptor activity in Sortilin1­/­ mice. Donepezil
treatment (DON, 3.0 mg/kg, 30 min, i.p.) increased hippocampal Trk receptor tyrosine Y674/5
phosphorylation in wildtype male and female mice (A, B). Figure B shows quantified data
averaged from six animals per group. Two­way ANOVA revealed a significant treatment effect
(p < 0.05) whereas gender did not affect Trk receptor phosphorylation (p = 0.865) or response
to donepezil treatment (p = 0.560). Trk phosphorylation response to donepezil treatment was
similar in wildtypes and Sortilin1­/­ mice (C, D). The bars in figure D are averages of 12
wildtype or four sortilin knockouts per treatment group. Donepezil treatment significantly
increased Trk receptor phosphorylation (p = 0.004) whereas genotype did not affect Trk
receptor phosphorylation (p = 0.322) or response to treatment (p = 0.903).
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(Rajagopal et al. 2004), which could explain why drug­induced Trk receptor
phosphorylation was normal despite deficient synaptic targeting of the receptors in
Sortilin1­/­ mice and decreased BDNF protein levels in Bdnf+/­ mice. Moreover,
similar to G­protein coupled receptor ligands, ChEIs only activate PI3K/AKT
pathway, but leave the MAPK/ERK pathway unaffected (Lee and Chao 2001).
Neurotrophin binding to Trk receptor, in contrast, would be expected to affect both
signaling cascades (Lee and Chao 2001, Huang and Reichardt 2003). Treatment with
oxotremorine­M alone, however, failed to increase hippocampal Trk receptor activity
arguing against Trk receptor transactivation through muscarinic receptors. Treatment
with ChEIs could conceivably result in release of other G­protein coupled receptor
ligands, which could eventually activate Trk receptors. Testing these drugs in
conditional NGF and BDNF knockouts combined with validated
immunoprecipitation strategies for TrkA and TrkB would further elucidate the
contribution of neurotrophins in the drug­induced Trk receptor phosphorylation.
5.1.3 Neurotrophin synthesis, protein levels and balance between mature and
proneurotrophins are unaffected by repeated galantamine treatment
Next, we wanted to study if the rapid Trk receptor phosphorylation leads to long­term
changes in hippocampal neurotrophin synthesis. The antidepressant fluoxetine, for
example, rapidly activates TrkB and increases BDNF synthesis when mice are treated
for three weeks with the drug (Nibuya et al. 1995, Saarelainen et al. 2003, Rantamaki
et al. 2007). We gave mice galantamine (3 mg/kg, i.p.) daily for two weeks and
analyzed NGF and BDNF mRNA and protein levels after the treatment. Repeated
daily treatment with galantamine, however, failed to affect neurotrophin mRNA or
protein levels in the mouse hippocampus (Fig. 16 A, B). Our findings are in line with
preceding studies, which showed that chronic treatment with donepezil or
galantamine did not increase BDNF, NGF, TrkA or p75 protein levels in the rat brain
(Hernandez et al. 2006, Kotani et al. 2008). Chronic treatment with AChEIs is known
to result in significant tolerance to drug effects on ACh levels (Sweeney et al. 1989,
Hernandez et al. 2006). Since neurotrophin ELISAs may detect both mature and
proneurotrophins, we wanted to confirm our findings with Western blotting.
Galantamine treatment did not alter the balance between mature and
proneurotrophins (Fig. 16 C, D). To confirm that our antibody was able to detect
proBDNF we analyzed tissue from knock­in mutant mice expressing cleavage­
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Figure 16. The effect of repeated galantamine exposure on neurotrophin synthesis and
protein levels in the mouse hippocampus. Mice received galantamine (3.0 mg/kg, i.p.) daily
for 14 days. The treatment did not affect hippocampal neurotrophin synthesis (A) or protein
levels analyzed with ELISA (B) and Western blotting (C, D). Immunoblotting against BDNF
from wildtype or cleavage­resistant proBDNF knock­in mice (E). The number of animals in
groups were SAL = 8, GAL = 12.
resistant proBDNF. We detected a clear BDNF­immunoreactive band of 26 kDa in
the knock­in mice confirming that the antibody recognizes proBDNF if the
proneurotrophin is present in significant amounts in the brain (Fig. 16 E).
Even though we did not detect long­term effects on neurotrophin signaling, chronic
treatment with galantamine, donepezil and ganstigmine reverse the loss of ChAT
positive neurons in the basal forebrain and deficits in the object recognition task in
anti­NGF mice (Capsoni et al. 2002, Capsoni et al. 2004). Moreover, rivastigmine
and donepezil reversed decreased cortical NGF levels in rats with experimental
allergic encephalomyelitis (D'Intino et al. 2005). Furthermore, Leyhe et al. (2008)
reported that donepezil treatment may normalize serum BDNF protein levels in
patients with AD. These findings suggest that although galantamine did not affect
hippocampal neurotrophin synthesis in healthy mice, ChEIs may be able to restore
the compromised neurotrophin signaling in various disorders.
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5.1.4 The lack of galantamine neuroprotection in vitro
According to previous studies, ChEIs protect cultured hippocampal and cortical
neurons from various toxins, including glutamate and Aβ in vitro (Takada et al. 2003,
Noh et al. 2009). Curiously, these effects were observed in dissociated cultures,
which lack cholinergic innervation and thus the main source of ACh. Moreover,
neuroprotection requires higher concentration of drugs than required to inhibit AChE
suggesting other mechanism of action (Akaike et al. 2010). Antagonists of NAChRs,
Src family kinases, PI3K, and janus­associated kinase (JAK2) block the
neuroprotective effects (Takada­Takatori et al. 2006). In contrast, the MAPKK
inhibitor PD98059 does not affect protection. These findings led us to hypothesize
that ChEIs could protect cultured neurons through transactivation of Trk receptors. To
test this idea we studied the effect of galantamine on Aβ1­42 toxicity in the presence of
the Trk tyrosine kinase inhibitor, k252a. First, we treated cultured rat cortical neurons
with Aβ1­42 in different concentrations and measured the amount of viable cells 24
hours later using the MTT assay. Aβ1­42 dose­dependently reduced the capability of
neurons to convert tetrazolium dye into formazan (Fig. 17 A). Next, we treated
neurons with BDNF or galantamine in doses previously reported to protect neurons
in vitro (Takada­Takatori et al. 2006). We pretreated cortical neurons with
galantamine for two or 24 hours before Aβ1­42 treatment. According to earlier studies,
Figure 17. The lack of protective effect of galantamine against amyloid toxicity. Dose­
dependent toxicity of Aβ1­42 peptide (24 h) in cultured cortical neurons measured with the MTT
assay (A). Pretreatment with BDNF for two hours (B) or 24 hours (C) protected neurons from
amyloid toxicity and concomitant treatment with Trk kinase inhibitor k252a reversed the effect.
Galantamine (GAL) did not affect the viability of neurons treated with Aβ (B, C). The bars show
average viability of neurons in six parallel wells compared to untreated controls. ***: p < 0.001,
ANOVA and Tukey’s post hoc test.
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24 hour ChEI pretreatment is required for neuroprotection (Takada et al. 2003,
Takada­Takatori et al. 2006). Again, Aβ reduced the viability of neurons to 56.0%.
BDNF partially rescued the neurons, but not in the presence of k252, indicating that
BDNF protects neurons through TrkB activation (Fig. 17 B, C). Galantamine, on the
other hand, did not protect neurons. Thus, we were unable to repeat previous findings
and could not clarify the role of TrkB in the putative neuroprotective effect of ChEIs.
5.2 The effects of β­amyloid pathology on BDNF­TrkB signaling
Post­mortem studies suggest that BDNF­TrkB signaling is perturbed in patients with
AD. Apart from one study (Durany et al. 2000), widespread downregulation of
BDNF synthesis and protein levels have been consistently reported in patients with
AD (Phillips et al. 1991, Narisawa­Saito et al. 1996, Ferrer et al. 1999, Hock et al.
2000, Peng et al. 2005). Moreover, patients with AD may have less full­length TrkB
and increased levels of the truncated TrkB.T1 isoform in the brain (Connor et al.
1996, Ferrer et al. 1999). Based on in vitro studies, TrkB.T1 appears to act as a
dominant negative BDNF receptor, because neurotrophin binding to the truncated
receptor does not elicit activation of intracellular tyrosine kinase activity (Eide et al.
1996, Haapasalo et al. 2001). Thus, upregulation of TrkB.T1 together with decreased
availability of BDNF could disturb TrkB signaling and neuronal plasticity and
contribute to memory deficit in AD.
We wanted to study how increased Aβ accumulation and deposition in a mouse
model of early­onset familial AD affects brain BDNF­TrkB signaling, and if
impaired or enhanced BDNF­TrkB signaling would affect memory deficits induced
by amyloid pathology. We used APdE9 transgenic mice expressing human APP with
the Swedish mutation (K595N, K596L), and presenilin­1 with exon 9 deletion, two
mutations that lead to early­onset familial AD in humans. These mice start to develop
amyloid plaques in the hippocampus and cortex at four months of age followed by
emergence of memory impairment at 8­12 months of age (Savonenko et al. 2005,
Garcia­Alloza et al. 2006). To study the effect of impaired or enhanced BDNF­TrkB
signaling on learning and memory in APdE9 mice we crossed these mutant mice with
Bdnf+/­ mice and with mice overexpressing full­length (TrkB.TK) or truncated TrkB
(TrkB.T1). Overexpression of TrkB in these mice is driven by Thy 1.2 expression
cassette, which promotes receptor expression in postnatal neurons in the brain.
Consequently, TrkB signaling in the cortex and spatial learning are enhanced in
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5.2.1 Increased cortical BDNF and TrkB.T1 protein levels in APdE9 mutant mice
TrkB.TK mice and disrupted in TrkB.T1 mice (Saarelainen et al. 2000b, Koponen et
al. 2004). Our collaborators tested the animals in various behavioral assays, and sent
us the frozen brain tissue afterwards. We then analyzed protein levels of BDNF, full­
length TrkB and TrkB.T1, and TrkB receptor activity from the samples.
Table 6 summarizes BDNF, TrkB.T1, full­length TrkB, and phospho­TrkB protein
levels in the frontal cortex (FCX), parietal cortex (PCX), temporal cortex (TCX) and
the hippocampus (HC) of 13 months old wildtype, TrkB.T1, APdE9, and double
transgenic female mice. As expected, the TrkB.T1 protein levels were significantly
elevated in mice overexpressing the receptor compared to wildtype controls in all
brain areas. However, overexpression of TrkB.T1 was only two­fold, which is
significantly less than in original studies, where the amount of TrkB.T1 mRNA was
20­fold higher in TrkB.T1 transgenic mice (Saarelainen et al. 2000b). This could
indicate a loss in the copy number of the transgene during this period. Although
phosphorylation of TrkB was unaltered, AKT and ERK2 activity in the parietal cortex
and AKT and GSK3β in the dentate gyrus were lower in TrkB.T1 mice (II). Together
with the behavioral data, these changes indicate that two­fold overexpression of
TrkB.T1 has functional consequences.
Notably, TrkB.T1 protein levels were also elevated in cortical samples from APdE9
mutant mice. TrkB.T1 protein levels were highest in TrkB.T1/APdE9 double mutants
indicating that APdE9 and TrkB.T1 mutations had additive effects on TrkB.T1
expression. Our collaborators in this study showed in vitro that treatment of cortical
and hippocampal neurons with Aβ25–35 (25 μM) results a in rapid decline in full­
length TrkB protein levels, followed by significant accumulation of TrkB.T1 protein
levels in the next two days (II). These data indicate that increased Aβ production and
accumulation to plaques may lead to upregulation of TrkB.T1, and could thus explain
the earlier clinical findings of elevated TrkB.T1 levels in patients with AD (Connor et
al. 1996, Ferrer et al. 1999). Full­length TrkB protein levels, in contrast, were
unaltered in APdE9 mice. This finding is in contradiction with decreased TrkB levels
in AD patients (Ferrer et al. 1999). The decrease in TrkB immunoreactivity in
patients, however, was observed in tangle­bearing neurons, which are absent in
APdE9 mice (Ferrer et al. 1999).
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Table 6. Levels of BDNF, full length and truncated TrkB, and phosphorylated TrkB in
APdE9 and TrkB.T1 overexpressing mice. BDNF levels were analyzed with ELISA and
TrkB.FL, TrkB.T1 and TrkB.pY816 levels with Western blotting from 13 month old female mice
overexpressing truncated TrkB (TrkB.T1), in APdE9 double transgenic mice expressing human
familial Alzheimer’s disease mutations APPswe/PS1dE9 (APP; K595N, K596L) and presenilin­
1 exon 9 deletion, or both. All values are given as average +/­ SEM normalized to wildtype
controls. The effects of genotypes were analyzed using two­way ANOVA and bolded texts
indicate significant genotype effects. The number of animals in each group was between 8­12.
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BDNF protein levels in APdE9 mice, on the other hand, were elevated in all brain
areas apart from the hippocampus. Our findings agree previous studies on BDNF
protein levels in APP mutant mice (Burbach et al. 2004, Szapacs et al. 2004).
However, Peng et al. (2009) detected a significant decrease in BDNF mRNA levels
in some, but not all, AD mutant mouse lines. According to Peng and co­workers
(2009) different mutations in APP and PS1 favor production of different ratios of
Aβ1­42 and Aβ1­40 leading to formation of a variety of Aβ oligomers, which
differentially affect BDNF synthesis. Thus, data from different AD mutant mouse
lines is not directly comparable. Overexpression of TrkB.T1 decreased BDNF protein
levels in the parietal cortex and the hippocampus, and limited the increase induced by
APdE9 mutation in the temporal cortex. This was unsurprising because activity­
induced BDNF synthesis is known to be reduced in TrkB.T1 mice (Saarelainen et al.
2000a).
Notably, we did not detect elevated BDNF protein levels in the hippocampus, where
plaque density in APdE9 mice is lowest (Garcia­Alloza et al. 2006). Moreover, we
did not detect increased cortical BDNF levels in young APdE9 mice that did not have
visible amyloid plaques (III). Burbach et al. (2004) reported that increased BDNF
levels in their APP­Swe mutant mice correlated with amyloid load. Furthermore, they
detected BDNF protein in amyloid plaques. In agreement with this finding, our
immunohistochemical analysis of aged APdE9 mice revealed BDNF
immunoreactivity in Aβ plaques (III). This finding indicates that increased BDNF
levels in the cortex of APdE9 mutant mice may reflect accumulation of the protein in
amyloid deposits. The exact source of BDNF is unclear, but Burbach et al. (2004)
reported that glial cells associated with plaques increased their BDNF synthesis. In
our study, however, BDNF mRNA levels were unaltered (III). Notably, some groups
have detected BDNF protein in amyloid plaques in patients with AD (Ferrer et al.
1999, Murer et al. 1999). Ferrer et al. (1999) detected strong BDNF
immunoreactivity in dystrophic neurites surrounding plaques in AD patients. Apart
from localization similarities, however, our findings in APdE9 mouse are in obvious
contrast with decreased cortical BDNF protein levels in patients with AD. This
discrepancy is an important reminder that the APdE9 mouse is by no means an
accurate model of human sporadic AD. Instead, it combines overexpression of two
mutant proteins into a model of hyperaccelerated Aβ accumulation. Nevertheless, our
study shows that accumulation and deposition of Aβ directly affects BDNF­TrkB
signaling in various ways likely to undermine synaptic plasticity.
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The role of p75 in the adult CNS is still unclear, partially due to the lack of
established methods to detect receptor signaling. Moreover, the number of ligands,
co­receptors and signaling pathways makes finding a straightforward detection
method challenging. Proteolytic processing of the receptor, however, is regarded as
common event in p75 signaling in both trophic and apoptotic signaling (chapters
2.1.5 and 2.1.6). The resulting cleavage products, especially the soluble intracellular
domain, are difficult to detect and often require overexpression of the receptor
combined with proteasome inhibitors (Jung et al. 2003, Kanning et al. 2003).
Therefore, we developed a reporter gene assay described in detail in chapter 4.2.1. to
detect proteolytic processing of p75.
To show that cells process p75­GVP fusion protein normally we transfected
5.2.2 Impairment of BDNF­TrkB signaling exacerbates memory defects in
APdE9 mice
To test how genetic impairment or enhancement of BDNF­TrkB signaling affects
memory deficits in APdE9 mice our collaborators tested the double transgenic
mutants in the Morris water maze task. ApdE9 mice were significantly impaired on
this task, displaying increased latency to escape, longer swim path length, and
thigmotaxic behavior as evidenced by tendency to swim along arena walls (II).
TrkB.T1 male mice did not differ from wildtype controls, but TrkB.T1/APdE9
double transgenic mice performed worse than APdE9 single mutants did. These
results indicate that subtle overexpression of TrkB.T1 does not have a significant
effect on learning and memory on its own, but aggravates the memory deficits seen
in APdE9 mice. Moreover, Bdnf+/­/APdE9 double mutants performed worse than
single mutants indicating that loss of other Bdnf allele , similarly to overexpression
of TrkB.T1, worsened performance of APdE9 mice on the task (III). In contrast,
overexpression of TrkB.TK reduced escape latency (II). TrkB.TK/APdE9 double
transgenic mice also performed better than APdE9 single mutant mice as evidenced
by significantly shorter swim path length and decreased escape latencies. Moreover,
TrkB.TK/APdE9 transgenics spent more time in the target area compared to APdE9
mutants. These findings indicate that increased TrkB signaling may counteract
memory deficits induced by perturbed APP processing and Aβ generation.
5.3 Characterization of p75 cleavage reporter gene assay
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HEK293T cells with FLp75­GVP. We treated the cells with phorbol 12­myristate 13­
acetate (PMA), which activates metalloproteases through protein kinase C, and has
been shown to lead to proteolytic processing of p75 (Kanning et al. 2003). PMA (100
ng/ml, 40 min) induced the processing of p75­GVP as indicated by the appearance of
p75ICD­immunoreactive bands corresponding to the molecular weights of p75CTF­
GVP and p75ICD­GVP. (Fig. 18 A). The production of p75ICD­GVP was blocked by
pretreatment with the γ­secretase inhibitor DAPT, which also led to accumulation of
p75CTF­GVP. To show that our reporter gene assay is capable of detecting
processing of the receptor, we plated the cells on 96­well plates and co­transfected
them with p75 fusion proteins and a reporter plasmid. This time the cells were treated
overnight with PMA to allow for accumulation of luciferase. PMA increased
luciferase activity by approximately two­fold in HEK293T cells transfected with
FLp75­GVP (Fig. 18 B) and p75ECD/TM­GVP (Fig. 18 C). These data show that the
reporter gene assay can efficiently detect the regulated intramembrane proteolysis of
p75 in vitro.
The truncated and full­length constructs, however, differed significantly from each
other. We compared signal intensity from the HEK293T cells transfected with either
Figure 18. Detection of proteolytic processing of p75 with reporter gene assay.
Treatment of full­length p75­GVP (FLp75­GVP) transfected HEK293T cells with phorbol 12­
myristate 13­acetate (PMA, 100 ng/ml, 40 min) resulted in proteolytic processing of the
receptor (A). Pretreatment with DAPT (2 µM, 90 min) prevented formation of p75ICD and
promoted accumulation of p75CTF. PMA treatment increased luciferase activity in HEK293T
cells cotransfected with UAS_Luc2P and FLp75­GVP (B) or C­terminally truncated p75EC/TM­
GVP (C). Basal luciferase activity was 20­fold higher in cells transfected with FLp75­GVP than
in cells transfected with p75EC/TM­GVP (D). The bars are average of six parallel wells. LAC =
clasto­lactacystin β­lactone.
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full­length or truncated construct and found that with similar amount of transfected
DNA, the FLp75­GVP resulted in 20­fold higher basal luciferase activity than
p75EC/TM­GVP (Fig. 18 D). Several explanations may be suggested. First, the
translocation of Gal4/VP16 to the nucleus may be less efficient in the absence of
interaction between p75ICD and its intracellular signaling partners. Second, Lac
increased luciferase signal from cells transfected with p75EC/TM more efficiently
(Fig. 18 B, C), indicating that the GVP domain in the absence of p75ICD may be
susceptible to proteasomal degradation. Third, subcellular localization of the
constructs may be different. Fourth, overexpression of p75 may lead to constitutive
activation (Rabizadeh et al. 1993) and possibly proteolysis of the receptor by an as
yet unknown mechanism. Constitutive processing of the overexpressed FLp75­GVP
could also explain the loss of assay dynamics: the γ­secretase inhibitor DAPT (2
µM) efficiently inhibited the production of p75ICD, but prevented the increase of
luciferase activity only in cells expressing p75EC/TM­GVP, but not FLp75­GVP
(Fig. 18 A­C). It is conceivable that ongoing constitutive processing of the receptor
masked the subtle change induced by the treatment. Careful optimization of
expression levels will be necessary for further in vitro experiments.
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The scientific rationale to target neurotrophin signaling for the treatment of AD still
exists 30 years after the neurotrophin hypothesis of the disease (Hefti 1983). After
decades of NGF research there is hardly any doubt if activation of TrkA receptors
would support cholinergic function in AD. Delivery of NGF to the basal forebrain
with adeno­associated virus (AAV2­NGF, CERE­110) is currently in phase II clinical
trial and, based on preclinical models, this treatment is very likely to have trophic
effects on cholinergic neurons (Bishop et al. 2008). Furthermore, the notable
plasticity of BFCNs is encouraging for NGF­based therapies: NGF is capable of
restoring the cholinergic function in Ts65Dn and anti­NGF mice after life­long
atrophy (Cooper et al. 2001, Capsoni et al. 2002). As most of the cholinergic neurons
do not actually die in AD, but shrink and lose their phenotype instead, activation of
TrkA signaling could potentially restore their function even in late stages of disease
(Vogels et al. 1990, Gilmor et al. 1999). The fundamental question, however, is
whether activation of TrkA has any significant impact on the progression of AD.
Maintenance of cholinergic neurotransmission via TrkA should somehow propagate
the survival of neurons in target areas of cholinergic innervation. Otherwise, NGF
gene therapy may turn out to be nothing but a highly invasive way to increase
cholinergic neurotransmission, an effect that can be achieved with current
pharmacotherapies. Curiously, work on the anti­NGF mouse suggests the existence
of a vicious cycle where perturbation of NGF action promotes Aβ pathology, which
in turn interferes with trophic actions of NGF (Fig. 7). Should such interdependency
exist, enhancement of TrkA activity could indeed have benefits beyond the
cholinergic system. More preclinical studies on the effects of NGF on Aβ
accumulation in mouse models of AD are warranted.
Synaptic failure and synapse loss in AD, on the other hand, suggest molecular
mechanisms underlying synaptic plasticity as potential therapeutic targets. The
BDNF receptor TrkB is ideally located in degenerating neurons of the cortex and the
hippocampus (Yan et al. 1997, Drake et al. 1999). Although these neurons do not
depend on BDNF for their survival (Rauskolb et al. 2010), the neurotrophin is
capable of protecting them from Aβ toxicity and from lesions in vivo (Nagahara et al.
2009). Moreover, overexpression of BDNF and genetic enhancement of TrkB
activity improved learning and memory in mouse models of familial AD (II,
Nagahara et al. 2009). Importantly, BDNF reversed synapse loss in the APP mutant
6. DISCUSSION
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mice (Nagahara et al. 2009). Moreover, 7, 8­dihydroxyflavone, an alleged TrkB
agonist, reversed memory deficit in AD mutant mice (Devi and Ohno 2012). When
the first signs of memory impairment appear in patients, a significant number of
neurons and synapses are already lost (Gomez­Isla et al. 1996, Kordower et al. 2001,
Scheff et al. 2006, Scheff et al. 2007). Activation of TrkB receptor at this point could
enhance synaptic transmission and protect the remaining synapses and neurons.
Ideally, to prevent pathogenesis of the one needs to be able to identify and treat
patients at risk of developing dementia years before the onset of symptoms.
Treatment of AD with neurotrophins would require invasive surgery. Moreover, since
both cholinergic and non­cholinergic degeneration are widespread in AD, effective
treatment with growth factors would require delivery of the peptides to a number of
locations in the brain. Poor diffusion of BDNF is very likely to make such an
approach unfeasible (Morse et al. 1993). Clearly, activation of Trk receptors with
small molecules would be more convenient. Such pharmacological approaches could
include molecules that act as Trk receptor agonists; transactivate the receptors, or
otherwise potentiate receptor signaling; promote neurotrophin synthesis, release or
maturation; or prevent neurotrophin degradation. Ideally, the novel drugs should
target both TrkA and TrkB receptors, and activate them independently of
neurotrophins and cholinergic neurotransmission. This way drug effect would persist
amid degeneration of the cholinergic system and potential perturbations in
neurotrophin action in AD (Podlesniy et al. 2006, Bruno et al. 2009, Kichev et al.
2009). The failure of retrograde transport of neurotrophin signaling complexes,
however, poses a serious challenge for any therapeutic strategy based on the
activation of Trk receptors (Mufson et al. 1995).
Another potential way to target neurotrophin signaling is inhibition of p75 function.
Massa et al. (2006) identified p75 ligands, which prevented cell death induced by Aβ
in young hippocampal neuron cultures, prevented neurite dystrophy in mature
cultures (Yang et al. 2008), and reversed memory deficits in a mouse model of
familial AD (Knowles et al. 2013). Indeed, inhibition of p75 signaling may prevent
detrimental effects of Aβ on BFCNs, and favor trophic effects of NGF on cholinergic
neurons (Sotthibundhu et al. 2008, Knowles et al. 2009). Theoretically, p75 ligands
could also prevent detrimental effects of proNGF and Aβ on non­cholinergic neurons.
Neurons in the CNS increase p75 expression in response to various traumas, and
binding of proNGF to the receptor promotes post­traumatic apoptosis (2.1.5). The
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evidence supporting a similar role for p75 in AD is, however, unconvincing. Given
the implications this question has on the potential of p75 as target for novel drugs, it
is surprising that a simple quantitative PCR approach to analyze receptor mRNA
levels in target areas of cholinergic innervation in post­mortem AD patients has not
been taken. Moreover, the limited expression of p75 in the mature CNS casts a
shadow of doubt on the translatability of in vitro findings that the receptor mediates
Aβ­induced neurite dystrophy of cultured hippocampal neurons (Knowles et al.
2009). Connecting synaptic failure, synapse loss, and hippocampal and cortical
neuronal degeneration in adult APP mutant mice to p75 signaling would significantly
increase confidence in the receptor as target for drug discovery.
The absence of good animal models is a major challenge for predictions of
therapeutic efficacy of new drugs. Testing NGF­based therapies in the anti­NGF
mouse would be redundant, despite the apparent face validity of the model. Mouse
models based on familial mutations in APP or PS1, on the other hand, bear good
construct validity, but mimic accurately only a small minority of human AD cases. It
may be too much to blame this for the failure of amyloid immunotherapies in clinical
trials, but undoubtedly the treatments were succesful preclinically in APP­based
mouse models (Mullard 2012). Ideally, new treatments should be tested both in APP­
and NGF­based animal models. Furthermore, comparative studies of these models
could elucidate the interrelationships between NGF­, BDNF­ and Aβ signaling in
AD. Our findings about BDNF signaling in APdE9 mice should be complemented
with analyses of NGF signaling in the same model. Similarly, changes in BDNF­
TrkB signaling in anti­NGF mice deserve a closer look.
Understanding the actions of existing drugs on brain neurotrophin signaling is the
first step towards development of novel therapies. Memantine, an uncompetitive
NMDA receptor antagonist indicated for moderate­to­severe AD, induces widespread
BDNF synthesis in the rat and monkey brain (Marvanová et al. 2001, Meisner et al.
2008). Memantine has beneficial effect on cognition, mood, behavior and the ability
to perform activities in patients with advanced AD, but the effect is modest in early
AD (McShane et al. 2006, Schneider et al. 2011). Whether increased BDNF synthesis
plays a role in its method of action is unclear, but memantine has been reported to
protect dopaminergic neurotransmission in SIV­infected rhesus monkeys, an effect
that could be potentially mediated through TrkB (Meisner et al. 2008). Long­term
studies on the effect of memantine on the progression from MCI to AD are
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warranted. Additionally, commonly used antidepressant drugs elicit effects on
neurotrophin signaling: they activate TrkB receptors in the mouse brain (Saarelainen
et al. 2003, Rantamäki et al. 2007), increase BDNF synthesis (Nibuya et al. 1995),
enhance synaptic plasticity (Karpova et al. 2011), and reopen developmental­like
plasticity in the adult rodent brain (Vetencourt et al. 2008, Karpova et al. 2011). Even
though antidepressants are commonly used to treat depression and behavioral
symptoms in patients with AD, clinical trials have not been designed to assess their
effects on cognitive capabilities or progression of the disease (Henry et al. 2011). As
inexpensive, safe, and reasonably well tolerated drugs, antidepressants should be
thoroughly studied in APP­ and NGF­based mouse models, as well as in clinical
trials.
Finally, our findings suggest that ChEIs, the current first­line therapy against AD,
activate neurotrophin signaling in the brain. As activators of both TrkA and TrkB, the
ChEIs appear to be ideal neurotrophic drugs. However, even though some studies
indicate that ChEIs may have modest disease­modifying effects, the consensus from
20 years of clinical experience is that they do not stop progression of the disease
(Mori et al. 2006, Russ and Morling 2012). This underlines the importance of
resolving where and how ChEIs activate Trk receptors, whether the rapid
phosphorylation of Trk receptors sustains in chronic treatment and if it translates into
long­term neurotrophic effects, and if ChEIs are indeed neurotrophic drugs in
patients with AD. If so, it will be imperative to understand why they are unable to
prevent progression of the disease. This will enable the evaluation of neurotrophin­
based treatment strategies in general, and facilitate the development of novel,
enhanced neurotrophic drugs for AD.
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7. SUMMARY AND CONCLUSIONS
ChEIs, the current first­line drugs for AD, activate TrkA and TrkB neurotrophin
receptors in the mouse hippocampus. Cholinergic activation of Trk receptors
requires simultaneous stimulation of nicotinic and muscarinic receptors. Drug­
induced Trk receptor phosphorylation is unaltered in Sortilin1­/­ mice and
Bdnf+/­ mice despite defects in anterograde transport and synaptic targeting of
Trk receptors, and BDNF signaling in these mice.
Increased Aβ production and deposition in the APdE9 mouse model of familial
AD perturbs BDNF­TrkB signaling indicated by accumulation of BDNF in
amyloid plaques and upregulation of dominant negative TrkB.T1.
Overexpression of TrkB.T1 or knocking down BDNF expression exacerbates
memory impairment in APdE9 mice, while overexpresson of TrkB.TK
alleviates these deficits. These findings elucidate functional and neurobiological
interactions between Aβ pathology and BDNF­TrkB signaling and provide
support for TrkB receptor as a potential target for novel pharmacotherapies
against AD.
p75 cleavage reporter gene assay is a sensitive and efficient method to detect
proteolytic processing of the receptor in vitro. Our knock­in mouse could
enable accurate temporal and spatial localization of p75 signaling in healthy,
aged and injured nervous system and serve as a tool to discover inhibitors of
detrimental p75 signaling.
1.
2.
3.
82
Akaike, A., Takada­Takatori, Y., Kume, T. & Izumi, Y. (2010) Mechanisms of neuroprotective effects of
nicotine and acetylcholinesterase inhibitors: Role of alpha 4 and alpha 7 receptors in neuroprotection.
Journal of Molecular Neuroscience 40, 211­216.
Alderson, R.F., Alterman, A.L., Barde, Y.A. & Lindsay, R.M. (1990) Brain­derived neurotrophic factor
increases survival and differentiated functions of rat septal cholinergic neurons in culture. Neuron 5,
297­306.
Allard, S., Leon, W.C., Pakavathkumar, P., Bruno, M.A., Ribeiro­da­Silva, A. & Cuello, A.C. (2012)
Impact of the NGF maturation and degradation pathway on the cortical cholinergic system phenotype.
Journal of Neuroscience 32, 2002­2012.
Apartis, E., Poindessous­Jazat, F.R., Lamour, Y.A. & Bassant, M.H. (1998) Loss of rhythmically
bursting neurons in rat medial septum following selective lesion of septohippocampal cholinergic
system. Journal of Neurophysiology 79, 1633­1642.
Appel, S.H. (1981) A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism,
and Alzheimer disease. Annals of Neurology 10, 499­505.
Bamji, S.X., Majdan, M., Pozniak, C.D., Belliveau, D.J., Aloyz, R., Kohn, J., Causing, C.G. & Miller,
F.D. (1998) The p75 neurotrophin receptor mediates neuronal apoptosis and is essential for naturally
occurring sympathetic neuron death. Journal of Cell Biology 140, 911­923.
Barker, P.A. & Shooter, E.M. (1994) Disruption of Ngf binding to the low­affinity neurotrophin receptor
P75(lntr) reduces Ngf binding to TrkA on PC12 Cells. Neuron 13, 203­215.
Barker­Gibb, A.L., Dougherty, K.D., Einheber, S., Drake, C.T. & Milner, T.A. (2001) Hippocampal
tyrosine kinase A receptors are restricted primarily to presynaptic vesicle clusters. Journal of
Comparative Neurology 430, 182­199.
Bartus, R.T., Dean, R.L., Beer, B. & Lippa, A.S. (1982) The cholinergic hypothesis of geriatric memory
dysfunction. Science 217, 408­417.
Bath, K.G., Mandairon, N., Jing, D., Rajagopal, R., Kapoor, R., Chen, Z., Khan, T., Proenca, C.C.,
Kraemer, R., Cleland, T.A., Hempstead, B.L., Chao, M.V. & Lee, F.S. (2008) Variant brain­derived
neurotrophic factor (Val66Met) alters adult olfactory bulb neurogenesis and spontaneous olfactory
discrimination. Journal of Neuroscience 28, 2383­2393.
Beattie, M.S., Harrington, A.W., Lee, R., Kim, J.Y., Boyce, S.L., Longo, F.M., Bresnahan, J.C.,
Hempstead, B.L. & Yoon, S.O. (2002) ProNGF induces p75­mediated death of oligodendrocytes
following spinal cord injury. Neuron 36, 375­386.
Bertrand, M.J.M., Kenchappa, R.S., Andrieu, D., Leclercq­Smekens, M., Nguyen, H.N.T., Carter, B.D.,
Muscatelli, F., Barker, P.A. & De Backer, O. (2008) NRAGE, a p75NTR adaptor protein, is required for
developmental apoptosis in vivo. Cell Death and Differentiation 15, 1921­1929.
REFERENCES
83
Birks, J. (2006) Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic
Reviews (1), 10.1002/14651858.CD005593.
Bishop, K.M., Hofer, E.K., Mehta, A., Ramirez, A., Sun, L., Tuszynski, M. & Bartus, R.T. (2008)
Therapeutic potential of CERE­110 (AAV2­NGF): Targeted, stable, and sustained NGF delivery and
trophic activity on rodent basal forebrain cholinergic neurons. Experimental Neurology 211, 574­584.
Blochl, A. & Thoenen, H. (1995) Characterization of nerve growth factor (Ngf) release from
hippocampal neurons ­ evidence for a constitutive and an unconventional sodium­dependent regulated
pathway. European Journal of Neuroscience 7, 1220­1228.
Blöchl, A. & Blöchl, R. (2007) A cell­biological model of p75(NTR) signaling. Journal of
Neurochemistry 102, 289­305.
Boissiere, F., Hunot, S., Faucheux, B., Hersh, L.B., Agid, Y. & Hirsch, E.C. (1997) Trk neurotrophin
receptors in cholinergic neurons of patients with Alzheimer's disease. Dementia and Geriatric Cognitive
Disorders 8, 1­8.
Bond, M., Rogers, G., Peters, J., Anderson, R., Hoyle, M., Miners, A., Moxham, T., Davis, S., Thokala,
P., Wailoo, A., Jeffreys, M. & Hyde, C. (2012) The effectiveness and cost­effectiveness of donepezil,
galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of
Technology Appraisal No. 111): a systematic review and economic model. Health Technology
Assessment 16, 1­470.
Braak, H. & Braak, E. (1991) Neuropathological staging of Alzheimer­related changes. Acta
Neuropathologica 82, 239­259.
Brigadski, T., Hartmann, M. & Lessmann, V. (2005) Differential vesicular targeting and time course of
synaptic secretion of the mammalian neurotrophins. Journal of Neuroscience 25, 7601­7614.
Bruno, M.A. & Cuello, A.C. (2006) Activity­dependent release of precursor nerve growth factor,
conversion to mature nerve growth factor, and its degradation by a protease cascade. Proceedings of the
National Academy of Sciences of the United States of America 103, 6735­6740.
Bruno, M.A. & Cuello, A.C. (2012) Cortical peroxynitration of nerve growth factor in aged and
cognitively impaired rats. Neurobiology of aging 33, 1927­1937.
Bruno, M.A., Leon, W.C., Fragoso, G., Mushynski, W.E., Almazan, G. & Cuello, A.C. (2009) Amyloid
beta­induced nerve growth factor dysmetabolism in Alzheimer disease. Journal of Neuropathology and
Experimental Neurology 68, 857­869.
Burbach, G.J., Hellweg, R., Haas, C.A., Del Turco, D., Deicke, U., Abramowski, D., Jucker, M.,
Staufenbiel, M. & Deller, T. (2004) Induction of brain­derived neurotrophic factor in plaque­associated
glial cells of aged APP23 transgenic mice. Journal of Neuroscience 24, 2421­2430.
Buttigieg, H., Kawaja, M.D. & Fahnestock, M. (2007) Neurotrophic activity of proNGF in vivo.
Experimental Neurology 204, 832­835.
84
Capsoni, S., Ugolini, G., Comparini, A., Ruberti, F., Berardi, N. & Cattaneo, A. (2000) Alzheimer­like
neurodegeneration in aged anti nerve growth factor transgenic mice. Proceedings of the National
Academy of Sciences of the United States of America 97, 6826­6831.
Capsoni, S. & Cattaneo, A. (2006) On the molecular basis linking Nerve Growth Factor (NGF) to
Alzheimer's disease. Cellular and Molecular Neurobiology 26, 619­633.
Capsoni, S., Giannotta, S. & Cattaneo, A. (2002) Nerve growth factor and galantamine ameliorate early
signs of neurodegeneration in anti­nerve growth factor mice. Proceedings of the National Academy of
Sciences of the United States of America 99, 12432­12437.
Capsoni, S., Giannotta, S., Stebel, M., Garcia, A.A., de Rosa, R., Villetti, G., Imbimbo, B.P., Pietra, C.
& Cattaneo, A. (2004) Ganstigmine and donepezil improve neurodegeneration in AD11 antinerve
growth factor transgenic mice. American Journal of Alzheimer's Disease and Other Dementias 19, 153­
160.
Capsoni, S., Tiveron, C., Vignone, D., Amato, G. & Cattaneo, A. (2010) Dissecting the involvement of
tropomyosin­related kinase A and p75 neurotrophin receptor signaling in NGF deficit­induced
neurodegeneration. Proceedings of the National Academy of Sciences 107, 12299­12304.
Carter, B.D., Kaltschmidt, C., Kaltschmidt, B., Offenhauser, N., BohmMatthaei, R., Baeuerle, P.A. &
Barde, Y.A. (1996) Selective activation of NF­kappa B by nerve growth factor through the neurotrophin
receptor p75. Science 272, 542­545.
Casaccia­Bonnefil, P., Carter, B.D., Dobrowsky, R.T. & Chao, M.V. (1996) Death of oligodendrocytes
mediated by the interaction of nerve growth factor with its receptor p75. Nature 383, 716­719.
Ceni, C., Kommaddi, R.P., Thomas, R., Vereker, E., Liu, X.Y., McPherson, P.S., Ritter, B. & Barker,
P.A. (2010) The p75NTR intracellular domain generated by neurotrophin­induced receptor cleavage
potentiates Trk signaling. Journal of Cell Science 123, 2299­2307.
Chakravarthy, B., Menard, M., Ito, S., Gaudet, C., Dal Pra, I., Armato, U. & Whitfield, J. (2012)
Hippocampal membrane­associated p75(NTR) levels are Increased in Alzheimer's disease. Journal of
Alzheimers Disease 30, 675­684.
Chao, M.V., Bothwell, M.A., Ross, A.H., Koprowski, H., Lanahan, A.A., Buck, C.R. & Sehgal, A.
(1986) Gene transfer and molecular cloning of the human ngf receptor. Science 232, 518­521.
Chapman, P.F., White, G.L., Jones, M.W., Cooper­Blacketer, D., Marshall, V.J., Irizarry, M., Younkin,
L., Good, M.A., Bliss, T.V.P., Hyman, B.T., Younkin, S.G. & Hsiao, K.K. (1999) Impaired synaptic
plasticity and learning in aged amyloid precursor protein transgenic mice. Nature Neuroscience 2, 271­
276.
Charalampopoulos, I., Vicario, A., Pediaditakis, I., Gravanis, A., Simi, A. & Ibanez, C.F. (2012) Genetic
Dissection of Neurotrophin Signaling through the p75 Neurotrophin Receptor. Cell Reports 2, 1563­
1570.
85
Chen, Z.Y., Ieraci, A., Teng, H., Dall, H., Meng, C.X., Herrera, D.G., Nykjaer, A., Hempstead, B.L. &
Lee, F.S. (2005) Sortilin controls intracellular sorting of brain­derived neurotrophic factor to the
regulated secretory pathway. Journal of Neuroscience 25, 6156­6166.
Conner, J.M., Franks, K.M., Titterness, A.K., Russell, K., Merrill, D.A., Christie, B.R., Sejnowski, T.J.
& Tuszynski, M.H. (2009) NGF is essential for hippocampal plasticity and learning. Journal of
Neuroscience 29, 10883­10889.
Connor, B., Young, D., Lawlor, P., Gai, W., Waldvogel, H., Faull, R.L.M. & Dragunow, M. (1996) Trk
receptor alterations in Alzheimer's disease. Molecular Brain Research 42, 1­17.
Connor, B., Young, D., Yan, Q., Faull, R.L.M., Synek, B. & Dragunow, M. (1997) Brain­derived
neurotrophic factor is reduced in Alzheimer's disease. Molecular Brain Research 49, 71­81.
Cooper, J.D., Salehi, A., Delcroix, J.D., Howe, C.L., Belichenko, P.V., Chua­Couzens, J., Kilbridge, J.F.,
Carlson, E.J., Epstein, C.J. & Mobley, W.C. (2001) Failed retrograde transport of NGF in a mouse
model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF
infusion. Proceedings of the National Academy of Sciences of the United States of America 98, 10439­
10444.
Costantini, C., Weindruch, R., Della Valle, G. & Puglielli, L. (2005) TrkA­to­p75(NTR) molecular
switch activates amyloid beta­peptide generation during aging. Biochemical Journal 391, 59­67.
Coulson, E.J., May, L.M., Osborne, S.L., Reid, K., Underwood, C.K., Meunier, F.A., Bartlett, P.F. &
Sah, P. (2008) p75 neurotrophin receptor mediates neuronal cell death by activating GIRK channels
through phosphatidylinositol 4,5­bisphosphate. Journal of Neuroscience 28, 315­324.
Coulson, E.J., Reid, K., Baca, M., Shipham, K.A., Hulett, S.M., Kilpatrick, T.J. & Bartlett, P.F. (2000)
Chopper, a new death domain of the p75 neurotrophin receptor that mediates rapid neuronal cell death.
Journal of Biological Chemistry 275, 30537­30545.
Counts, S.E., Nadeem, M., Wuu, J., Ginsberg, S.D., Saragovi, H.U. & Mufson, E.J. (2004) Reduction of
cortical TrkA but not p75(NTR) protein in early­stage Alzheimer's disease. Annals of Neurology 56,
520­531.
Crowley, C., Spencer, S.D., Nishimura, M.C., Chen, K.S., Pittsmeek, S., Armanini, M.P., Ling, L.H.,
Mcmahon, S.B., Shelton, D.L., Levinson, A.D. & Phillips, H.S. (1994) Mice lacking nerve growth
factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic
neurons. Cell 76, 1001­1011.
Crutcher, K.A., Scott, S.A., Liang, S., Everson, W.V. & Weingartner, J. (1993) Detection of NGF­like
activity in human brain tissue: increased levels in Alzheimer's disease. Journal of Neuroscience 13,
2540­2550.
Davies, A.M., Lee, K.F. & Jaenisch, R. (1993) P75­Deficient Trigeminal Sensory Neurons have an
Altered Response to Ngf but Not to Other Neurotrophins. Neuron 11, 565­574.
86
Davies, C.A., Mann, D.M.A., Sumpter, P.Q. & Yates, P.O. (1987) A quantitative morphometric analysis
of the neuronal and synaptic content of the frontal and temporal Cortex in patients with Alzheimers
disease. Journal of the Neurological Sciences 78, 151­164.
Davies, P. & Maloney, A.J.F. (1976) Selective loss of central cholinergic neurons in Alzheimers disease.
Lancet 2, 1403­1403.
Davis, K.L., Mohs, R.C., Marin, D., Purohit, D.P., Perl, D.P., Lantz, M., Austin, G. & Haroutunian, V.
(1999) Cholinergic markers in elderly patients with early signs of Alzheimer disease. Journal of the
American Medical Association 281, 1401­1406.
De Rosa, R., Garcia, A.A., Braschi, C., Capsoni, S., Maffei, L., Berardi, N. & Cattaneo, A. (2005)
Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11
anti­NGF transgenic mice. Proceedings of the National Academy of Sciences of the United States of
America 102, 3811­3816.
DeKosky, S.T., Ikonomovic, M.D., Styren, S.D., Beckett, L., Wisniewski, S., Bennett, D.A., Cochran,
E.J., Kordower, J.H. & Mufson, E.J. (2002) Upregulation of choline acetyltransferase activity in
hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Annals of
Neurology 51, 145­155.
Deppmann, C.D., Mihalas, S., Sharma, N., Lonze, B.E., Niebur, E. & Ginty, D.D. (2008) A Model for
Neuronal Competition During Development. Science 320, 369­373.
Devi, L. & Ohno, M. (2012) 7,8­Dihydroxyflavone, a Small­Molecule TrkB Agonist, Reverses Memory
Deficits and BACE1 Elevation in a Mouse Model of Alzheimer's Disease. Neuropsychopharmacology
37, 434­444.
Dieni, S., Matsumoto, T., Dekkers, M., Rauskolb, S., Ionescu, M.S., Deogracias, R., Gundelfinger, E.D.,
Kojima, M., Nestel, S., Frotscher, M. & Barde, Y. (2012) BDNF and its pro­peptide are stored in
presynaptic dense core vesicles in brain neurons. Journal of Cell Biology 196, 775­788.
D'Intino, G., Paradisi, M., Fernandez, M., Giuliani, A., Aloe, L., Giardino, L. & Calzà, L. (2005)
Cognitive deficit associated with cholinergic and nerve growth factor down­regulation in experimental
allergic encephalomyelitis in rats. Proceedings of the National Academy of Sciences of the United States
of America 102, 3070­3075.
DiStefano, P.S., Friedman, B., Radziejewski, C., Alexander, C., Boland, P., Schick, C.M., Lindsay, R.M.
& Wiegand, S.J. (1992) The Neurotrophins Bdnf, Nt­3, and Ngf Display Distinct Patterns of Retrograde
Axonal­Transport in Peripheral and Central Neurons. Neuron 8, 983­993.
Dougherty, K.D. & Milner, T.A. (1999) p75(NTR) immunoreactivity in the rat dentate gyrus is mostly
within presynaptic profiles but is also found in some astrocytic and postsynaptic profiles. Journal of
Comparative Neurology 407, 77­91.
Drake, C.T., Milner, T.A. & Patterson, S.L. (1999) Ultrastructural Localization of Full­Length trkB
Immunoreactivity in Rat Hippocampus Suggests Multiple Roles in Modulating Activity­Dependent
Synaptic Plasticity. Journal of Neuroscience 19, 8009­8026.
87
Durany, N., Michel, T., Kurt, J., Cruz­Sanchez, F.F., Cervos­Navarro, J. & Riederer, P. (2000) Brain­
derived neurotrophic factor and neurotrophin­3 levels in Alzheimer's disease brains. International
Journal of Developmental Neuroscience 18, 807­813.
Eide, F.F., Vining, E.R., Eide, B.L., Zang, K., Wang, X. & Reichardt, L.F. (1996) Naturally Occurring
Truncated trkB Receptors Have Dominant Inhibitory Effects on Brain­Derived Neurotrophic Factor
Signaling. Journal of Neuroscience 16, 3123­3129.
Ernfors, P., Wetmore, C., Olson, L. & Persson, H. (1990) Identification of Cells in Rat­Brain and
Peripheral­Tissues Expressing Messenger­Rna for Members of the Nerve Growth­Factor Family.
Neuron 5, 511­526.
Fagan, A.M., Garber, M., Barbacid, M., Silos­Santiago, I. & Holtzman, D.M. (1997) A role for TrkA
during maturation of striatal and basal forebrain cholinergic neurons in vivo. Journal of Neuroscience
17, 7644­7654.
Fahnestock, M., Michalski, B., Xu, B. & Coughlin, M.D. (2001) The Precursor Pro­Nerve Growth
Factor Is the Predominant Form of Nerve Growth Factor in Brain and Is Increased in Alzheimer's
Disease. Molecular and Cellular Neuroscience 18, 210­220.
Ferrer, I., Marin, C., Rey, M.J., Ribalta, T., Goutan, E., Blanco, R., Tolosa, E. & Marti, E. (1999) BDNF
and full­length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic
strategies. Journal of Neuropathology and Experimental Neurology 58, 729­739.
Frade, J.M., RodriguezTebar, A. & Barde, Y.A. (1996) Induction of cell death by endogenous nerve
growth factor through its p75 receptor. Nature 383, 166­168.
French, S.J., Humby, T., Horner, C.H., Sofroniew, M.V. & Rattray, M. (1999) Hippocampal
neurotrophin and trk receptor mRNA levels are altered by local administration of nicotine, carbachol
and pilocarpine. Molecular Brain Research 67, 124­136.
Friedman, W.J. (2000) Neurotrophins induce death of hippocampal neurons via the p75 receptor. Journal
of Neuroscience 20, 6340­6346.
Gall, C.M. & Isackson, P.J. (1989) Limbic Seizures Increase Neuronal Production of Messenger­Rna for
Nerve Growth­Factor. Science 245, 758­761.
Garcia­Alloza, M., Robbins, E.M., Zhang­Nunes, S.X., Purcell, S.M., Betensky, R.A., Raju, S., Prada,
C., Greenberg, S.M., Bacskai, B.J. & Frosch, M.P. (2006) Characterization of amyloid deposition in the
APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiology of Disease 24, 516­524.
Gatzinsky, K.P., Haugland, R.P., Thrasivoulou, C., Orike, N., Budi­Santoso, A.W. & Cowen, T. (2001)
p75 and TrkA receptors are both required for uptake of NGF in adult sympathetic neurons: use of a
novel fluorescent NGF conjugate. Brain Research 920, 226­238.
Geerts, H., Guillaumat, P., Grantham, C., Bode, W., Anciaux, K. & Sachak, S. (2005) Brain levels and
acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits. Brain
Research, 1033, 186­193.
88
Geetha, T., Kenchappa, R.S., Wooten, M.W. & Carter, B.D. (2005) TRAF6­mediated ubiquitination
regulates nuclear translocation of NRIF, the p75 receptor interactor. The EMBO Journal 24, 3859­3868.
Gilmor, M.L., Erickson, J.D., Varoqui, H., Hersh, L.B., Bennett, D.A., Cochran, E.J., Mufson, E.J. &
Levey, A.I. (1999) Preservation of nucleus basalis neurons containing choline acetyltransferase and the
vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's
disease. Journal of Comparative Neurology 411, 693­704.
Ginsberg, S.D., Che, S.L., Wuu, J., Counts, S.E. & Mufson, E.J. (2006) Down regulation of trk but not
p75(NTR) gene expression in single cholinergic basal forebrain neurons mark the progression of
Alzheimer's disease. Journal of Neurochemistry 97, 475­487.
Gnahn, H., Hefti, F., Heumann, R., Schwab, M.E. & Thoenen, H. (1983) NGF­mediated increase of
choline acetyltransferase (ChAT) in the neonatal rat forebrain: evidence for a physiological role of NGF
in the brain?. Brain Research 285, 45­52.
Goedert, M., Fine, A., Hunt, S.P. & Ullrich, A. (1986) Nerve growth factor mRNA in peripheral and
central rat tissues and in the human central nervous system: lesion effects in the rat brain and levels in
Alzheimer's disease. Brain Research 387, 85­92.
Gomez­Isla, T., Price, J.L., McKeel, D.W., Morris, J.C., Growdon, J.H. & Hyman, B.T. (1996) Profound
loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. Journal of
Neuroscience 16, 4491­4500.
Goodman, L.J., Valverde, J., Lim, F., Geschwind, M.D., Federoff, H.J., Geller, A.I. & Hefti, F. (1996)
Regulated release and polarized localization of brain­derived neurotrophic factor in hippocampal
neurons. Molecular and Cellular Neuroscience 7, 222­238.
Greferath, U., Bennie, A., Kourakis, A., Bartlett, P.F., Murphy, M. & Barrett, G.L. (2000) Enlarged
cholinergic forebrain neurons and improved spatial learning in p75 knockout mice. European Journal of
Neuroscience 12, 885­893.
Greferath, U., Trieu, J. & Barrett, G.L. (2012) The p75 neurotrophin receptor has nonapoptotic
antineurotrophic actions in the basal forebrain. Journal of Neuroscience Research 90, 278­287.
Griesbeck, O., Canossa, M., Campana, G., Gartner, A., Hoener, M.C., Nawa, H., Kolbeck, R. &
Thoenen, H. (1999) Are there differences between the secretion characteristics of NGF and BDNF?
Implications for the modulatory role of neurotrophins in activity­dependent neuronal plasticity.
Microscopy Research and Technique 45, 262­275.
Haapasalo, A., Koponen, E., Hoppe, E., Wong, G. & Castren, E. (2001) Truncated trkB.T1 is dominant
negative inhibitor of trkB.TK+­mediated cell survival. Biochemical and Biophysical Research
Communications 280, 1352­1358.
Hallbook, F., Ibanez, C.F. & Persson, H. (1991) Evolutionary Studies of the Nerve Growth­Factor
Family Reveal a Novel Member Abundantly Expressed in Xenopus Ovary. Neuron 6, 845­858.
Hardy, J.A. & Higgins, G.A. (1992) Alzheimers­Disease ­ the Amyloid Cascade Hypothesis. Science
256,184­185.
89
Harrington, A.W., Leiner, B., Blechschmitt, C., Arevalo, J.C., Lee, R., Mörl, K., Meyer, M., Hempstead,
B.L., Yoon, S.O. & Giehl, K.M. (2004) Secreted proNGF is a pathophysiological death­inducing ligand
after adult CNS injury. Proceedings of the National Academy of Sciences of the United States of
America 101, 6226­6230.
Hefti, F. (1986) Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial
transections. Journal of Neuroscience 6, 2155­2162.
Hefti, F. (1983) Is Alzheimer­Disease Caused by Lack of Nerve Growth­Factor. Annals of Neurology
13, 109­110.
Hefti, F., Dravid, A. & Hartikka, J. (1984) Chronic Intraventricular­Injections of Nerve Growth­Factor
Elevate Hippocampal Choline­Acetyltransferase Activity in Adult­Rats with Partial Septo­Hippocampal
Lesions. Brain Research 293, 305­311.
Hefti, F., Hartikka, J., Eckenstein, F., Gnahn, H., Heumann, R. & Schwab, M. (1985) Nerve growth
factor increases choline acetyltransferase but not survival or fiber outgrowth of cultured fetal septal
cholinergic neurons. Neuroscience 14, 55­68.
Hefti, F., Hartikka, J., Salvatierra, A., Weiner, W.J. & Mash, D.C. (1986) Localization of Nerve Growth­
Factor Receptors in Cholinergic Neurons of the Human Basal Forebrain. Neuroscience Letters 69, 37­
41.
Hempstead, B.L., Martin­Zanca, D., Kaplan, D.R., Parada, L.F. & Chao, M.V. (1991) High­affinity NGF
binding requires coexpression of the trk proto­oncogene and the low­affinity NGF receptor. Nature 350,
678­683.
Henry, G., Williamson, D. & Tampi, R.R. (2011) Efficacy and Tolerability of Antidepressants in the
Treatment of Behavioral and Psychological Symptoms of Dementia, A Literature Review of Evidence.
American Journal of Alzheimers Disease and Other Dementias 26, 169­183.
Hernandez, C.M., Gearhart, D.A., Parikh, V., Hohnadel, E.J., Davis, L.W., Middlemore, M.L., Warsi,
S.P., Waller, J.L. & Terry, A.V.,Jr (2006) Comparison of Galantamine and Donepezil for Effects on
Nerve Growth Factor, Cholinergic Markers, and Memory Performance in Aged Rats. Journal of
Pharmacology And Experimental Therapeutics 316, 679­694.
Hock, C., Heese, K., Hulette, C., Rosenberg, C. & Otten, U. (2000) Region­specific neurotrophin
imbalances in Alzheimer disease Decreased levels of brain­derived neurotrophic factor and increased
levels of nerve growth factor in hippocampus and cortical areas. Archives of Neurology 57, 846­851.
Hofer, M., Pagliusi, S.R., Hohn, A., Leibrock, J. & Barde, Y.A. (1990) Regional Distribution of Brain­
Derived Neurotrophic Factor Messenger­Rna in the Adult­Mouse Brain. The EMBO Journal 9, 2459­
2464.
Hohn, A., Leibrock, J., Bailey, K. & Barde, Y.A. (1990) Identification and Characterization of a Novel
Member of the Nerve Growth­Factor Brain­Derived Neurotrophic Factor Family. Nature 344, 339­341.
90
Holsinger, R.M.D., Schnarr, J., Henry, P., Castelo, V.T. & Fahnestock, M. (2000) Quantitation of BDNF
mRNA in human parietal cortex by competitive reverse transcription­polymerase chain reaction:
decreased levels in Alzheimer's disease. Molecular Brain Research 76, 347­354.
Holtzman, D.M., Li, Y.W., Parada, L.F., Kinsman, S., Chen, C.K., Valletta, J.S., Zhou, J., Long, J.B. &
Mobley, W.C. (1992) P140trk Messenger­Rna Marks Ngf­Responsive Forebrain Neurons ­ Evidence
that Trk Gene­Expression is Induced by Ngf. Neuron 9, 465­478.
Hu, Y., Lee, X., Shao, Z., Apicco, D., Huang, G., Gong, B., Pepinsky, R. & Mi, S. (2013) A
DR6/p75(NTR) complex is responsible for beta­amyloid­induced cortical neuron death. Cell Death and
Disease 4, e579.
Hu, X.Y., Zhang, H.Y., Qin, S., Xu, H., Swaab, D.F. & Zhou, J.N. (2002) Increased p75(NTR)
expression in hippocampal neurons containing hyperphosphorylated tin Alzheimer patients.
Experimental Neurology 178, 104­111.
Huang, E.J. & Reichardt, L.F. (2003) Trk receptors: Roles in neuronal signal transduction. Annual
Review of Biochemistry 72, 609­642.
Huang, Y.Z. & McNamara, J.O. (2010) Mutual Regulation of Src Family Kinases and the Neurotrophin
Receptor TrkB. Journal of Biological Chemistry 285, 8207­8217.
Hwang, J.J., Park, M.H., Choi, S.Y. & Koh, J.Y. (2005) Activation of the Trk signaling pathway by
extracellular zinc ­ Role of metalloproteinases. Journal of Biological Chemistry 280, 11995­12001.
Ibanez, C.F. & Simi, A. (2012) P75 Neurotrophin Receptor Signaling in Nervous System Injury and
Degeneration: Paradox and Opportunity. Trends in Neurosciences 35, 431­440.
Irie, S., Hachiya, T., Rabizadeh, S., Maruyama, W., Mukai, J., Li, Y., Reed, J.C., Bredesen, D.E. & Sato,
T.A. (1999) Functional interaction of Fas­associated phosphatase­1 (FAP­1) with p75(NTR) and their
effect on NF­kappa B activation. FEBS Letters 460, 191­198.
Iwakura, Y., Nawa, H., Sora, I. & Chao, M.V. (2008) Dopamine D1 Receptor­induced Signaling through
TrkB Receptors in Striatal Neurons. Journal of Biological Chemistry 283, 15799­15806.
Jansen, P., Giehl, K., Nyengaard, J.R., Teng, K., Lioubinski, O., Sjoegaard, S.S., Breiderhoff, T.,
Gotthardt, M., Lin, F., Eilers, A., Petersen, C.M., Lewin, G.R., Hempstead, B.L., Willnow, T.E. &
Nykjaer, A. (2007) Roles for the pro­neurotrophin receptor sortilin in neuronal development, aging and
brain injury. Nature Neuroscience 10, 1149­1157.
Johnson, D., Lanahan, A., Buck, C.R., Sehgal, A., Morgan, C., Mercer, E., Bothwell, M. & Chao, M.
(1986) Expression and Structure of the Human Ngf Receptor. Cell 47, 545­554.
Jonsson, T., Atwal, J.K., Steinberg, S., Snaedal, J., Jonsson, P.V., Bjornsson, S., Stefansson, H., Sulem,
P., Gudbjartsson, D., Maloney, J., Hoyte, K., Gustafson, A., Liu, Y., Lu, Y., Bhangale, T., Graham, R.R.,
Huttenlocher, J., Bjornsdottir, G., Andreassen, O.A., Jonsson, E.G., Palotie, A., Behrens, T.W.,
Magnusson, O.T., Kong, A., Thorsteinsdottir, U., Watts, R.J. & Stefansson, K. (2012) A mutation in APP
protects against Alzheimer's disease and age­related cognitive decline. Nature 488, 96­99.
91
Jung, K., Tan, S., Landman, N., Petrova, K., Murray, S., Lewis, R., Kim, P.K., Kim, D.S., Ryu, S.H.,
Chao, M.V. & Kim, T. (2003) Regulated Intramembrane Proteolysis of the p75 Neurotrophin Receptor
Modulates Its Association with the TrkA Receptor. Journal of Biological Chemistry 278, 42161­42169.
Kang, H.J. & Schuman, E.M. (1995) Long­Lasting Neurotrophin­Induced Enhancement of Synaptic
Transmission in the Adult Hippocampus. Science 267, 1658­1662.
Kanning, K.C., Hudson, M., Amieux, P.S., Wiley, J.C., Bothwell, M. & Schecterson, L.C. (2003)
Proteolytic Processing of the p75 Neurotrophin Receptor and Two Homologs Generates C­Terminal
Fragments with Signaling Capability. Journal of Neuroscience 23, 5425­5436.
Kaplan, D.R., Hempstead, B.L., Martinzanca, D., Chao, M.V. & Parada, L.F. (1991) The Trk
Protooncogene Product ­ a Signal Transducing Receptor for Nerve Growth­Factor. Science 252, 554­
558.
Karpova, N.N., Pickenhagen, A., Lindholm, J., Tiraboschi, E., Kulesskaya, N., Agustsdottir, A., Antila,
H., Popova, D., Akamine, Y., Sullivan, R., Hen, R., Drew, L.J. & Castren, E. (2011) Fear Erasure in
Mice Requires Synergy Between Antidepressant Drugs and Extinction Training. Science 334, 1731­
1734.
Kenchappa, R.S., Tep, C., Korade, Z., Urra, S., Bronfman, F.C., Yoon, S.O. & Carter, B.D. (2010) p75
Neurotrophin Receptor­mediated Apoptosis in Sympathetic Neurons Involves a Biphasic Activation of
JNK and Up­regulation of Tumor Necrosis Factor­alpha­converting Enzyme/ADAM17. Journal of
Biological Chemistry 285, 20358­20368.
Kenchappa, R.S., Zampieri, N., Chao, M.V., Barker, P.A., Teng, H.K., Hempstead, B.L. & Carter, B.D.
(2006) Ligand­Dependent Cleavage of the P75 Neurotrophin Receptor Is Necessary for NRIF Nuclear
Translocation and Apoptosis in Sympathetic Neurons. Neuron 50, 219­232.
Khursigara, G., Bertin, J., Yano, H., Moffett, H., DiStefano, P.S. & Chao, M.V. (2001) A prosurvival
function for the p75 receptor death domain mediated via the caspase recruitment domain receptor­
interacting protein 2. Journal of Neuroscience 21, 5854­5863.
Kichev, A., Ilieva, E.V., Pinol­Ripoll, G., Podlesniy, P., Ferrer, I., Portero­Otin, M., Pamplona, R. &
Espinet, C. (2009) Cell Death and Learning Impairment in Mice Caused by in Vitro Modified Pro­NGF
Can Be Related to Its Increased Oxidative Modifications in Alzheimer Disease. American Journal of
Pathology 175, 2574­2585.
Klein, R., Conway, D., Parada, L.F. & Barbacid, M. (1990) The Trkb Tyrosine Protein­Kinase Gene
Codes for a 2nd Neurogenic Receptor that Lacks the Catalytic Kinase Domain. Cell 61, 647­656.
Klein, R., Jing, S.Q., Nanduri, V., Orourke, E. & Barbacid, M. (1991) The Trk Protooncogene Encodes a
Receptor for Nerve Growth­Factor. Cell 65, 189­197.
Klein, R., Lamballe, F., Bryant, S. & Barbacid, M. (1992) The Trkb Tyrosine Protein­Kinase is a
Receptor for Neurotrophin­4. Neuron 8, 947­956.
92
Klein, R., Nanduri, V., Jing, S.Q., Lamballe, F., Tapley, P., Bryant, S., Cordoncardo, C., Jones, K.R.,
Reichardt, L.F. & Barbacid, M. (1991) The Trkb Tyrosine Protein­Kinase is a Receptor for Brain­
Derived Neurotrophic Factor and Neurotrophin­3. Cell 66, 395­403.
Knowles, J., Simmons, D., Nguyen, T., Van der Griend, L., Xie, Y., Zhang, H., Yang, T., Pollak, J.,
Chang, T., Arancio, O., Buckwalter, M., Wyss­Coray, T., Massa, S. & Longo, F. (2013) A small molecule
p75(NTR) ligand prevents cognitive deficits and neurite degeneration in an Alzheimer's mouse model.
Neurobiology of Aging 34, 2052­2063.
Knowles, J.K., Rajadas, J., Nguyen, T.V., Yang, T., LeMieux, M.C., Griend, L.V., Ishikawa, C., Massa,
S.M., Wyss­Coray, T. & Longo, F.M. (2009) The p75 Neurotrophin Receptor Promotes Amyloid­beta(1­
42)­Induced Neuritic Dystrophy In Vitro and In Vivo. Journal of Neuroscience 29, 10627­10637.
Kolbeck, R., Bartke, I., Eberle, W. & Barde, Y.A. (1999) Brain­derived neurotrophic factor levels in the
nervous system of wild­type and neurotrophin gene mutant mice. Journal of neurochemistry 72, 1930­
1938.
Kommaddi, R.P., Thomas, R., Ceni, C., Daigneault, K. & Barker, P.A. (2011) Trk­dependent ADAM17
activation facilitates neurotrophin survival signaling. Faseb Journal 25, 2061­2070.
Koponen, E., Rantamaki, T., Voikar, V., Saarelainen, T., MacDonald, E. & Castren, E. (2005) Enhanced
BDNF signaling is associated with an antidepressant­like behavioral response and changes in brain
monoamines. Cellular & Molecular Neurobiology 25, 973­980.
Koponen, E., Võikar, V., Riekki, R., Saarelainen, T., Rauramaa, T., Rauvala, H., Taira, T. & Castrén, E.
(2004) Transgenic mice overexpressing the full­length neurotrophin receptor trkB exhibit increased
activation of the trkB–PLCγ pathway, reduced anxiety, and facilitated learning. Molecular and Cellular
Neuroscience 26, 166­181.
Kordower, J.H., Bartus, R.T., Bothwell, M., Schatteman, G. & Gash, D.M. (1988) Nerve Growth­Factor
Receptor Immunoreactivity in the Nonhuman Primate (Cebus­Apella) ­ Distribution, Morphology, and
Colocalization with Cholinergic Enzymes. Journal of Comparative Neurology 277, 465­486.
Kordower, J.H., Chu, Y.P., Stebbins, G.T., DeKosky, S.T., Cochran, E.J., Bennett, D. & Mufson, E.J.
(2001) Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive
impairment. Annals of Neurology 49, 202­213.
Korsching, S., Auburger, G., Heumann, R., Scott, J. & Thoenen, H. (1985) Levels of Nerve Growth­
Factor and its Messenger­Rna in the Central Nervous­System of the Rat Correlate with Cholinergic
Innervation. The EMBO Journal 4, 1389­1393.
Korte, M., Carroll, P., Wolf, E., Brem, G., Thoenen, H. & Bonhoeffer, T. (1995) Hippocampal Long­
Term Potentiation is Impaired in Mice Lacking Brain­Derived Neurotrophic Factor. Proceedings of the
National Academy of Sciences of the United States of America 92, 8856­8860.
Korte, M., Griesbeck, O., Gravel, C., Carroll, P., Staiger, V., Thoenen, H. & Bonhoeffer, T. (1996) Virus­
mediated gene transfer into hippocampal CA1 region restores long­term potentiation in brain­derived
neurotrophic factor mutant mice. Proceedings of the National Academy of Sciences 93, 12547­12552.
93
Kotani, S., Yamauchi, T., Teramoto, T. & Ogura, H. (2008) Donepezil, an acetylcholinesterase inhibitor,
enhances adult hippocampal neurogenesis. Chemico­Biological Interactions 175, 227­230.
Kramer, B.M.R., Van der Zee, C.E.E.M. & Hagg, T. (1999) P75 nerve growth factor receptor is
important for retrograde transport of neurotrophins in adult cholinergic basal forebrain neurons.
Neuroscience 94, 1163­1172.
Krol, K., Crutcher, K., Kalisch, B., Rylett, R. & Kawaja, M. (2000) Absence of p75(NTR) expression
reduces nerve growth factor immunolocalization in cholinergic septal neurons. Journal of Comparative
Neurology 427, 54­66.
Krygier, S. & Djakiew, D. (2001) The neurotrophin receptor p75(NTR) is a tumor suppressor in human
prostate cancer. Anticancer Research 21, 3749­3755.
Lee, F.S. & Chao, M.V. (2001) Activation of Trk neurotrophin receptors in the absence of neurotrophins.
Proceedings of the National Academy of Sciences of the United States of America 98, 3555­3560.
Lee, F.S., Rajagopal, R., Kim, A.H., Chang, P.C. & Chao, M.V. (2002) Activation of Trk neurotrophin
receptor signaling by pituitary adenylate cyclase­activating polypeptides. Journal of Biological
Chemistry 277, 9096­9102.
Lee, K.F., Li, E., Huber, L.J., Landis, S.C., Sharpe, A.H., Chao, M.V. & Jaenisch, R. (1992) Targeted
Mutation of the Gene Encoding the Low Affinity Ngf Receptor P75 Leads to Deficits in the Peripheral
Sensory Nervous­System. Cell 69, 737­749.
Lee, R., Kermani, P., Teng, K.K. & Hempstead, B.L. (2001) Regulation of Cell Survival by Secreted
Proneurotrophins. Science 294, 1945­1948.
Leibrock, J., Lottspeich, F., Hohn, A., Hofer, M., Kulli, A., Hengerer, B., Masiakowski, P., Thoenen, H.
& Barde, Y.A. (1989) Molecular­Cloning and Expression of Brain­Derived Neurotrophic Factor. Nature
341, 149­152.
Leyhe, T., Stransky, E., Eschweiler, G.W., Buchkremer, G. & Laske, C. (2008) Increase of BDNF serum
concentration during donepezil treatment of patients with early Alzheimer's disease. European Archives
of Psychiatry & Clinical Neuroscience 258, 124­128.
Linggi, M.S., Burke, T.L., Williams, B.B., Harrington, A., Kraemer, R., Hempstead, B.L., Yoon, S.O. &
Carter, B.D. (2005) Neurotrophin receptor interacting factor (NRIF) is an essential mediator of
apoptotic signaling by the p75 neurotrophin receptor. Journal of Biological Chemistry 280, 13801­
13808.
Livak, K.J. & Schmittgen, T.D. (2001) Analysis of relative gene expression data using real­time
quantitative PCR and the 2(T)(­Delta Delta C) method. Methods 25, 402­408.
Lott, I.T. (2012) Neurological phenotypes for Down syndrome across the life span. Progress in Brain
Research 197, 101­121.
Lu, B., Pang, P.T. & Woo, N.H. (2005) The yin and yang of neurotrophin action. Nature Reviews
Neuroscience 6, 603­614.
94
Maisonpierre, P.C., Belluscio, L., Squinto, S., Ip, N.Y., Furth, M.E., Lindsay, R.M. & Yancopoulos,
G.D. (1990) Neurotrophin­3 ­ a Neurotrophic Factor Related to Ngf and Bdnf. Science 247, 1446­1451.
Mandel, R.J. (2010) CERE­110, an adeno­associated virus­based gene delivery vector expressing
human nerve growth factor for the treatment of Alzheimer's disease. Current opinion in molecular
therapeutics 12, 240­247.
Martinowich, K., Schloesser, R.J., Lu, Y., Jimenez, D.V., Paredes, D., Greene, J.S., Greig, N.H., Manji,
H.K. & Lu, B. (2012) Roles of p75(NTR), long­term depression, and cholinergic transmission in
anxiety and acute stress coping. Biological Psychiatry 71, 75­83.
Marvanová, M., Lakso, M., Pirhonen, J., Nawa, H., Wong, G. & Castrén, E. (2001) The
Neuroprotective Agent Memantine Induces Brain­Derived Neurotrophic Factor and trkB Receptor
Expression in Rat Brain. Molecular and Cellular Neuroscience, 18, 247­258.
Masoudi, R., Ioannou, M.S., Coughlin, M.D., Pagadala, P., Neet, K.E., Clewes, O., Allen, S.J.,
Dawbarn, D. & Fahnestock, M. (2009) Biological Activity of Nerve Growth Factor Precursor Is
Dependent upon Relative Levels of Its Receptors. Journal of Biological Chemistry 284, 18424­18433.
Massa, S.M., Xie, Y.M., Yang, T., Harrington, A.W., Kim, M.L., Yoon, S.O., Kraemer, R., Moore, L.A.,
Hempstead, B.L. & Longo, F.M. (2006) Small, nonpeptide p75(NTR) ligands induce survival signaling
and inhibit proNGF­induced death. Journal of Neuroscience 26, 5288­5300.
Matsumoto, T., Rauskolb, S., Polack, M., Klose, J., Kolbeck, R., Korte, M. & Barde, Y. (2008)
Biosynthesis and processing of endogenous BDNF: CNS neurons store and secrete BDNF, not pro­
BDNF. Nature Neuroscience 11, 131­133.
Matusica, D., Skeldal, S., Sykes, A., Palstra, N., Sharma, A. & Coulson, E. (2013) An Intracellular
Domain Fragment of the p75 Neurotrophin Receptor (p75NTR) Enhances Tropomyosin Receptor
Kinase A (TrkA) Receptor Function. Journal of Biological Chemistry 288, 11144­11154.
McShane, R., Sastre, A.A. & Minakaran, N. (2006) Memantine for dementia. Cochrane Database of
Systematic Reviews (2), 10.1002/14651858.CD003154.pub5.
Meisner, F., Scheller, C., Kneitz, S., Sopper, S., Neuen­Jacob, E., Riederer, P., ter Meulen, V.,
Koutsilieri, E. & German Competence Network HIV AIDS (2008) Memantine upregulates BDNF and
prevents dopamine deficits in SIV­infected macaques: A novel pharmacological action of memantine.
Neuropsychopharmacology 33, 2228­2236.
Micheau, J. & Marighetto, A. (2011) Acetylcholine and memory: A long, complex and chaotic but still
living relationship. Behavioural Brain Research 221, 424­429.
Middlemas, D.S., Lindberg, R.A. & Hunter, T. (1991) TrkB, a neural receptor protein tyrosine kinase ­
evidence for a full­length and 2 truncated receptors. Molecular and Cellular Biology 11, 143­153.
Middlemas, D.S., Meisenhelder, J. & Hunter, T. (1994) Identification of Trkb Autophosphorylation Sites
and Evidence that Phospholipase C­Gamma­1 is a Substrate of the Trkb Receptor. Journal of Biological
Chemistry 269, 5458­5466.
95
Minichiello, L., Calella, A.M., Medina, D.L., Bonhoeffer, T., Klein, R. & Korte, M. (2002) Mechanism
of TrkB­mediated hippocampal long­term potentiation. Neuron 36, 121­137.
Minichiello, L., Korte, M., Wolfer, D., Kuhn, R., Unsicker, K., Cestari, V., Rossi­Arnaud, C., Lipp, H.P.,
Bonhoeffer, T. & Klein, R. (1999) Essential role for TrkB receptors in hippocampus­mediated learning.
Neuron 24, 401­414.
Mori, E., Hashimoto, M., Krishnan, K.R. & Doraiswamy, P.M. (2006) What constitutes clinical
evidence for neuroprotection in Alzheimer disease ­ Support for the cholinesterase inhibitors? Alzheimer
Disease &Associated Disorders 20, S19­S26.
Morse, J., Wiegand, S., Anderson, K., You, Y., Cai, N., Carnahan, J., Miller, J., DiStefano, P., Altar, C. &
Lindsay, R. (1993) Brain­derived neurotrophic factor (BDNF) prevents the degeneration of medial
septal cholinergic neurons following fimbria transection. Journal of Neuroscience 13, 4146­4156.
Mowla, S.J., Pareek, S., Farhadi, H.F., Petrecca, K., Fawcett, J.P., Seidah, N.G., Morris, S.J., Sossin,
W.S. & Murphy, R.A. (1999) Differential sorting of nerve growth factor and brain­derived neurotrophic
factor in hippocampal neurons. Journal of Neuroscience 19, 2069­2080.
Mufson, E., Ma, S., Cochran, E., Bennett, D., Beckett, L., Jaffar, S., Saragovi, H. & Kordower, J. (2000)
Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive
impairment and early Alzheimer's disease. Journal of Comparative Neurology 427, 19­30.
Mufson, E.J., Bothwell, M., Hersh, L.B. & Kordower, J.H. (1989) Nerve Growth­Factor Receptor
Immunoreactive Profiles in the Normal, Aged Human Basal Forebrain ­ Colocalization with Cholinergic
Neurons. Journal of Comparative Neurology 285, 196­217.
Mufson, E.J., Conner, J.M. & Kordower, J.H. (1995) Nerve growth factor in Alzheimer's disease:
defective retrograde transport to nucleus basalis. Neuroreport 6, 1063­1066.
Mufson, E.J. & Kordower, J.H. (1992) Cortical neurons express nerve growth factor receptors in
advanced Age and Alzheimer disease. Proceedings of the National Academy of Sciences of the United
States of America 89, 569­573.
Mufson, E.J., Lavine, N., Jaffar, S., Kordower, J.H., Quirion, R. & Saragovi, H.U. (1997) Reduction in
p140­TrkA receptor protein within the nucleus basalis and cortex in Alzheimer's disease. Experimental
Neurology 146, 91­103.
Mufson, E., Li, J., Sobreviela, T. & Kordower, J. (1996) Decreased trkA gene expression within basal
forebrain neurons in Alzheimer's disease. Neuroreport 8, 25­29.
Mufson, E.J., He, B., Nadeem, M., Perez, S.E., Counts, S.E., Leurgans, S., Fritz, J., Lah, J., Ginsberg,
S.D., Wuu, J. & Scheff, S.W. (2012) Hippocampal proNGF signaling pathways and beta­amyloid levels
in mild cognitive impairment and Alzheimer disease. Journal of Neuropathology and Experimental
Neurology 71, 1018­1029.
Mullard, A. (2012) Sting of Alzheimer's failures offset by upcoming prevention trials. Nature Reviews
Drug Discovery 11, 657­660.
96
Murer, M.G., Boissiere, F., Yan, Q., Hunot, S., Villares, J., Faucheux, B., Agid, Y., Hirsch, E. &
Raisman­Vozari, R. (1999) An immunohistochemical study of the distribution of brain­derived
neurotrophic factor in the adult human brain, with particular reference to Alzheimer's disease.
Neuroscience 88, 1015­1032.
Nagahara, A.H., Merrill, D.A., Coppola, G., Tsukada, S., Schroeder, B.E., Shaked, G.M., Wang, L.,
Blesch, A., Kim, A., Conner, J.M., Rockenstein, E., Chao, M.V., Koo, E.H., Geschwind, D., Masliah, E.,
Chiba, A.A. & Tuszynski, M.H. (2009) Neuroprotective effects of brain­derived neurotrophic factor in
rodent and primate models of Alzheimer's disease. Nature Medicine 15, 331­337.
Nagappan, G., Zaitsev, E., Senatorov, V.V., Yang, J., Hempstead, B.L. & Lu, B. (2009) Control of
extracellular cleavage of ProBDNF by high frequency neuronal activity. Proceedings of the National
Academy of Sciences 106, 1267­1272.
Narisawa­Saito, M., Wakabayashi, K., Tsuji, S., Takahashi, H. & Nawa, H. (1996) Regional specificity
of alterations in NGF, BDNF and NT­3 levels in Alzheimer's disease. Neuroreport 7, 2925­2928.
Naumann, T., Casademunt, E., Hollerbach, E., Hofmann, J., Dechant, G., Frotscher, M. & Barde, Y.A.
(2002) Complete deletion of the neurotrophin receptor p75(NTR) leads to long­lasting increases in the
number of basal forebrain cholinergic neurons. Journal of Neuroscience 22, 2409­2418.
Nestler, E., Hyman, S. & Malenka, R. 2009Widely projecting systems: Monoamines, acetylcholine, and
orexin. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience. , 2nd edition, pp. 145­
180. The McGraw­Hill Companies, Inc.
Nibuya, M., Morinobu, S. & Duman, R. (1995) Regulation of BDNF and trkB mRNA in rat brain by
chronic electroconvulsive seizure and antidepressant drug treatments. Journal of Neuroscience 15, 7539­
7547.
Nikolaev, A., McLaughlin, T., O'Leary, D.D.M. & Tessier­Lavigne, M. (2009) APP binds DR6 to trigger
axon pruning and neuron death via distinct caspases. Nature 457, 981­U1.
Noh, M.Y., Koh, S.H., Kim, Y., Kim, H.Y., Cho, G.W. & Kim, S.H. (2009) Neuroprotective effects of
donepezil through inhibition of GSK­3 activity in amyloid­beta­induced neuronal cell death. Journal of
Neurochemistry 108, 1116­1125.
Nykjaer, A., Lee, R., Teng, K.K., Jansen, P., Madsen, P., Nielsen, M.S., Jacobsen, C., Kliemannel, M.,
Schwarz, E., Willnow, T.E., Hempstead, B.L. & Petersen, C.M. (2004) Sortilin is essential for proNGF­
induced neuronal cell death. Nature 427, 843­848.
Nykjaer, A. & Willnow, T.E. (2012) Sortilin: a receptor to regulate neuronal viability and function.
Trends in Neurosciences 35, 261­270.
Olesen, J., Gustavsson, A., Svensson, M., Wittchen, H., Jonsson, B., CDBE2010 Study Grp & European
Brain Council (2012) The economic cost of brain disorders in Europe. European Journal of Neurology
19, 155­162.
97
Origlia, N., Capsoni, S., Domenici, L. & Cattaneo, A. (2006) Time window in cholinomimetic ability to
rescue long­term potentiation in neurodegenerating anti­nerve growth factor mice. Journal of
Alzheimers Disease 9, 59­68.
Pang, P.T., Teng, H.K., Zaitsev, E., Woo, N.T., Sakata, K., Zhen, S., Teng, K.K., Yung, W., Hempstead,
B.L. & Lu, B. (2004) Cleavage of proBDNF by tPA/Plasmin Is Essential for Long­Term Hippocampal
Plasticity. Science 306, 487­491.
Parent, M.B. & Baxter, M.G. (2004) Septohippocampal acetylcholine: Involved in but not necessary for
learning and memory? Learning & Memory 11, 9­20.
Park, H. & Poo, M. (2013) Neurotrophin regulation of neural circuit development and function. Nature
Reviews Neuroscience 14, 7­23.
Peng, S., Wuu, J., Mufson, E.J. & Fahnestock, M. (2005) Precursor form of brain­derived neurotrophic
factor and mature brain­derived neurotrophic factor are decreased in the pre­clinical stages of
Alzheimer's disease. Journal of Neurochemistry 93, 1412­1421.
Peng, S.Y., Wuu, J., Mufson, E.J. & Fahnestock, M. (2004) Increased proNGF levels in subjects with
mild cognitive impairment and mild Alzheimer disease. Journal of Neuropathology and Experimental
Neurology 63, 641­649.
Peng, S., Garzon, D.J., Marchese, M., Klein, W., Ginsberg, S.D., Francis, B.M., Mount, H.T.J., Mufson,
E.J., Salehi, A. & Fahnestock, M. (2009) Decreased Brain­Derived Neurotrophic Factor Depends on
Amyloid Aggregation State in Transgenic Mouse Models of Alzheimer's Disease. Journal of
Neuroscience 29, 9321­9329.
Perry, E.K., Tomlinson, B.E., Blessed, G., Bergmann, K., Gibson, P.H. & Perry, R.H. (1978) Correlation
of Cholinergic Abnormalities with Senile Plaques and Mental Test­Scores in Senile Dementia. British
Medical Journal 2, 1457­1459.
Peterson, D.A., Dickinson­Anson, H.A., Leppert, J.T., Lee, K.F. & Gage, F.H. (1999) Central neuronal
loss and behavioral impairment in mice lacking neurotrophin receptor p75. Journal of Comparative
Neurology 404, 1­20.
Phillips, H.S., Hains, J.M., Armanini, M., Laramee, G.R., Johnson, S.A. & Winslow, J.W. (1991) BDNF
mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 7, 695­702.
Phillips, H.S., Hains, J.M., Laramee, G.R., Rosenthal, A. & Winslow, J.W. (1990) Widespread
Expression of Bdnf but Not Nt3 by Target Areas of Basal Forebrain Cholinergic Neurons. Science 250,
290­294.
Podlesniy, P., Kichev, A., Pedraza, C., Saurat, J., Encinas, M., Perez, B., Ferrer, I. & Espinet, C. (2006)
Pro­NGF from Alzheimer's disease and normal human brain displays distinctive abilities to induce
processing and nuclear translocation of intracellular domain of p75NTR and apoptosis. American
Journal of Pathology 169, 119­131.
Querfurth, H.W. & LaFerla, F.M. (2010) Alzheimer's Disease. New England Journal of Medicine 362,
329­344.
98
Rabizadeh, S., Bitler, C.M., Butcher, L.L. & Bredesen, D.E. (1994) Expression of the Low­Affinity
Nerve Growth­Factor Receptor Enhances Beta­Amyloid Peptide Toxicity. Proceedings of the National
Academy of Sciences of the United States of America 91, 10703­10706.
Rabizadeh, S., Oh, J., Zhong, L.T., Yang, J., Bitler, C.M., Butcher, L.L. & Bredesen, D.E. (1993)
Induction of Apoptosis by the Low­Affinity Ngf Receptor. Science 261, 345­348.
Radeke, M.J., Misko, T.P., Hsu, C., Herzenberg, L.A. & Shooter, E.M. (1987) Gene­Transfer and
Molecular­Cloning of the Rat Nerve Growth­Factor Receptor. Nature 325, 593­597.
Rajagopal, R., Chen, Z., Lee, F.S. & Chao, M.V. (2004) Transactivation of Trk Neurotrophin Receptors
by G­Protein­Coupled Receptor Ligands Occurs on Intracellular Membranes. Journal of Neuroscience
24, 6650­6658.
Rantamaki, T., Hendolin, P., Kankaanpaa, A., Mijatovic, J., Piepponen, P., Domenici, E., Chao, M.V.,
Mannisto, P.T. & Castren, E. (2007) Pharmacologically diverse antidepressants rapidly activate brain­
derived neurotrophic factor receptor TrkB and induce phospholipase­Cgamma signaling pathways in
mouse brain. Neuropsychopharmacology 32, 2152­2162.
Rauskolb, S., Zagrebelsky, M., Dreznjak, A., Deogracias, R., Matsumoto, T., Wiese, S., Erne, B.,
Sendtner, M., Schaeren­Wiemers, N., Korte, M. & Barde, Y. (2010) Global Deprivation of Brain­
Derived Neurotrophic Factor in the CNS Reveals an Area­Specific Requirement for Dendritic Growth.
Journal of Neuroscience 30, 1739­1749.
Rodriguez­Tebar, A., Dechant, G. & Barde, Y.A. (1990) Binding of Brain­Derived Neurotrophic Factor
to the Nerve Growth­Factor Receptor. Neuron 4, 487­492.
Roux, P.P. & Barker, P.A. (2002) Neurotrophin signaling through the p75 neurotrophin receptor.
Progress in Neurobiology 67, 203­233.
Roux, P.P., Colicos, M.A., Barker, P.A. & Kennedy, T.E. (1999) p75 Neurotrophin Receptor Expression
Is Induced in Apoptotic Neurons After Seizure. Journal of Neuroscience 19, 6887­6896.
Ruberti, F., Capsoni, S., Comparini, A., Di Daniel, E., Franzot, J., Gonfloni, S., Rossi, G., Berardi, N. &
Cattaneo, A. (2000) Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe
deficits in basal forebrain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy.
Journal of Neuroscience 20, 2589­2601.
Russ, T.C. & Morling, J.R. (2012) Cholinesterase inhibitors for mild cognitive impairment. Cochrane
Database of Systematic Reviews (9), 10.1002/14651858.CD009132.pub2.
Saarelainen, T., Lukkarinen, J.A., Koponen, S., Grohn, O.H.J., Jolkkonen, J., Koponen, E., Haapasalo,
A., Alhonen, L., Wong, G., Koistinaho, J., Kauppinen, R.A. & Castren, E. (2000a) Transgenic mice
overexpressing truncated trkB neurotrophin receptors in neurons show increased susceptibility to
cortical injury after focal cerebral ischemia. Molecular and Cellular Neuroscience 16, 87­96.
Saarelainen, T., Pussinen, R., Koponen, E., Alhonen, L., Wong, G., Sirvio, J. & Castren, E. (2000b)
Transgenic mice overexpressing truncated trkB neurotrophin receptors in neurons have impaired long­
term spatial memory but normal hippocampal LTP. Synapse 38, 102­104.
99
Saarelainen, T., Hendolin, P., Lucas, G., Koponen, E., Sairanen, M., MacDonald, E., Agerman, K.,
Haapasalo, A., Nawa, H., Aloyz, R., Ernfors, P. & Castren, E. (2003) Activation of the TrkB
Neurotrophin Receptor Is Induced by Antidepressant Drugs and Is Required for Antidepressant­Induced
Behavioral Effects. Journal of Neuroscience 23, 349­357.
Sadowski, I., Ma, J., Triezenberg, S. & Ptashne, M. (1988) Gal4­Vp16 is an Unusually Potent
Transcriptional Activator. Nature 335, 563­564.
Salehi, A., Verhaagen, J., Dijkhuizen, P.A. & Swaab, D.F. (1996) Co­localization of high­affinity
neurotrophin receptors in nucleus basalis of Meynert neurons and their differential reduction in
Alzheimer's disease. Neuroscience 75, 373­387.
Salehi, A., Delcroix, J., Belichenko, P.V., Zhan, K., Wu, C., Valletta, J.S., Takimoto­Kimura, R.,
Kleschevnikov, A.M., Sambamurti, K., Chung, P.P., Xia, W., Villar, A., Campbell, W.A., Kulnane, L.S.,
Nixon, R.A., Lamb, B.T., Epstein, C.J., Stokin, G.B., Goldstein, L.S.B. & Mobley, W.C. (2006)
Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes
cholinergic neuron degeneration. Neuron 51, 29­42.
Samochocki, M., Hoffle, A., Fehrenbacher, A., Jostock, R., Ludwig, J., Christner, C., Radina, M., Zerlin,
M., Ullmer, C., Pereira, E.F.R., Lubbert, H., Albuquerque, E.X. & Maelicke, A. (2003) Galantamine is
an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors.
Journal of Pharmacology and Experimental Therapeutics 305, 1024­1036.
Sanchez­Ortiz, E., Yui, D., Song, D., Li, Y., Rubenstein, J.L., Reichardt, L.F. & Parada, L.F. (2012)
TrkA Gene Ablation in Basal Forebrain Results in Dysfunction of the Cholinergic Circuitry. Journal of
Neuroscience 32, 4065­4079.
Savonenko, A., Xu, G.M., Melnikova, T., Morton, J.L., Gonzales, V., Wong, M.P.F., Price, D.L., Tang,
F., Markowska, A.L. & Borchelt, D.R. (2005) Episodic­like memory deficits in the APPswe/PS1dE9
mouse model of Alzheimer's disease: Relationships to beta­amyloid deposition and neurotransmitter
abnormalities. Neurobiology of Disease 18, 602­617.
Schatteman, G.C., Gibbs, L., Lanahan, A.A., Claude, P. & Bothwell, M. (1988) Expression of Ngf
Receptor in the Developing and Adult Primate Central Nervous­System. Journal of Neuroscience 8,
860­873.
Scheff, S.W., Price, D.A., Schmitt, F.A., DeKosky, S.T. & Mufson, E.J. (2007) Synaptic alterations in
CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 68, 1501­1508.
Scheff, S.W., Price, D.A., Schmitt, F.A. & Mufson, E.J. (2006) Hippocampal synaptic loss in early
Alzheimer's disease and mild cognitive impairment. Neurobiology of Aging 27, 1372­1384.
Schneider, L.S., Dagerman, K.S., Higgins, J.P.T. & McShane, R. (2011) Lack of Evidence for the
Efficacy of Memantine in Mild Alzheimer Disease. Archives of Neurology 68, 991­998.
Scott, S., Mufson, E., Weingartner, J., Skau, K. & Crutcher, K. (1995) Nerve growth factor in
Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis.
Journal of Neuroscience 15, 6213­6221.
100
Scoville, W.B. & Milner, B. (1957) Loss of Recent Memory After Bilateral Hippocampal Lesions.
Journal of Neurology Neurosurgery and Psychiatry 20, 11­21.
Segal, R.A., Bhattacharyya, A., Rua, L.A., Alberta, J.A., Stephens, R.M., Kaplan, D.R. & Stiles, C.D.
(1996) Differential utilization of Trk autophosphorylation sites. Journal of Biological Chemistry 271,
20175­20181.
Seidah, N.G., Benjannet, S., Pareek, S., Chretien, M. & Murphy, R.A. (1996a) Cellular processing of the
neurotrophin precursors of NT3 and BDNF by the mammalian proprotein convertases. FEBS Letters
379, 247­250.
Seidah, N.G., Benjannet, S., Pareek, S., Savaria, D., Hamelin, J., Goulet, B., Laliberte, J., Lazure, C.,
Chretien, M. & Murphy, R.A. (1996b) Cellular processing of the nerve growth factor precursor by the
mammalian pro­protein convertases. Biochemical Journal 314, 951­960.
Seiler, M. & Schwab, M.E. (1984) Specific Retrograde Transport of Nerve Growth­Factor (Ngf) from
Neocortex to Nucleus Basalis in the Rat. Brain research 300, 33­39.
Selkoe, D.J. (2002) Alzheimer's disease is a synaptic failure. Science 298, 789­791.
Shankar, G.M., Li, S., Mehta, T.H., Garcia­Munoz, A., Shepardson, N.E., Smith, I., Brett, F.M., Farrell,
M.A., Rowan, M.J., Lemere, C.A., Regan, C.M., Walsh, D.M., Sabatini, B.L. & Selkoe, D.J. (2008)
Amyloid­beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and
memory. Nature Medicine 14, 837­842.
Shulga, A., Magalhaes, A.C., Autio, H., Plantman, S., di Lieto, A., Nykjaer, A., Carlstedt, T., Risling,
M., Arumae, U., Castren, E. & Rivera, C. (2012) The Loop Diuretic Bumetanide Blocks Posttraumatic
p75(NTR) Upregulation and Rescues Injured Neurons. Journal of Neuroscience 32, 1757­1770.
Skeldal, S., Matusica, D., Nykjaer, A. & Coulson, E.J. (2011) Proteolytic processing of the p75
neurotrophin receptor: A prerequisite for signalling? Bioessays 33, 614­625.
Smeyne, R.J., Klein, R., Schnapp, A., Long, L.K., Bryant, S., Lewin, A., Lira, S.A. & Barbacid, M.
(1994) Severe Sensory and Sympathetic Neuropathies in Mice Carrying a Disrupted Trk/ngf Receptor
Gene. Nature 368, 246­249.
Sobreviela, T., Clary, D.O., Reichardt, L.F., Brandabur, M.M., Kordower, J.H. & Mufson, E.J. (1994)
TrkA­Immunoreactive profiles in the central nervous system ­ Colocalization with neurons containing
p75 nerve growth factor receptor, choline acetyltransferase, and serotonin. Journal of Comparative
Neurology 350, 587­611.
Sofroniew, M.V., Galletly, N.P., Isacson, O. & Svendsen, C.N. (1990) Survival of Adult Basal Forebrain
Cholinergic Neurons After Loss of Target Neurons. Science 247, 338­342.
Soppet, D., Escandon, E., Maragos, J., Middlemas, D.S., Reid, S.W., Blair, J., Burton, L.E., Stanton,
B.R., Kaplan, D.R., Hunter, T., Nikolics, K. & Parada, L.F. (1991) The Neurotrophic Factors Brain­
Derived Neurotrophic Factor and Neurotrophin­3 are Ligands for the Trkb Tyrosine Kinase Receptor.
Cell 65, 895­903.
101
Sotthibundhu, A., Sykes, A.M., Fox, B., Underwood, C.K., Thangnipon, W. & Coulson, E.J. (2008)
{beta}­Amyloid1­42 Induces Neuronal Death through the p75 Neurotrophin Receptor. Journal of
Neuroscience 28, 3941­3946.
Squinto, S.P., Stitt, T.N., Aldrich, T.H., Davis, S., Bianco, S.M., Radziejewski, C., Glass, D.J.,
Masiakowski, P., Furth, M.E., Valenzuela, D.M., Distefano, P.S. & Yancopoulos, G.D. (1991) Trkb
Encodes a Functional Receptor for Brain­Derived Neurotrophic Factor and Neurotrophin­3 but Not
Nerve Growth­Factor. Cell 65, 885­893.
Stephens, R.M., Loeb, D.M., Copeland, T.D., Pawson, T., Greene, L.A. & Kaplan, D.R. (1994) Trk
Receptors use Redundant Signal­Transduction Pathways Involving Shc and Plc­Gamma­1 to Mediate
Ngf Responses. Neuron 12, 691­705.
Sweeney, J.E., Puttfarcken, P.S. & Coyle, J.T. (1989) Galanthamine, an Acetylcholinesterase Inhibitor ­
a Time Course of the Effects on Performance and Neurochemical Parameters in Mice. Pharmacology
Biochemistry and Behavior 34, 129­137.
Szapacs, M.E., Numis, A.L. & Andrews, A.M. (2004) Late onset loss of hippocampal 5­HT and NE is
accompanied by increases in BDNF protein expression in mice co­expressing mutant APP and PS1.
Neurobiology of Disease 16, 572­580.
Takada, Y., Yonezawa, A., Kume, T., Katsuki, H., Kaneko, S., Sugimoto, H. & Akaike, A. (2003)
Nicotinic Acetylcholine Receptor­Mediated Neuroprotection by Donepezil Against Glutamate
Neurotoxicity in Rat Cortical Neurons. Journal of Pharmacology and Experimental Therapeutics 306,
772­777.
Takada­Takatori, Y., Kume, T., Sugimoto, M., Katsuki, H., Sugimoto, H. & Akaike, A. (2006)
Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity
via nicotinic acetylcholine receptors and phosphatidylinositol 3­kinase cascade. Neuropharmacology,
51, 474­486.
Teng, H.K., Teng, K.K., Lee, R., Wright, S., Tevar, S., Almeida, R.D., Kermani, P., Torkin, R., Chen, Z.,
Lee, F.S., Kraemer, R.T., Nykjaer, A. & Hempstead, B.L. (2005) ProBDNF Induces Neuronal Apoptosis
via Activation of a Receptor Complex of p75NTR and Sortilin. Journal of Neuroscience 25, 5455­5463.
Terry, R.D., Masliah, E., Salmon, D.P., Butters, N., Deteresa, R., Hill, R., Hansen, L.A. & Katzman, R.
(1991) Physical Basis of Cognitive Alterations in Alzheimers­Disease ­ Synapse Loss is the Major
Correlate of Cognitive Impairment. Annals of Neurology 30, 572­580.
Troy, C.M., Friedman, J.E. & Friedman, W.J. (2002) Mechanisms of p75­mediated death of
hippocampal neurons ­ Role of caspases. Journal of Biological Chemistry 277, 34295­34302.
Vaegter, C.B., Jansen, P., Fjorback, A.W., Glerup, S., Skeldal, S., Kjolby, M., Richner, M., Erdmann, B.,
Nyengaard, J.R., Tessarollo, L., Lewin, G.R., Willnow, T.E., Chao, M.V. & Nykjaer, A. (2011) Sortilin
associates with Trk receptors to enhance anterograde transport and neurotrophin signaling. Nature
Neuroscience 14, 54­U78.
102
Wahlberg, L.U., Lind, G., Almqvist, P.M., Kusk, P., Tornoe, J., Juliusson, B., Soderman, M., Sellden, E.,
Seiger, A., Eriksdotter­Jonhagen, M. & Linderoth, B. (2012) Targeted delivery of nerve growth factor
via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative
neurosurgery Clinical article. Journal of neurosurgery 117, 340­347.
Van der Weyden, L., Adams, D.J., Harris, L.W., Tannahill, D., Arends, M.J. & Bradley, A. (2005) Null
and conditional Semaphorin 3B alleles using a flexible puro Delta tk LoxP/FRT vector. Genesis 41, 171­
178.
Wang, K.C., Kim, J.A., Sivasankaran, R., Segal, R. & He, Z.G. (2002) p75 interacts with the Nogo
receptor as a co­receptor for Nogo, MAG and OMgp. Nature 420, 74­78.
Wang, L.M., Rahn, J.J., Lun, X.Q., Sun, B.C., Kelly, J.J.P., Weiss, S., Robbins, S.M., Forsyth, P.A. &
Senger, D.L. (2008) Gamma­secretase represents a therapeutic target for the treatment of invasive
glioma mediated by the p75 neurotrophin receptor. PLOS Biology 6, 2496­2511.
Webster, N., Jin, J.R., Green, S., Hollis, M. & Chambon, P. (1988) The Yeast Uasg is a Transcriptional
Enhancer in Human Hela­Cells in the Presence of the Gal4 Trans­Activator. Cell 52, 169­178.
Weskamp, G., Schlondorff, J., Lum, L., Becherer, J.D., Kim, T., Saftig, P., Hartmann, D., Murphy, G. &
Blobel, C.P. (2004) Evidence for a critical role of the tumor necrosis factor alpha convertase (TACE) in
ectodomain shedding of the p75 neurotrophin receptor (p75NTR). Journal of Biological Chemistry 279,
4241­4249.
Vetencourt, J.F.M., Sale, A., Viegi, A., Baroncelli, L., De Pasquale, R., F. O'Leary, O., Castren, E. &
Maffei, L. (2008) The Antidepressant Fluoxetine Restores Plasticity in the Adult Visual Cortex. Science
320, 385­388.
Whitehouse, P.J., Price, D.L., Struble, R.G., Clark, A.W., Coyle, J.T. & Delon, M.R. (1982) Alzheimer's
disease and senile dementia: loss of neurons in the basal forebrain. Science 215, 1237­1239.
Vogels, O.J.M., Broere, C.A.J., Terlaak, H.J., Tendonkelaar, H.J., Nieuwenhuys, R. & Schulte, B.P.M.
(1990) Cell Loss and Shrinkage in the Nucleus Basalis Meynert Complex in Alzheimers­Disease.
Neurobiology of Aging 11, 3­13.
Volosin, M., Trotter, C., Cragnolini, A., Kenchappa, R.S., Light, M., Hempstead, B.L., Carter, B.D. &
Friedman, W.J. (2008) Induction of Proneurotrophins and Activation of p75NTR­Mediated Apoptosis
via Neurotrophin Receptor­Interacting Factor in Hippocampal Neurons after Seizures. Journal of
Neuroscience 28, 9870­9879.
Von Schack, D., Casademunt, E., Schweigreiter, R., Meyer, M., Bibel, M. & Dechant, G. (2001)
Complete ablation of the neurotrophin receptor p75(NTR) causes defects both in the nervous and the
vascular system. Nature Neuroscience 4, 977­978.
Woo, N.H., Teng, H.K., Siao, C.J., Chiaruttini, C., Pang, P.T., Milner, T.A., Hempstead, B.L. & Lu, B.
(2005) Activation of p75(NTR) by proBDNF facilitates hippocampal long­term depression. Nature
Neuroscience 8, 1069­1077.
103
Woolf, N.J. & Butcher, L.L. (2011) Cholinergic systems mediate action from movement to higher
consciousness. Behavioural Brain Research 221, 488­498.
Yaar, M., Zhai, S., Pilch, P.F., Doyle, S.M., Eisenhauer, P.B., Fine, R.E. & Gilchrest, B.A. (1997)
Binding of beta­amyloid to the p75 neurotrophin receptor induces apoptosis ­ A possible mechanism for
Alzheimer's disease. Journal of Clinical Investigation 100, 2333­2340.
Yamashita, T. & Tohyama, M. (2003) The p75 receptor acts as a displacement factor that releases Rho
from Rho­GDI. Nature Neuroscience 6, 461­467.
Yamashita, T., Tucker, K.L. & Barde, Y.A. (1999) Neurotrophin binding to the p75 receptor modulates
Rho activity and axonal outgrowth. Neuron 24, 585­593.
Yan, Q. & Johnson, E.M. (1988) An Immunohistochemical Study of the Nerve Growth­Factor Receptor
in Developing Rats. Journal of Neuroscience 8, 3481­3498.
Yan, Q., Radeke, M.J., Matheson, C.R., Talvenheimo, J., Welcher, A.A. & Feinstein, S.C. (1997)
Immunocytochemical localization of TrkB in the central nervous system of the adult rat. Journal of
Comparative Neurology 378, 135­157.
Yang, J., Siao, C., Nagappan, G., Marinic, T., Jing, D., McGrath, K., Chen, Z., Mark, W., Tessarollo, L.,
Lee, F.S., Lu, B. & Hempstead, B.L. (2009) Neuronal release of proBDNF. Nature Neuroscience 12,
115.
Yang, T., Knowles, J.K., Lu, Q., Zhang, H., Arancio, O., Moore, L.A., Chang, T., Wang, Q., Andreasson,
K., Rajadas, J., Fuller, G.G., Xie, Y.M., Massa, S.M. & Longo, F.M. (2008) Small Molecule, Non­
Peptide p75(NTR) Ligands Inhibit A beta­Induced Neurodegeneration and Synaptic Impairment. PLoS
One 3, e3604.
Yano, K., Koda, K., Ago, Y., Kobayashi, H., Kawasaki, T., Takuma, K. & Matsuda, T. (2009)
Galantamine improves apomorphine­induced deficits in prepulse inhibition via muscarinic ACh
receptors in mice. British Journal of Pharmacology 156, 173­180.
Yeo, T.T., ChuaCouzens, J., Butcher, L.L., Bredesen, D.E., Cooper, J.D., Valletta, J.S., Mobley, W.C. &
Longo, F.M. (1997) Absence of p75(NTR) causes increased basal forebrain cholinergic neuron size,
choline acetyltransferase activity, and target innervation. Journal of Neuroscience 17, 7594­7605.
Zafra, F., Hengerer, B., Leibrock, J., Thoenen, H. & Lindholm, D. (1990) Activity dependent regulation
of BDNF and NGF mRNAs in the rat hippocampus is mediated by non­NMDA glutamate receptors.
EMBO Journal 9, 3545­3550.
